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Abstract 
Respiratory tract (lung and head and neck) cancers constitute a significant public health 
burden, contributing greatly to the cancer-related mortality worldwide. Folate is an essential 
nutrient for genome stability through its role in regulating DNA biosynthesis, repair and 
methylation processes. The deregulation of specific genes encoding for enzymes in this 
pathway has been implicated in several types of cancer including respiratory tract cancer and 
might be critical for cancer cell growth. Certain folate-related genes are targets of very 
common anticancer drugs and their expression has been associated associated with the 
relevant chemotherapeutic response.  
The current study sought to expand the current knowledge on folate pathway deregulation 
in respiratory tract cancer and shed light on as yet unexplored areas. In particular it aims to: 
1) explore the expression profile of the core genes of the folate pathway in lung cancer. 
2)  investigate the potential of sensitising respiratory tract cancer cells to antifolates 
using well-known epigenetic drugs. 
3) assess the impact of manipulating the activity of previously unexplored folate genes 
on cancer cell response to antifolates. 
We evaluated the mRNA expression levels of MTR, AHCY, MAT2A, CBS, DHFR, MTHFR, 
TYMS, DNMT1 and SHMT1 genes in 104 primary non-small cell lung carcinomas (NSCLC) 
and adjacent normal tissues, utilising quantitative real time PCR (qPCR). Expression 
analysis revealed significant expression differences between normal and tumour lung 
tissues in only six of the examined genes (DHFR, DNMT1, SHMT1, CBS, TYMS and MTHFR) 
(p=0.003, p<0.001, p=0.015, p=0.002, p<0.001 and p=0.014) respectively. The relative 
expression of CBS and SHMT1 splice variants was assessed in 53 NSCLC, paired with 
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adjacent normal tissues using relative fluorescent quantification and qPCR, respectively. 
CBS variant 3 (CBSv3) and SHMT1 variant 2 (SHMT1v2) were found to be differentially 
expressed in NSCLC tumour samples compared to adjacent normal tissues.  
A significant reduction was observed in the viability of A549 and SK-MES NSCLC cell lines 
when exposed to the HDAC inhibitor sodium valproate 48 hours prior to treatment with 
5-Fluorouracil (5-FU), while no epigenetic sensitisation was established for methotrexate 
and pemetrexed.  
Finally, SHMT1 expression was knocked down in the PE/CA-PJ15 head and neck squamous 
cell carcinoma (HNSCC) cell line, using short hairpin RNA (shRNA). SHMT1-low clones 
consistently showed increased sensitivity to the 5-FU anticancer drug in a n expression 
dose dependent manner. Inhibition of SHMT1 enzymatic activity by the selective inhibitor 
aminomethylphosphonic (AMPA) acid also potentiated 5-FU activity in the same cell line. 
In conclusion, the data generated from this study provides compelling new evidence into 
the functional role of CBS and SHMT1 splice variants that might influence NSCLC 
pathogenesis. Moreover, this study uncovers a new role of SHMT1 as a potential 
modulator of 5-FU based chemotherapy and points to a new strategy for exploiting 
SHMT1 as a valuable metabolic target for precision 5-FU therapy. 
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Abbreviation Table 
Symbol Description 
3’UTRs 3’ Untranslated regions 
3DCRT Three-Dimensional Conformal Radiotherapy 
5-FU 5-Fluorouracil 
ABC ATP-dependent Binding Cassette 
AC Atypical Carcinoid 
AMPA Amonimethyl Phosphonic Acid 
APS Adenosine 5’ phosphosulfate 
BCA BicinChoninic Acid 
BSA Bovine Serum Albumin 
Ct Cycle-threshold 
DAC 5-aza-2’-deoxycytidine (decitabine) 
DHF Dihydrofolate 
DHFU Dihydrofluorouracil 
DNMTs DNA Methyltransferases 
DPD Dihydropyrimidine dehydrogenase 
DTYMK Deoxythymidylate kinase 
dTMP Deoxythymidine Monophosphate 
dTTP Deoxythymidyne triphosphate 
dUMP Deoxyuridine Monophosphate 
EBV Epstein-Barr virus 
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EGFR Epidermal Growth Factor Receptor 
FDA Food and Drug Administration 
FdUMP Fluorodeoxyuridine Monophosphate 
FdUTP Fluorodeoxyuridine Triphosphate 
FOCM Folate-Mediated One Carbon Metabolism 
FPGS Folylpolyglutamate synthase 
FRs Folate Receptors 
FUTP Fluorouridine Triphosphate 
GGH Gamma-glutamyl hydrolase 
GWAS Genome Wide Association Study 
HBEC Human Bronchial Epithelial Cells 
HCY Homocysteine 
HDACi Histone Deacetylase Inhibitor 
HER2 Heregulin Receptor 
HNSCC Head and Neck Squamous Cell Carcinoma 
HPV Human Papilloma Virus 
IMRT Intensity-Modulated Radiotherapy 
KRAS Kirsten Rat Sarcoma viral gene 
LA locoregionally Advanced  
LCNEC Large Cell Neuroendocrine Carcinoma 
LDCT Low Dose Computed Tomography 
LINES Long Interspersed Nuclear Elements 
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LLP Liverpool Lung Project 
LLPi Liverpool Lung Project Risk Projection Model for Lung Cancer 
Incidence 
MET Methionine 
MRPs Multidrug-Resistant Proteins 
MTT 3-(4,5-Dimethylthiazol-2-Yl)-2,5-Diphenyltetrazolium 
Bromide 
MTX Methotrexate 
MTX-PGs Polyglutamated derivatives of MTX 
NSCLC  Non-Small Cell Lung Cancer 
OPSCC Oropharyngeal Squamous Cell Carcinoma 
PCFT Proton coupled folate transporter 
PcG Poly-comb Group proteins 
PLP Pyridoxal Phosphate 
PEM Pemetrexed 
PNECs Pulmonary neuroendocrine cells 
R/M Recurrent/or Metastatic 
RFC Reduced folate carrier 
RIN RNA Integrity Number 
ROS Reactive Oxygen Species 
rp Ribosomal proteins 
RQ Relative Quantification 
RTCs Respiratory Tract Cancers 
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RTX Raltitrexed 
SABR Stereotactic Ablative Radiotherapy 
SAH S-adenosylhomocysteine 
SAHA Suberoylanilide Hydroxamic Acid 
SAM S-adenosylmethionine 
SCC Squamous Cell Carcinoma 
SCLC Small Cell Lung Cancer 
shRNA Short hairpin RNA 
shRNA Short hairpin RNA 
SINES Short Interspersed Nuclear Elements 
SNP Single Nucleotide Polymorphism 
T/N Tumour/Normal 
TC Typical Carcinoid 
THF Tetrahydrofolate 
TKIs Tyrosine Kinase Inhibitors 
TRAIL Tumour necrosis factor-Related Apoptosis Inducing Ligand 
TSGs Tumour Suppressor Genes 
UNG Uracil DNA glycosylase 
VNTR Variable Number Tandem Repeat 
VPA Valproic Acid 
ΔCt Delta Cycle threshold 
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Chapter 1: Introduction 
Respiratory tract cancers (RTCs) include lung and head and neck carcinomas, which, 
combined, represent the highest incidence and mortality rates among cancers world-wide. 
Almost 2.72 million people (representing 21% of all cancer cases) are affected, demonstrating 
a combined mortality rate of 28% of all cancer related deaths (Marcus et al. 2013). 
1.1 Lung cancer 
Lung cancer is one of the most life threatening medical conditions worldwide. For several 
decades, it has been the most common cancer in the world (Ferlay et al. 2015). In the UK 
(Figure 1.1), lung cancer is the third most commonly diagnosed cancer, accounting for 13% of 
all new cases. It has the second highest incident rate in males after prostate cancer with 
24,769 diagnosed in 2014. While in females the figures are different; lung cancer has the 
second highest incidence rate following breast cancer with 21,634 new cases observed in the 
year 2014. The male: female ratio is around 11:10 (Cancer Research UK, 2014).  
 
Figure 1.1: Incidence rates of the most frequently diagnosed cancers for the year 2014 in the UK. 
Number of cases includes both sexes. Taken from Cancer Stats, CRUK website (2014). 
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Lung cancer is by far the leading cause of cancer-related death worldwide. The lung 
cancer mortality rates are more than that of colon, prostate and breast combined 
(Marcus et al. 2013).  In the UK, also, it was the most common cause of cancer 
related death with 35,900 deaths in 2014  accounting for 22% of all cancer deaths 
in that year (Figure 1.2). The mortality rate is higher in males (19,600 deaths) 
compared to females, with around 16,300 deaths in the UK. (Cancer Research UK, 
2014). 
 
Figure 1.2: Mortality rates for the most common causes of cancer-related death for the year 
2014 in the UK. Number of deaths includes both sexes. Taken from Cancer Stats, CRUK website, 
2014. 
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1.1.1 Histological classification of lung cancer 
The histological classification of lung cancer is very important, as it determines to a high 
degree the therapeutic and prognostic implications of the disease.  Lung cancer is divided into 
three main categories: non-small cell lung carcinomas (NSCLC), small cell lung cancer (SCLC) 
and carcinoid tumours (Davidson et al. 2013). NSCLC is further divided into three major 
subgroups: adenocarcinoma, squamous cell carcinoma and large cell carcinoma. The 2015 
World Health organisation (WHO) Classification of lung cancer is shown in Table (1.1) (Travis 
et al. 2015).  
1.1.1.1 Adenocarcinoma 
Adenocarcinoma is the most frequent histological subtype of NSCLC. It is a quite 
heterogeneous peripheral pulmonary tumour (Figure 1.3) and the prognosis primarily 
depends on several factors including histological subtype, molecular profile, type of surgical 
resection and tumour size (Beasley, Dembitzer, & Flores, 2016). The different histological 
subtypes of adenocarcinomas are shown in (Figure 1.3)(Cagle 2010).  
  
 
 
  
 
Figure 1.3: Histological presentation of acinar adenocarcinoma (left) and Papillary 
adenocarcinoma (right). Taken from Cagle (2010). 
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Table 1. 1: 2015 WHO Classification of malignant epithelial lung tumours. Taken from Travis et al. 
(2015). 
 Adenocarcinoma  Other and unclassified carcinomas  
     Lepidic adenocarcinoma                                                                                                                         
     Acinar adenocarcinoma 
     Lymphoepithelioma-like carcinoma                                                                                                   
     NUT cell tumour 
      Papillary adenocarcinoma   Salivary  gland-type tumours    
       Micropapillary adenocarcinoma       Mucoepidermoid carcinoma 
       Solid adenocarcinoma        Adenoid cystic adenoma 
       Invasive mucinous adenocarcinoma     
            Mixed invasive mucinous and  
            nonmucinous adenocarcinoma 
       Colloid adenocarcinoma 
       Foetal adenocarcinoma 
       Enteric adenocarcinoma 
       Minimally invasive adenocarcinoma 
             Nonmucinous 
             Mucinous 
       Preinvasive lesions 
              Atypical adenomatous 
hyperplasia 
              Adenocarcinoma insitu 
                  Nonmucinous  
                  Mucinous 
   Squamous cell carcinoma 
      Keratinising squamous cell  carcinoma                   
        Non-keratinising squamous cell 
        carcinoma 
        Basaloid squamous cell carcinoma 
        Preinvasive lesions 
              Squamous cell carcinoma insitu 
Neuroendocrine tumours 
    Small cell carcinoma 
        Combined small cell carcinoma 
    Large cell neuroendocrine carcinoma 
         Combined large cell neuroendocrine 
          carcinoma 
   Carcinoid tumours 
         Typical carcinoid tumours 
         Atypical carcinoid tumours 
   Preinvasive lesions 
         Diffuse idiopathic pulmonary           
       Epithelial-myoepithelial carcinoma    
       Pleomorphic adenoma 
       Papilloma 
          Squamous cell papilloma 
               Exophytic 
               Inverted 
           Glandular papilloma 
           Mixed squamous and glandular papilloma 
        Adenomas 
            Sclerosing pneumocytoma 
            Alveolar adenoma 
            Papillary adenoma 
            Mucinous cystadenoma 
            Mucous gland adenoma 
    
         
         
         
         
               
     
        
     
        
           
    
          
         
   
                  
         neuroendocrine cell hyperplasia 
  Large cell carcinoma 
  Adenosquamous carcinoma 
  Sarcomatoid carcinomas 
         Pleomorphic carcinoma 
         Spindle cell carcinoma 
         Giant cell carcinoma 
         Carcinosarcoma 
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1.1.1.2 Squamous cell carcinoma  
Squamous cell carcinoma (SCC) is the second most common type of malignant lung tumour 
after adenocarcinoma. The typical presentation of squamous cell carcinoma involves a central 
endobronchial mass with haemoptysis, obstructive pneumonia or lobar collapse. Distant 
metastasis usually appears later in the course of the disease (Collin et al. 2007). Well-
differentiated SCC is characterised by keratinisation with pearl formation and intracellular 
bridges, however, these features are usually lost in poorly differentiated SCCs. (Figure 
1.4)(Drilon et al. 2012). 
 
 
  
  
 
 
 
 
 
Figure 1.4: Squamous cell carcinoma of lung. A-Keratinising, B-Non-Keratinising subtypes. 
Taken from Drilon et al. (2012). 
A B 
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1.1.1.3 Large cell carcinoma 
Large cell carcinomas (LCCs) are a heterogeneous group of lung neoplasms that lack the 
morphological features of adenocarcinoma, squamous cell carcinoma or small cell lung 
cancer, thus being referred to as a diagnosis of exclusion (Barbareschi et al. 2011). These 
poorly differentiated tumours often have a peripheral location, although they may also arise 
centrally. LCCs tend to be large partially necrotic tumours, composed of nests of large 
polygonal cells with vesicular nuclei and prominent nucleoli (Figure 1.5) (Travis et al. 2004). 
       
Figure 1.5: Large cell carcinoma of lung. The tumour is often large and partially necrotic (A) and 
composed of patternless nests of polygonal cells with no obvious histological differentiation. Taken 
from Travis et al. (2004).   
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1.1.1.4 Small cell carcinoma 
Small cell lung cancer (SCLC) is a highly aggressive tumour with neuroendocrine properties 
and early development of metastasis (Gustafsson et al. 2008). It has a central location in the 
majority of cases (Davidson et al. 2013). The tumour cells are characteristically small with 
distinctive cytological features like an oval-shaped nucleus, scanty cytoplasm and fine 
granular chromatin (Figure 1.6)(Travis et al. 2004). SCLC has the highest association with 
cigarette smoking compared to other types of lung cancer (Tartarone et al. 2017). Generally, 
the prognosis is very poor with a median survival of less than 12 months in case of extensive 
SCLC (Gaspar et al. 2012). 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6: Small cell lung carcinoma with typical scanty cytoplasm and hyperchromatic nuclei 
at A- low  B- high magnification. Taken from Davidson et al. (2013). 
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1.1.1.5 Carcinoid lung tumours 
Lung carcinoids are rare neuroendocrine tumours arising from pulmonary neuroendocrine 
cells (PNECs)(Filosso et al. 2014). They include heterogeneous groups of malignancies that 
range from the well-differentiated low grade typical carcinoids (TC) and the intermediate 
grade atypical carcinoids (AC) to the poorly differentiated high grade large cell 
neuroendocrine carcinomas (LCNEC) and small cell lung carcinomas (SCLC)(Caplin et al. 2015). 
Histologically, TCs are characterised by their distinctive trabecular growth pattern as a highly 
vascularised stroma, while the punctuated necrotic (Comedo-like) appearance is the 
predominate feature of ACs (Figure 1.7)(Rekhtman, 2010). 
 
 
Figure 1.7:  Low grade pulmonary carcinoids. A-Typical Carcinoid and B-Atypical Carcinoid. Taken from 
Rekhtman (2010). 
 
 
 
 
 
A B 
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1.1.2 Risk factors 
The single most important risk factor for lung cancer is cigarette smoking (Furrukh 2013) . 
Smokers risk of developing lung cancer is estimated to be on average 10-fold higher than that 
of non-smokers. Although the overall aim in any lung cancer prevention strategy is to stop 
smoking, former smokers still have the potential to develop lung cancer years after breaking 
their cigarette habit (Szabo et al. 2013). In addition to tobacco smoking, important risk factors 
for lung cancer include age, male gender, a previous history of chronic obstructive pulmonary 
disease, a family history of early onset lung cancer and other malignancy elsewhere. All these 
factors are included in the Liverpool Lung Project Risk Projection Model for Lung Cancer 
Incidence (LLPi)(M. W. Marcus, Chen, Raji, Duffy, & Field, 2015) and are used currently in the 
UK lung cancer screening trial  (UKLS) to identify individuals at high risk of lung cancer that 
would benefit from a low dose computed tomography (LDCT) scan (Brain et al. 2017).  
There are also several lines of evidence suggesting that genomic susceptibility has the 
potential to modulate lung cancer risk. Genome wide association studies (GWAS) have 
reported certain loci to be associated with inherited patterns of lung cancer (Amos et al. 2008; 
Hung et al. 2008). 
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1.1.3 Therapeutic intervention in lung cancer 
1.1.3.1 Surgery 
Although not all lung carcinomas are operable at the time of presentation, surgery is still 
considered to be the cornerstone in the efficient treatment of lung cancer (Baltayiannis et al. 
2013). Surgical resection remains the treatment of choice for patients with localised NSCLC 
(Cortés et al. 2015). The 5-year survival rates for stage I and stage II NSCLC patients treated 
with complete resection are between 60-80% (Baltayiannis et al. 2013). Due to the rapid 
development and early metastasis of SCLC, pulmonary resection alone is rarely an option, 
although a small minority of cases with limited disease may benefit from a combination of 
surgery and chemotherapy (Inoue et al. 2012; Veronesi et al. 2015).  
1.1.3.2 Radiotherapy 
Radiotherapy plays a major role in treating inoperable lung cancer patients, for instance 
elderly patients or those with cardiovascular problems (Oshiro & Sakurai, 2013). Another 
indication for radiation is widely metastasized incurable tumours, in which radiotherapy is 
mainly palliative (Shultz et al. 2014). More than 50% of lung cancer patients receive radiation 
therapy at some point during their treatment course. The ultimate goal of radiotherapy is to 
achieve a high rate of tumour control with minimal damage to the nearby normal tissue 
(Oshiro & Sakurai, 2013). Several irradiation techniques such as three-dimensional conformal 
radiotherapy (3DCRT) and intensity-modulated radiotherapy (IMRT) have been used in lung 
cancer. Moreover, Stereotactic ablative radiotherapy (SABR) has been approved as a standard 
care option for inoperable peripheral early stage NSCLC and has shown relatively high local 
tumour control (Hurst & Chetty 2014). 
24 
1.1.3.3 Chemotherapy 
Several chemotherapeutic schemes are applied for the treatment of SCLC patients with both 
limited and extensive-stage disease, bur most patients relapse, despite initial responsiveness, 
because of the aggressiveness of the tumour and its metastasis at time of presentation 
(Arcaro 2015). Chemotherapeutic drugs have a significant role in the management of NSCLC, 
including being utilised either as neoadjuvant therapy (before surgery) or as adjuvant therapy 
(after surgery). While using adjuvant or neoadjuvant chemotherapy is still controversial, 
postoperative chemotherapy has become the regimen of choice in clinical practice (Cortés et 
al. 2015; McElnay & Lim 2014). The most common chemotherapeutic agents available for lung 
cancer treatment include: (i) Antimetabolites such as pemetrexed and methotrexate 
(Tomasini, Barlesi, Mascaux, & Greillier, 2016); (ii) Antimitotic drugs such as paclitaxel (Ferrara 
et al. 2016) and  (iii) organometallics, for instance cisplatin (Fennell et al. 2016).  
1.1.3.4 Targeted therapy 
Novel approaches have been developed for the treatment of cancer patients over the last few 
years. The discovery of new generations of targeted therapies has revolutionised the 
management strategy for certain types of cancer including advanced NSCLC (Czarnecka-
Kujawa & Yasufuku 2014; Hurvitz et al. 2014) . Several types of targeted therapy are available, 
including monoclonal antibodies, tyrosine kinase inhibitors and growth factor inhibitors 
(Arora & Scholar 2005). The most important molecular target in NSCLC is epidermal growth 
factor receptor (EGFR) mutation. EGFR-tyrosine kinase inhibitors (TKIs) have dramatically 
improved treatment outcomes in NSCLC patients harbouring these mutations (Milano 2015).  
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1.2 Head and Neck Squamous Cell carcinoma  
The majority of head and neck malignancies (~90%) are squamous cell carcinomas (HNSCC), 
arising from the epithelial linings of the oral cavity, pharynx and larynx (Vigneswaran & 
Williams 2014). 
1.2.1 Incidence and mortality 
Worldwide, head and neck cancers represent the sixth most frequent cancers with around 
630,000 new cases reported annually causing more than 350,000 deaths every year 
(Vigneswaran & Williams 2014). In the UK, head and neck cancers represent the eighth most 
commonly diagnosed cancer (accounting for 3% of cancer incidence) with 11,449 new cases 
reported in 2014 (7,918 males and 3,531 females)(Figure 1.1). Moreover, the mortality from 
several types of head and neck cancers was 3704 deaths in year 2014 in the UK. The figures 
are higher in men with 2604 cases compared to women with 1100 cases (Figure 1.2) (Cancer 
Research UK, 2014). 
 
1.2.2 Risk factors  
1.2.2.1 Tobacco and alcohol 
Cigarette smoking and heavy alcohol consumption are the most important predisposing 
factors for HNSCC carcinogenesis (Lacko et al. 2014). More than moderate alcohol 
consumption appears to increase risk of HNSCC particularly cancers of larynx, oropharynx and 
hypopharynx. Alcohol has also been shown to act in a synergistic way with tobacco smoke 
resulting in magnifying the latter effects (Pai & Westra 2009). Furthermore, genetic 
predisposition may have a significant role in HNSCC pathogenesis, since even among heavy 
smokers, only a small proportion will eventually develop HNSCC (Lacko et al. 2014). 
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1.2.2.2 Human papilloma virus 
Human papilloma virus (HPV) is an important independent risk factor for HNSCC, particularly 
oropharyngeal squamous cell carcinoma (OPSCC)(Gillison et al. 2000). HPV infection, 
specifically with the high risk HPV type 16, has been found to play a significant role in the 
tumourigenesis of OPSCC, often with distinct molecular and clinical criteria (Gillison et al. 
2008; Ang et al. 2010; Ndiaye et al. 2014). Interestingly, several studies have shown that HPV 
positive OPSCC patients have a better prognosis than those with HPV negative smoking 
related cancers, despite using the same therapeutic intervention (Vigneswaran & Williams 
2014; Marur & Forastiere 2016).  
 
1.2.3 Histological description 
HNSCCs present a spectrum of histopathological patterns that often develop through 
multistep processes and are governed by certain genetic and epigenetic alterations 
progressing from precancerous lesions, through to dysplasia and thence to the full-blown 
picture of HNSCC (BOŽENA 2016). Disappointingly, the disease is well documented to be 
highly associated with the development of second tumours, mainly in the lungs, oesophagus, 
or other parts of the head and neck according to what is called field cancerisation (Leemans 
et al. 2011). Several histological subtypes of HNSCC have been recognised, some of them have 
distinctive clinical and molecular features correlating with specific risk factors (Figure 1.8), 
these include: Human Papilloma virus associated squamous cell carcinoma (Figure 1.8A), 
Spindle cell carcinoma which is strongly associated with tobacco smoking and alcohol (Fig 
1.8B) and Epstein-Barr virus (EBV) associated squamous cell carcinoma (Figure 1.8C) (Shah et 
al. 2014). 
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1.2.4 Therapeutic Interventions  
Therapeutic strategies for HNSCC basically depend on the stage and anatomical location of 
the tumour (Vermorken et al. 2008; Aung & Siu 2016). For early stage disease, a single 
modality treatment approach is often used with surgery or radiotherapy (Vermorken et al. 
2008). Unfortunately, HNSCCs demonstrate highly malignant phenotypes and the majority of 
patients present clinically with locoregionally advanced disease (LA-HNSCC)(Pulte & Brenner 
2010; Koontongkaew 2013; Safdari et al. 2014). For the best oncologic results, a 
multidisciplinary treatment regimen is required to manage advanced HNSCCs. In this setting, 
a combination of chemotherapy with radiotherapy or surgery is often used; however, 
concurrent cisplatin-based chemo-radiotherapy is the gold standard approach for controlling 
LA-HNSCC (Forastiere & Trotti 1999; Vermorken et al. 2008; Aung & Siu, 2016). Patients with 
recurrent and/or metastatic (R/M) HNSCC are not amenable to curative treatment and the 
therapeutic goal in this situation is mainly palliation. Platinum based chemotherapy is the 
cornerstone of palliative treatment, either as a single or combined chemotherapy and the 
most active paradigm of systemic palliative therapy is composed of platinum (cisplatin or 
Figure 1 .8: Histological types of HNSCC (A) HPV associated HNSCC, (B) Spindle cell carcinoma, (C) 
Epstein Bar virus associated HNSCC. Taken from Shah et al. (2014). 
A B C 
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carboplatin) plus fluorouracil or taxanes (Sacco & Cohen 2015). Despite providing some 
benefit to R/M HNSCC disease patients, the toxicity of platinum based-combination therapy 
is higher than that with single agent chemotherapy and the prognosis remains dismal (Colevas 
2006; Bernier et al. 2009).  Recently, cetuximab, a chimeric monoclonal antibody directed 
against epidermal growth factor receptor (EGFR) has demonstrated some survival benefit in 
combination with platinum based therapy or as a single agent in platinum refractory patients 
(Vermorken et al. 2008; Price & Cohen 2012). So far, however, the EGFR inhibitors are the 
only targeted drugs to be approved and routinely used in the treatment of head and neck 
carcinomas (Rieke et al. 2016). 
1.3 Folate metabolic pathway and cancer 
1.3.1 Folate chemistry 
In 1931, Lucy Willis, an honorary consultant pathologist at the Royal Free Hospital, made her 
discovery of a factor in yeast (Willis factor) that she used to treat pregnant women with 
megaloplastic anaemia (Wills 1931). A few years later, this Willis factor was recognised to be 
folate (Mitchell et al. 1941). 
Folates are essential micronutrients, and include a group of water soluble B-vitamins 
occurring naturally in foods and as a synthetic form (folic acid). Folate encompasses a family 
of chemical compounds that have a similar core structure; the parent of this family is folic 
acid, which is the fully oxidised synthetic form of folates (Scaglione & Panzavolta 2014), and  
is composed of pteridine ring, para-amino benzoic acid (PABA) and glutamic acid (Figure 
1.9)(Gazzali et al. 2016). Folic acid by itself, however, is biologically inactive and needs to be 
activated through several cellular metabolic steps to be reduced into dihydrofolate (DHF) and 
then converted to the metabolically active form tetrahydrofolate (THF)(Ducker & Rabinowitz 
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2016).  
 
1.3.2 Folate Metabolism and transport 
Humans do not have the ability to synthesise folates. Instead, they primarily depend on 
intestinal absorption from nutritional sources, mainly green leafy vegetables, oranges and 
livers in the form of polyglutamates (Liu & Ward 2010; Scaglione & Panzavolta 2014). To be 
absorbed from the intestinal lumen, dietary polyglutamates must be converted into 
monoglutamates by the action of intestinal mucosal and the brush border gammaglutamyl-
carboxypeptidase enzyme. Unlike dietary folates, folic acid is well absorbed from the intestine 
without deconjugation of the polyglutamate forms. The most efficient absorption of folates 
occurs primarily in the proximal small intestine (jejunum) at the cell surface acidic 
microenvironment by a carrier mediated, pH-dependent mechanism. Following enterocyte 
uptake, absorbed folate is biotransformed into 5-methyTHF, and then transported by the 
mesenteric vein to the portal circulation in order to be released in the liver and subsequently 
delivered to peripheral tissues via systemic circulation as polyglutamated folates (Figure 
1.10)(Kim 2007a; Liu & Ward 2010).  
Figure 1.9:  Molecular structure of folic acid. Taken from Gazzali et al. (2016). 
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Figure 1.10: Folate absorption and transport. Taken from  Liu & Ward (2010). 
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1.3.2.1 Cellular folate transporters 
Folates are hydrophilic negatively charged molecules and therefore only have minimal ability 
to permeate the plasma membrane through passive diffusion. Instead, specific uptake 
systems are required for intestinal absorption and delivery of folate cofactors into the 
peripheral tissues (Zhao et al. 2013). To date, three folate specific transporters are known to 
facilitate folate cellular entry: (i) Reduced folate carrier (RFC) (ii) Proton coupled folate 
transporter (PCFT) and (iii) Folate receptors (FRs). RFC is the major folate transporter from 
blood to the peripheral tissues, relying on a bidirectional ion exchange mechanism to transfer 
folates across the plasma membrane. While FRs utilise endocytotic mechanism to facilitate 
folate cellular entry (Liu & Ward 2010). PCFT, the crucial transporter for intestinal folate 
absorption, functions as a unidirectional symporter, transporting folate as well as protons into 
cells (Qiu et al. 2006). The structural analogues of natural folate compounds (antifolate drugs) 
utilise folate transport systems in a similar way to enter the cell and produce their 
pharmacological effect; for example, RFC has been implicated as the primary transporter for 
methotrexate (MTX), raltitrexed (RTX) and pemetrexed (PEM) in both normal and neoplastic 
tissues (Matherly et al. 2007; Gonen & Assaraf 2012). RCF-mediated transport of MTX has 
been extensively documented as an important parameter for determining MTX inhibitory 
effect. Further, impaired MTX uptake by RFC results in drug resistance in several malignancies 
including ALL and osteogenic sarcoma (Zhao et al. 2003; Matherly et al. 2007; Gonen & 
Assaraf 2012). Although pemetrexed is an excellent substrate for both RFC and PCFT, it has 
shown higher affinity for the PCFT mechanism as a means to enter into tumour cells (Zhao et 
al. 2008). 
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1.3.3 Folate mediated one carbon metabolism 
Folate-mediated one carbon metabolism (FOCM) is a complex network of interconnected 
metabolic pathways. Although it is highly compartmentalised, occurring mainly in the cytosol, 
nucleus and mitochondria, there is an interdependence of one carbon transfer reactions 
between these different cellular regions (Desai et al. 2016). Within the folate metabolic 
network, folate molecules function to activate and transfer one-carbon units obtained from 
amino acid catabolism (serine, glycine and methionine) for crucial cellular biological processes 
including methylation reactions, nucleotide biosynthesis and thymidylate and amino acid 
metabolism (Fox & Stover 2008). While mitochondrial derived formate provides the major 
supply of one carbons for cytosolic and nuclear FOCM (Fox & Stover 2008; Tibbetts & Appling 
2010), direct cytoplasmic serine catabolism can be another source of one carbon moiety 
through the activity of cytosolic serine hydroxymethyltransferase 1 enzyme (SHMT1), which 
catalyses the conversion of serine to glycine and the formation of 5,10-methyleneTHF (Fox & 
Stover 2008; Ducker et al. 2016). Before entering the folate cycle, folic acid passes through a 
series of chemical transformations in order to be reduced to dihydrofolate, and then to the 
metabolically active form THF in a reaction catalysed by the critical enzyme dihydrofolate 
reductase (DHFR). At that point, the one-carbon groups can be carried at N-5 and N-10 
positions of THF with different covalent bonds formed between (one-carbon), units and these 
nitrogen atoms giving rise to different folate coenzymes, these include 5,10-methylene THF, 
5-methyl THF, 5-formyl THF and 10- formyl THF (Liu & Ward, 2010; Ducker et al. 2016). Each 
of those has specific biological roles except 5-formyl THF; instead, it functions as a (one-
carbon) reservoir. Interestingly, the intracellular folate metabolism is at the branch of two 
metabolically interconnected pathways; thymidylate synthesis and homocysteine 
remethylation (Scaglione & Panzavolta, 2014). Hence, several drugs targeting folate 
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metabolising enzymes (Figure 1.11) have taken advantage of folates critical role in 
maintaining cellular growth and proliferation such as 5-FU, MTX and pemetrexed (Figure 
1.11)(Robien et al. 2005).  
  
    
 
 
 
 
 
 
Figure 1.11: Graphic representation of part of the folate metabolic pathway illustrating 
its connections with the thymidylate biosynthesis pathway and the homocysteine 
metabolic pathway. Folate genes are shown as red ovals while yellow boxes denote 
folate targeting drugs. 
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1.3.3.1 Biochemistry of folate mediated one carbon metabolism 
The one carbon transfer performed by folate coenzymes plays an important role in the 
fundamental cellular processes such as nucleotide biosynthesis and methylation reactions 
(Chon, Stover, & Field, 2017). 5,10 methylene THF has been implicated as the key player that 
is required for these important biosynthetic pathways (Ducker et al. 2016). Intracellular 
folates exist in numerous functionally distinct but metabolically interrelated pools (Figure 
1.12)(Liu & Ward 2010). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Thymidylate biosynthesis  
Folate dependent de novo thymidylate biosynthesis is catalysed by the thymidylate synthase 
enzyme (TYMS), which uses 5,10 methylene THF as a cofactor to methylate deoxyuridine 
monophosphate (dUMP) into deoxythymidine monophosphate (dTMP), resulting in oxidation 
Figure 1.12: Folate metabolic pathway with the main intracellular folate 
pools. Taken from Liu & ward (2010).  
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of the THF into DHF. Moreover, thymidylate synthesis is a rate limiting reaction for nucleotide 
synthesis and for maintaining the balanced pool of dNTPs pool that is crucial for DNA synthesis 
and repair (Lucock 2000). Given the importance of the thymidylate biosynthesis pathway, 
drugs targeting it, such as 5-FU, pemetrexed and RTX have had a significant impact on cancer 
treatment (Wright & Anderson 2012).  
Purine biosynthesis  
10-formyl THF plays an important role in purine synthesis by donating two one carbon groups 
to the purine ring at 2 and 8 carbon atoms positions. Two enzymes are required to perform 
this chemistry; glycinamide ribonucleotide transformylase (GAR Tfase) and 
aminoimidazolecarboxamide ribonucleotide transformylase (AICAR Tfase)(Scotti et al. 2013;  
Ducker & Rabinowitz 2016).  
Methyltransferase reaction 
The 5,10-methylene THF is reduced into 5-methyl THF by the cytosolic NADPH dependent 
methylene tetrahydrofolate reductase (MTHFR) enzyme. Then, the unique cellular fate of the 
most reduced folate form (5-methylTHF) is the synthesis of methionine (MET) from 
homocysteine (HCY) within the homocysteine remethylation cycle (Mudd et al. 2007). The 
HCY metabolic pathway has a significant physiological importance because it produces MET, 
the critical amino acid for protein synthesis initiation. Furthermore, MET is the precursor of 
S-adenosylmethionine (SAM), a general methyl group donor for the most important 
biochemical cellular reactions, including methylation reactions of RNA, phospholipids and 
chromatin (CpG islands in DNA and histone proteins)(Scotti et al. 2013). For instance, SAM is 
the substrate for DNA methyltransferases, which convert it into S-adenosylhomocysteine 
(SAH) after the transfer of methyl group to an acceptor substrate. SAH, in turn, is hydrolysed 
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by a SAH hydrolase enzyme into adenosine and HCY (Mentch & Locasale 2016). To this end, 
HCY is located at the branch point of the pathway, so it is either degraded into cysteine and 
cystathionine through the transsulfuration pathway or remethylated back to MET by 
methionine synthase (MS) enzyme (Stead et al. 2004; Mentch & Locasale 2016).    
 
Unsubstituted folates 
Unsubstituted folates include DHF and THF folate molecules. They do not have a direct 
contribution in the folate metabolic pathway but instead, receive one carbon units and 
transfer them towards either DNA biosynthesis or methylation processes. The MTX antifolate 
drug is an irreversible inhibitor of DHFR which is required for the reduction of folic acid and 
DHF into THF, thereby, inhibiting both nucleotide synthesis and methylation reactions (Liu & 
Ward 2010). 
1.3.4 Deregulation of the folate metabolic pathway in human cancer 
Given the metabolic importance of folate in maintaining genomic stability by regulating DNA 
synthesis, repair and methylation, folate depletion can have a potential role in promoting 
carcinogenesis. Further, folate deficiency has been associated with the development of 
pancreatic, breast, cervical, oesophageal, colorectal and gastric cancers (Choi & Mason 2000). 
Limited dietary folate affects normal cellular proliferation and accelerates tumourigenesis 
through several mechanisms (Figure 1.13)(Liu & Ward, 2010; Duthie, 2011), including: 
            (i)     Impairment of thymidylate synthesis.   
            (ii)     Impairment of purine synthesis.  
      (iii)   Alteration of DNA methylation.  
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Figure 1.13: Consequences of folate depletion. Taken from Duthie (2011). 
 
 
1.3.4.1 Impairment of DNA synthesis and repair  
Low availability of 5,10-methylene THF retards thymidylate biosynthesis and results in the 
misincorporation of uracil into DNA instead of thymidine, which is normally removed by DNA 
repair enzymes. This creates a temporary single strand break in the DNA. If folate limitation 
continues, the cycle of DNA break and repair is continuously repeated and ultimately results 
in a double strand break in the DNA, chromosomal instability and cellular transformation 
(Blount et al. 1997). Excessive uracil content and double strand breakage of DNA have been 
demonstrated in folate deficient cultured tumour cells of human tissues and blood (Beetstra 
et al. 2005; Duthie et al. 2008).  Likewise, reduced dietary folate perturbs de novo purine 
synthesis leading to alteration of purine and pyrimidine precursors balance and inhibiting 
normal DNA repair activity. Impaired dNTPs synthesis due to folate deficiency has been 
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suggested as inducing chromosomal aberration in vitro. Cultured cells grown in a folate-
depleted media exhibit different patterns of chromosomal breaks, whereas, cells cultured in 
hypoxanthine supplemented folate deficient medium (hypoxanthine is a purine precursor 
that bypasses the need for folate in purine synthesis) demonstrate significantly less 
chromosomal damage (Libbus et al. 1990). 
1.3.4.2 Alteration of DNA methylation 
Folate deficiency has been associated with an aberrant DNA methylation pattern (Kim 
2007).Specifically. Reduced availability of one carbon moieties leads to an attenuation of the 
homocysteine remethylation cycle, resulting in accumulation of homocysteine and inhibition 
of DNA methytransferases with subsequent DNA hypomethylation (Yi et al. 2000), disruption 
of gene regulation, protocogene activation and chromosomal instability (Duthie 2011). 
Moreover, the DNA damaging effect of folate depletion also includes regional promotor 
hypermethylation of specific genes, mainly tumour suppressor genes (James et al. 2003; 
Arasaradnam et al. 2008)   
 
 
 
 
 
 
 
 
 
39 
1.4 Molecular pathogenesis of lung cancer 
The malignant transformation of normal lung cells passes through an orchestrated multistep 
process driven by several permanent genetic mutations, mainly point mutation, deletion and 
translocation, as well as dynamic epigenetic alterations, including abnormal DNA 
methylation, histone modification, chromatin remodelling and micro RNAs (mRNAs) ( Risch & 
Plass 2008; Langevin et al. 2015). As in all types of cancer, the accumulation of these genetic 
and epigenetic changes gives rise to dysregulation of growth-promoting oncogenes and 
growth-suppressing genes and ultimately results in the initiation and progression of lung 
cancer (Figure 1.13) (Hanahan & Weinberg 2011; Mehta et al. 2015). 
1.4.1 Lung Cancer Genetics 
It is widely acknowledged that genetic aberrations are the key events in triggering lung 
carcinogenesis, affecting both oncogenes and tumour suppressor genes (Risch & Plass 2008; 
Cooper et al. 2013). Oncogenic activation of growth-promoting genes has been observed in 
>50% of adenocarcinoma subtypes of NSCLC (Yip et al. 2013). 
1.4.1.1 Proto-oncogene activation 
 Genomic studies have identified the most frequently activated oncogenes in lung cancer 
including KRAS, one of RAS proto-oncogene family which encodes RAS proteins involved in 
regulation of cellular proliferation, differentiation and survival through controlling signal 
transduction pathway (Schubbert et al. 2007). KRAS mutation occurs in approximately 20% of 
all NSCLCs, most commonly in adenocarcinomas (25-40%)(Cooper et al. 2013). Interestingly, 
KRAS mutant NSCLC cell lines have shown a high level of dependency on folate metabolic 
pathway in vivo with enhanced response to pemetrexed and MTX antifolate drugs compared 
with wild-type ones (Moran et al. 2014). Deregulation of EGFR that encodes a transmembrane 
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tyrosine kinase is also involved in the pathogenesis of lung cancer (Fenizia et al. 2015). Active 
mutation of EGFR has been reported in 10-35% of NSCLC patients (Califano et al. 2015). Along 
with EGFR, human epidermal growth factor receptor 2 HER2 gene is frequently activated in 
lung carcinomas. HER2 gene amplification occurs in 20% of NSCLC cases and is also associated 
with poor outcome and short survival (Heinmöller et al. 2003). Other less frequent activated 
oncogenes that have been reported in lung cancer include BRAF (Schmid et al. 2009), 
MET(Engelman et al. 2006)  and ALK  (Choi et al. 2008). 
 
1.4.1.2 Tumour suppressor genes inactivation  
Tumour suppressor genes (TSGs) are crucial for regulating normal cell growth; hence, 
inactivation of TSGs is an essential mechanism for tumour initiation and progression (Cooper 
et al. 2013). TP53 is one of the most notable tumour suppressor genes that plays a 
fundamental role in tumourigenesis (Gibbons et al.2014). The TP53 gene encodes a critical 
transcription factor that regulates the expression of various genes involved in DNA repair, cell 
cycle progression and apoptosis. Levels of p53 proteins are induced in response to a variety 
of stress signals including hypoxia, DNA damage and oncogenic activation (Flöter et al. 2017). 
Consequently, p53 response triggers different types of cellular protective reactions including 
cell cycle arrest, DNA repair, senescence or apoptosis (Lazo 2017). TP53 inactivating 
mutations have been implicated as the most significant genetic events in lung cancers (Cooper 
et al. 2013). Mutations mainly occur in SCLCs (70-80%) and to lesser extent in NSCLCs (50%) 
of cases, being more frequent in squamous cell carcinomas than adenocarcinomas (Campling 
& el-Deiry 2003; Viktorsson et al. 2005).  
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RB1 is another tumour suppressor gene that is widely disturbed in lung cancer and mostly 
altered by small deletion, splicing abnormalities and non-sense mutation and has been 
reported in more than 90% of SCLCs and 20-30% of NSCLCs (Osada & Takahashi 2002).  
Less frequent tumour suppressor inactivated genes in lung cancer include the LKB1 whose 
encoded protein (a serine-threonine kinase) is involved in regulation of important cellular 
biological process such as cell polarity, cell cycle, chromatin remodelling and energy 
metabolism (Marignani 2005). LKB1 inhibition occurs in 11-30% of adenocarcinomas through 
a range of somatic mutation and deletion (Parrella et al. 2002; Matsumoto et al. 2007). In 
addition, inhibition of the PTEN tumour suppressor gene is seen in only 5% of NSCLCs and 
more frequently in squamous cell carcinoma than adenocarcinoma patients (Jin et al. 2010). 
 
1.4.1.3 Deregulation folate pathway genes and cancer 
Folate is an essential nutrient for preserving genomic stability and DNA methylation. 
Consequently, deregulation of folate pathway genes might influence cancer risk. Several 
studies have shown that variation in particular folate genes could be associated with lung 
cancer risk, including methylenetetrahydrofolate reductase (MTHFR) (Shen et al. 2005; Liu et 
al. 2008; Piskac-Collier et al. 2011), thymidylate synthase (TYMS) (Shi et al. 2005; Liu et al. 
2008), serine hydroxymethyl transferase 1 (SHMT1) (Wang et al. 2007), and cystathionine 
betasynthase (CBS) (Shen et al. 2005). 
 
1.4.1.3.1 Serine hydroxymethyl transferase  
Serine hydroxymethyl transferase proteins encoded by SHMT genes have a key role in the 
metabolic reprogramming of cancer cells. It catalyses the interconversion of serine to glycine 
thereby providing the one carbon units for nucleotide biosynthesis and methylation reactions 
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(Paone et al. 2014). Two SHMTs are found in the human genome, cytoplasmic (SHMT1) and 
mitochondrial (SHMT2)(Stover et al. 1977; Garrow et al. 1993; Girgis et al. 1998). SHMT2 
encodes for two transcripts; SHMT2 and SHMT2α. Interestingly, SHMT2α can not be imported 
to the mitochondria, and is thus localised mainly in the cytoplasm and nucleus together with 
SHMT1. The main function of SHMT2 is supporting cytosolic one carbon metabolism 
(Anderson & Stover 2009). The cytosolic isoform serine hydroxymethyl transferase1 that is 
encoded by SHMT1 gene is an important player in maintaining cell proliferation by using 
serine to generate cytosolic 5,10-methylene-THF; with the latter is poised to perform all the 
major cellular physiological tasks of 1C groups including thymidine synthesis, methylation 
reaction and purine biosynthesis (Ducker et al. 2016). SHMT1 is frequently deregulated in 
several types of cancers (Both et al. 2012; Davidson et al. 2014; Kim et al. 2014; Gupta et al. 
2017) including lung cancer (Paone et al. 2014; Wu et al. 2016); probably because of its crucial 
role in sustaining one carbon homeostasis for fuelling essential nucleotides and amino acids 
as well as adjusting cellular methylation capacities of the rapidly proliferating malignant cells. 
Interestingly, there is some evidence to suggest that activated SHMT1 may act as a metabolic 
switch which offers high metabolic priority for thymidylate biosynthesis (Herbig et al. 2002; 
Anderson & Stover 2009). Moreover, genetic variants of SHMT1 have been found to be 
associated with increased risk of HNSCC (Zhang et al. 2005) and lung cancer (Wang et al. 
2007). Recently, Paone et al. (2014) demonstrated that SHMT1 knockdown in lung cancer cells 
induces cell cycle arrest and promotes p53 dependent apoptosis, which is caused by uracil 
misincorporation into the genomic DNA during the DNA replication process. Based on these 
findings, SHMT1 might be a promising therapeutic target for the treatment of lung cancer 
patients. 
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1.4.1.3.2  Cystathionine-beta-synthase  
Cystathionine-beta-synthase is a cytosolic enzyme encoded by the CBS gene. It is a member 
of the pyridoxal phosphate PLP dependant family of enzymes that use (PLP) as a coenzyme in 
their reactions (Jhee & Kruger 2005). Cystathionine-beta-synthase enzyme is allosterically 
activated by SAM (Miles & Kraus 2004; Jhee & Kruger 2005). Cystathionine beta-synthase 
catalyses the conversion of homocysteine to cystathionine through the transsulfuration 
pathway (Refsum et al. 2004). In addition to clearing homocysteine, CBS is also involved in 
the production of endogenous biological mediator hydrogen sulphide (H2S), which is a 
tumour growth promoting factor that has been implicated in the pathogenesis of breast and 
ovarian cancer (Bhattacharyya et al. 2013; Sen et al. 2015). CBS expression is tightly regulated 
by transcriptional, post-translational and epigenetic mechanisms in addition to the hormonal 
control. CBS deregulation has been reported in numerous malignancies (Kim et al. 2009; 
Bhattacharyya et al. 2013; Sen et al. 2015; Gai et al. 2016). Moreover, Genomic studies on 
CBS SNPs have demonstrated a potential association between CBS genetic variants and the 
risk of developing lung cancer (Shen et al. 2005). The variant allele, rs2850146 (-8283G > C) 
showed a positive correlation with reduced CBS expression and, elevated levels of 
homocysteine, as well as increasing the liability for gene specific promoter hypermethylation 
in the pulmonary epithelium of smokers (Flores et al. 2012).  
1.4.1.3.3 Thymidylate synthetase  
Thymidylate synthase, the gene product of TYMS is a constitutive enzyme for maintaining 
cellular the dTMP pools essential for faithful DNA replication and repair through the 
methylation of deoxyuridylate into deoxythymidylate in the presence of 5,methyleneTHF as 
a cofactor (Carreras & Santi 1995). Given its importance as the unique source of cellular 
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thymidylate, TYMS has been of interest as a valuable target for several chemotherapeutic 
drugs, including 5-FU, MTX, PEM and RTX (Marsh 2005). High levels of TYMS expression have 
been correlated with resistance to these agents in advanced lung cancer in vivo (Shimizu et 
al. 2012; Wang et al. 2013) and in vitro (Oguri et al. 2005). Moreover, TYMS overexpression 
has been linked with poor outcomes in lung cancers (Grimminger et al. 2010; Ceppi et al. 
2012; Sun et al. 2015). Along with other folate pathway genes, TYMS polymorphisms have 
been identified (Horie et al. 1995). In one case control study, the TS3’UTR variant was 
associated with an increased risk of lung cancer; however, gene-diet interaction evidence may 
necessitate further studies (Shi et al. 2005).   
1.4.1.3.4 Dihydrofolate reductase   
Dihydrofolate reductase enzyme which is encoded by DHFR gene converts the 
polyglutamated folate into tetrahydrofolate which is in turn loaded with the crucial one 
carbon units needed for subsequent cellular reactions (Salbaum & Kappen 2012). Diminished 
dihydrofolate reductase activity contributes to reduction of the cellular THF level and 
ultimately affects purine and pyrimidine synthesis and methylation processes (Askari & 
Krajinovic 2010). Dihydrofolate reductase is targeted by antifolate cancer chemotherapeutics 
including pemetrexed and MTX (Robien et al. 2005). Furthermore, DHFR overexpression is the 
most important mechanism for acquired resistance to these drugs (Ducker & Rabinowitz, 
2016). Genetic studies have suggested that the DHFR genetic variant rs1650697 G>A is 
associated with favourable prognosis in NSCLC and might be a potential candidate biomarker 
in this type of lung cancer ( Jin et al. 2010).  
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1.4.1.3.5 Methylenetetrahydrofolate reductase  
The methylenetetrahydrofolate reductase that is encoded by the MTHFR gene, is the central 
enzyme in folate metabolism and homeostasis. It catalyses the irreversible conversion of 5,10-
methylene-THF into 5-methyl-THF, the one carbon donor in the homocysteine remethylation 
reaction (Scotti et al. 2013). Methylenetetrahydrofolate reductase enzymatic activity is 
affected by several factors such as the potent inhibitor SAM; when present in high 
concentrations, SAM competitively inhibits methylenetetrahydrofolate reductase, affecting 
the flux of methyl group for homocysteine remethylation (Crider et al. 2012). 
Methylenetetrahydrofolate reductase enzymatic activity is also modulated by common 
MTHFR polymorphisms. The C677T MTHFR genetic variant has been reported to divert the 
one carbon group in the direction of the thymidine and purine synthesis pathway away from 
DNA methylation pathway (Quinlivan et al. 2005). Moreover, the most important biological 
effect of C677T mutation is the aberrant DNA methylation pattern, which is an exceedingly 
common finding in carcinogenesis (Stern et al. 2000). The MTHFR C677T polymorphism has 
been shown to be associated with numerous malignancies in (Kim 2007). The association with 
lung cancer is still controversial, however, with some studies reporting that this type of 
MTHFR genetic variant is significantly associated with an increased risk of lung cancer (Liu et 
al. 2013; Wang et al. 2015; Yang et al. 2016) while others have failed to reveal a considerable 
role of C677T mutation in lung carcinogenesis (Mao et al. 2008; Zhang et al. 2012; Yilmaz et 
al. 2014).  
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1.4.2 Lung cancer epigenetics 
Epigenetic modifications are the heritable changes in gene expression that exist without 
alterations in the primary DNA sequence; they include DNA methylation, histone 
modification, chromatin remodelling and non-coding RNAs (Ong et al. 2012). The interplay of 
these mechanisms makes up an “epigenetic landscape” that controls the way the human 
genome expresses itself in different tissues, developmental stages and pathological disorders, 
including cancer (Sharma et al. 2010). Several studies have identified the role of epigenetic 
reprogramming in cancer cell initiation and progression (Sharma et al. 2010; Martin et al. 
2011). 
1.4.2.1 DNA methylation 
DNA methylation is credited as the first and the most widely studied epigenetic modification 
(Holliday & Pugh 1975; Langevin & Kelsey 2013). It plays an important role in epigenetic 
regulation by controlling gene expression and chromatin architecture (Sharma et al. 2010; Lin 
et al. 2014). DNA methylation primarily occurs by the covalent addition of the methyl group 
on the fifth carbon position of cytosine residue (5mC) within the CpG dinucleotide sequence 
(Langevin & Kelsey 2013). CpG dinucleotides are under-represented and unevenly distributed 
across the genome, often found as small clusters called CpG islands that are located in the 5’ 
end of genes occupying about 60% of human promoters (Saxonov et al. 2006). During 
development and differentiation, the genome is globally methylated, thereby maintaining 
genomic stability, while most promoter CpG islands (CGIs) remain predominately 
unmethylated (Liloglou et al. 2014). DNA methylation is accomplished by DNA 
methyltransferase enzymes (DNMTs) that catalyse the transfer of the methyl group from the 
universal methyl donor (SAM) into the cytosine residue. To date, five DNMTs have been 
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discovered: DNMT1, DNMT2, DNMT3a, DNMT3b and DNMT3L (Kulis & Esteller 2010). 
DNMT1, or maintenance methyltransferase enzyme, plays a major role in transmitting 
original DNA methylation patterns through multiple generations with high fidelity. In this 
context, DNMT1 is responsible for restoring the pre-existing methylation patterns onto the 
newly synthesised DNA following DNA replication process (Kulis & Esteller 2010; Liloglou et 
al. 2014; Subramaniam et al. 2014). While DNMT3a and DNMT3b are the de novo 
methyltransferases that are involved in de novo DNA methylation (Jones & Liang 2009). 
Interestingly, DNMT2 is mainly involved in RNA methylation instead of DNA (Okano et al. 
1998). Although DNMT3L does not act as cytosine methyltransferase, it stimulates de novo 
methylation mediated by DNMT3a, as well as provoking transcriptional silencing through 
interaction with histone deacetalyse 1 (Chedin et al. 2002; Deplus et al. 2002). Moreover, the 
establishment of the DNA methylation machinery is mediated by the organised activity of 
DNMTs and associated factors such as poly-comb group proteins (PcG), which interact with 
DNMTs in the presence of the general methyl donor (SAM) (Robertson 2001). The DNA 
methylation process is generally associated with the cessation of gene expression (Figure 
1.14) (Liloglou et al. 2014). This is achieved either by creating a physical barrier for some 
transcriptional factors such as AP-2, c-myc, CREB/ATF, E2F and NF-kB, thereby inhibiting the 
transcriptional factors binding to promoter binding sites, and ultimately blocking 
transcriptional activation (Kulis & Esteller 2010; Sharma et al. 2010) or by recruiting methyl 
binding proteins (MBPs) that in turn interact with histone deacetylases (HDACs), called 
repressive epigenetic modification enzymes, resulting in chromatin reorganisation so that it 
becomes compacted and no longer accessible for transcriptional machinery (Figure 1.15) 
(Lopez-Serra & Esteller 2008). In addition to mediating transcriptional suppression, DNA 
methylation has a profound impact on maintaining genomic stability through other 
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mechanisms, including inactivation of X-chromosome, genomic imprinting (Jones & Baylin 
2007; Portela & Esteller 2010) as well as silencing of repetitive and parasitic DNA sequences 
that otherwise have a detrimental illegitimate effect on genetic stability by causing 
transcriptional deregulation of adjacent genes (Robertson 2005).  
 
 
 
 
 
Figure 1.14: DNA methylation at 5-position of cytosine residue and associated gene 
silencing. Taken from Kulis & Esteller (2010).  
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Figure 1.15: transcriptional repression mechanism induced by DNA methylation through recruitment 
of methyl binding domain proteins (MBD) with subsequent association with histone deacetylases 
(HDACs) resulting in chromatin reorganisation and inhibition of transcription machinery. Taken from 
Kulis & Esteller (2010). 
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1.4.2.1.1 DNA Methylation in lung cancer  
The relationship between DNA methylation and cancer was first observed in 1983, when the 
genome of tumour cells was shown to be hypomethylated, compared to their normal 
counterparts (Feinberg & Vogelstein 1983). It is now well established that genomic 
methylation patterns are profoundly altered in tumour cells (Frigola et al. 2006; Wilson et al. 
2007; Irizarry et al. 2009). Indeed, cancer cells methylome is quite different from that of 
normal ones; the fact that both genome-wide hypomethylation and regional promoter 
hypermethylation events occur concomitantly in cancer suggests the importance of 
epigenetic mechanisms in tumour initiation and progression (Baylin & Jones 2016). Studies 
on DNA methylation in lung cancer have strongly emphasised the importance of aberrant 
genomic DNA methylation in the pathogenesis of lung cancer (Heller et al. 2010; Heller et al. 
2013). In this context, an increasing number of tumour suppressor genes (TSG) have been 
reported to be inactivated by hypermethylation of their promoter CpG islands during lung 
carcinogenesis (Li et al. 2013; Mehta et al. 2015). While regional promoter hypermethylation 
is a high incidence early event in lung carcinogenesis, global DNA hypomethylation is an 
equally common phenomenon in lung cancer. Genome-wide loss of methylation 
predominately affects repeated DNA sequences such as LINES (long interspersed nuclear 
elements), SINES (short interspersed nuclear elements), satellite repeats and imprinted genes 
(Kulis & Esteller 2010) and can result in genomic instability (Daskalos et al. 2009) 
1.4.2.1.1.1 DNA methylation in the diagnosis of lung cancer 
Several studies have suggested the potential of using aberrant DNA methylation patterns as 
a biomarker for the diagnosis and clinical monitoring of patients with lung cancer, particularly 
the aberrant methylation of promoter regions affecting the driver genes involved in critical 
cellular functions (Sandoval et al. 2013). In this context, numerous aberrantly methylated 
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genes have been identified in the tumour tissue, bronchioalveolar lavage, sputum, plasma 
and serum of lung cancer patients (Table 1.2) such as RAR2 (Ponomaryova et al. 2011), SHOX2 
(Kneip et al. 2011). (Dietrich et al. 2012). Over the last decade, a plethora of blood-based DNA 
methylation assays have been used in clinical research as a minimally invasive source of 
samples to detect aberrant DNA methylation signatures in cell free DNA (cfDNA) in plasma, 
serum (Begum et al. 2011) or peripheral blood leukocytes (Wang et al. 2010) in lung cancer 
(Balgkouranidou et al. 2013). 
 
Table 1.2: DNA methylation biomarkers in diagnosis of lung cancer. Taken from Sandoval  et al. (2013) 
Epigenetic marker Biological material Diagnostic value 
SHOX2 Bronchioalveolar lavages 78% Sn, 96% Sp 
SHOX2 Plasma 60% Sn, 90% Sp 
RARB2 Plasma (Csb-CirDNA) 70% Sn, 63% Sp 
RARB2 Csb-CirDNA 63% Sn, 51% Sp 
APC, CDH1, MGMT, 
RASSF1, DCC and AIM1 
Serum 75% Sn, 73% Sp 
Cir: Circulating; Csb: Cell surface-bound; Sn: Sensitivity; Sp: Specificity 
 
1.4.2.1.1.2 DNA methylation in lung cancer treatment 
DNA methylation has been aggressively pursued as a promising therapeutic target for lung 
cancer (Liu et al. 2013). In fact, DNA methyltransferase inhibitors (DNMTi) are the most 
extensively studied agents (Mehta et al. 2015). The US Food and Drug Administration (FDA) 
has approved decitabine (5-aza’-2-deoxycytidine and azacytidine (5-azacytidine) 
hypomethylating agents for the treatment of myeloid malignancy (Issa 2007; Yang et al. 
2010). Both drugs are cytidine analogues, incorporating themselves into the DNA of rapidly 
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growing tumour cells during replication and forming covalent adducts with DNA 
methyltransferases (DNMTs), and thereby specifically inhibiting these enzymes and inducing 
hypomethylation (Zeller & Brown 2010) and re-expression of previously silenced genes 
through promoter hypermethylation in vitro (Figure 1.16) (Sharma et al. 2010; Belinsky 
2015)). Although both decitabine and azacytidine have the same biological mechanism of 
action, decitabine is considered to be a more potent DNA methylation inhibitor than 
azacytidine, since it is able to incorporate specifically into DNA, while 5-azacytidine is 
predominately integrated into RNA and can only bind DNA after conversion into 5-aza-2’-
deoxycytidine (decitabine)(Navada et al. 2014; Mehta et al. 2015). Although they have shown 
substantial therapeutic potential in haematological malignancies, the effectiveness of 
decitabine and 5-azacytidine in solid tumours remains limited, however (Graham et al. 2009). 
Interestingly, these demethylating agents have demonstrated a promising response in lung 
cancer cell line models through inhibition of DNA methylation and reactivation of 
epigenetically silenced tumour suppressor genes (Merlo et al. 1995; Cantor et al. 2007; Fang 
et al. 2012). There is, therefore, a sound rationale for the use of 5-azacytidine and decitabine 
therefore in lung cancer treatment; as yet however, clinical studies employing 
hypomethylating drugs have not generally revealed an objective disease response (Digel & 
Lübbert 2005; Schrump et al. 2006).  
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Figure 1.16: Mechanism of depletion of DNMTs for decitabine and 5-azacytidine. (A) 
Chemical structure of cytidine, azacytidine and decitabine (B) Gene promoter methylation 
of cytidine blocks transcriptional factor binding resulting in transcription repression and 
epigenetic silencing (C) During replication, azacytidine is converted into decitabine, and 
then integrated into DNA, substituting cytidine. Both drugs inactivate DNMTs, thereby 
blocking DNA methylation and resurrecting the expression of previously inactivated genes. 
Taken from Navada et al. (2014). 
 
54 
1.5 Epigenomic footprint of folate 
Various epigenomic molecular modalities depend largely on DNA methylation reactions to 
define the activities of epigenetic factors, as well as for identifying the specific epigenetic 
mark (Salbaum & Kappen 2012). While the biological relevance of folate for epigenetic events 
has been derived from the view of folate involvement in the provision of SAM for methylation 
reactions and in maintaining the cellular methyl donor pool (Kim 2004; Kim 2005), a direct 
and positive link between DNA methylation status and folate level must be assumed given 
that folate is a rate-limiting factor for DNA methylation reactions. In this scenario, a high level 
of folate results in an increase in DNA methylation status; conversely, low folate levels lead 
to reduced DNA methylation. This prevailing view has changed dramatically recently, however 
(Salbaum & Kappen 2012). Evidence from several experimental studies has suggested a higher 
level of complexity in this relationship since folate deficiency could result in different aberrant 
DNA methylation patterns ranging from global DNA hypomethylation, global DNA 
hypomethylation associated with promoter hypermethylation for specific genes, global 
hypermethylation and no change at all in DNA methylation status (Kim et al. 1995; Duthie et 
al. 2000; Crott et al. 2008; Protiva et al. 2011). Indeed, the effect of folate deficiency on DNA 
methylation and subsequent tumourigenesis is more sophisticated, variable and influenced 
by several factors, including the cell and organ type, stage of transformation, extent and 
duration of folate limitation and genetic variants of folate pathway genes (Kim 2007). 
Moreover, folate has been found to have a significant effect on gene expression through 
mechanisms other than DNA methylation. Provita et al. (2011) for example, provided support 
for the notion that folate can significantly regulate gene expression without changing global 
or promoter DNA methylation status in colorectal cancer (Protiva et al. 2011).  
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As well as affecting DNA methylation, the epigenetic impact of folate involves other realms of 
the epigenome such as microRNA (Davis & Ross 2008; Shookhoff & Gallicano 2010) and 
histone methylation (Luka et al. 2011; Garcia et al. 2016). Overall, therefore, more 
complicated regulatory relationships need to be considered than were previously anticipated 
(Salbaum & Kappen 2012).   
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1.6 Folate pathway targeting therapy 
Chemotherapeutics targeting folate metabolism are among the most successful drugs used in 
cancer treatment (Wright & Anderson 2012). They inhibit key enzymes in the folate metabolic 
pathway (Table 1.3) (Robien et al. 2005) namely TYMS, DHFR, MTHFR, B-glycinamide 
ribonucleotide transformylase (GARFT), 5-amino-4-imidazolecarboxamide ribonucleotide 
transformylase (AICARFT). The therapeutic effectiveness of drugs targeting folate 
metabolising enzymes is largely attributed to folate role in cellular replication, with disruption 
of folate resulting in the interruption of nucleotide biosynthesis as well as reduced growth 
and proliferation of neoplastic cells (Robien et al. 2005).  
1.6.1 Thymidylate synthase inhibitors 
TS targeting agents are well-established anticancer drugs used in the management of the 
most-difficult-to-treat haematological and solid malignancies, including NSCLC and colorectal 
and pancreatic carcinomas, either alone or in combination with other therapeutic regimens 
(Wilson et al. 2014). TS plays a key role in maintaining the proliferation and survival of cancer 
cells by providing the sole source of deoxythymidyne triphosphate (dTTP), the essential 
precursor for DNA replication and repair (Taddia et al. 2015). Additionally TS has been 
reported to repress p53 tumour suppressor gene activity (Ju et al. 1999) and demonstrate 
oncogenic-like behaviour when forcibly overexpressed in mammalian cells (Rahman et al. 
2004). The TS enzyme is therefore a critical pinch-point for inhibition in cancer 
chemotherapeutics. The enzyme is a homodimer that contains binding sites for folate (5,10-
CH2THF) and nucleotide (dUMP) substrates; hence, disruption of TS enzymatic activity is 
achieved by inhibitors binding to these sites. Agents targeting TS fall into two structurally 
different categories: fluoropyrimidine, which targets nucleotide binding sites, and antifolates, 
which target folate binding sites (Wilson et al. 2014). 
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Table 1.3: Clinically used folate antagonists and TYMS inhibitors. Taken from Robien et al. (2005) 
Generic name Target enzyme(s) Approved clinical oncology use 
Methotrexate DHFR (primary), TYMS, 
MTHFR, GART, 
AICARFT 
Leukemia, lymphoma (Burkitt and Non.Hodgkin), 
breast cancer, head and neck cancer, 
osteosarcoma. 
Trimetrexate DHFR NSCLC, prostate and colorectal cancers 
Edatrexate DHFR NSCLC, advanced braest cancer, head and neck 
cancers, soft tissue sarcomaand non. Hodgkin 
lymphoma 
PT523 DHFR NSCLC, cervical, breast and endometrial cancers 
Lometrexol GART (primary), 
AICARFT 
NSCLC 
5-Fluorouracil (5-
FU) 
TYMS Colorectal, pancreatic, stomach, breast cancers, 
basal cell carcinoma 
Capecitabine TYMS Colorectal and breast cancers 
Pemetrexed TYMS (primary), DHFR, 
GART 
Malignant pleural mesothelioma, NSCL 
Ralitrexed TYMS Colon cancer 
Nolatrexed TYMS Hepatocellular carcinoma 
Tegafur TYMS Breast, gall bladder, gastrointestinal, head and 
neck, liver and pancreatic cancers 
Plevitrexed TYMS Gastric, pancreatic and ovarian cancers 
 
 
1.6.1.1 Fluoropyrimidines 
5-Fluorouracil (5-FU) is the best-known fluoropyrimidine, it was first synthesised by 
Heidelburger et al. in 1957 (Heidelberger et al. 1957), and continues to be one of the most 
widely used drugs in cancer therapy for numerous types of solid tumours (Table 1.3), such as 
head and neck, breast and pancreatic cancers (medlineplus.gov). Furthermore, several 
randomised clinical trials have demonstrated the effectiveness of 5-FU derivatives in the 
treatment of NSCLC (Kawahara et al. 2001; Ichinose et al. 2004; Kato et al. 2004). 5-FU has 
also shown a promising effect in mutant KRAS NSCLC cells in vitro, in combination with tumour 
necrosis factor-related apoptosis inducing ligand (TRAIL)(Wang et al. 2015).  
 
58 
1.6.1.1.1 Mechanism of 5-Fluorouracil action  
5-FU is a uracil analogue with a flourine atom at the C-5 position instead of hydrogen. It enters 
the cell via a facilitated transport mechanism (Wohlhueter et al. 1980), then undergoes 
intracellular conversion into three main active metabolites, fluorodeoxyuridine 
monophosphate (FdUMP), fluorodeoxyuridine triphosphate (FdUTP) and fluorouridine 
triphosphate (FUTP). These 5-FU active metabolites interfere with RNA synthesis and TYMS 
activity. Also, they can be misincorporated into DNA, resulting in DNA strand breaks and 
eventually apoptotic cell death (Longley et al. 2003).  
 Approximately 80% of administered 5-FU is degraded in the liver by the action of 
dihydropyrimidine dehydrogenase (DPD) enzyme that converts 5-FU into dihydrofluorouracil 
(DHFU)(Figure 1.17)(Diasio & Harris 1989).  
TYMS inhibition: Fluorodeoxyuridine monophosphate (FdUMP) metabolite forms a covalent 
ternary complex with the TYMS enzyme and 5,10 MTHF, thereby inhibiting dTMP synthesis 
by blocking dUMP binding (Sommer & Santi 1974). Depletion of dTMP causes 
deoxynucleotide pool imbalances and disrupts DNA synthesis and repair leading to lethal DNA 
damage (Yoshioka et al. 1987; Houghton et al. 1995). Furthermore, 5-FU induced TYMS 
inhibition results in dUMP accumulation that may subsequently result in increased dUTP 
levels (Mitrovskiet al. 1994; Aherneet al. 1996).  
RNA misincorportaion: FUTP metabolite is extensively incorporated into RNA and interferes 
with normal RNA processing and function (Longley et al. 2003). 5-FU containing RNA has been 
shown to inhibit normal processing and maturation of mRNA, tRNA and rRNA precursors 
thereby potentially disrupting normal cell viability and metabolism (Cammico & Glazer 1979; 
Santi & Hardy 1987; Ghoshal & Jacob 1994; Mojard et al. 2013).  
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Figure 1.17: Structure and metabolism of 5-fluorouracil. The 5-FU activation pathway is either direct, 
through the action of orotate phosphoribosyl transferase (OPRT) using phosphoribosyl pyrophosphate 
(PRPP) as a cofactor, or indirect, through fluorouridine (FUR) by the activity of uridine phosphorylase 
(UP) and uridine kinase (UK) enzymes, thereby converting 5-FU into (FUMP), which is then 
phosphorylated to fluorouridine diphosphate (FUDP). In turn, (FUDP) can either be converted to 
fluorodeoxyuridine diphosphate (FdUDP) through the enzymatic activity of ribonucleotide reductase 
(RR) or phosphorylated to fluorouridine triphosphate (FUTP). The latter can in turn be phosphorylated 
or dephosphorylated, generating FdUTP and FdUMP active metabolites, respectively. An alternative 
pathway for 5-FU activation is through conversion into fluorodeoxyuridine (FUDR) in a thymidine 
phosphorylase dependent reaction. The latter is then phosphorylated into FdUMP by thimydine kinase 
(TK). Taken from Longley et al. (2003). 
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1.6.1.1.2 Resistance to 5-Fluorouracil 
Despite its anticancer efficacy, resistance to 5-FU based chemotherapy remains an important 
reason for treatment failure, and a significant limitation on its use in clinical applications 
(Zhang et al. 2008). Several factors have been implicated in 5-FU resistance, such as cell cycle 
disorders, abnormal metabolism of target enzymes, mismatch repair deficiency, deregulation 
of drug transportation and apoptosis resistance; nonetheless, the molecular mechanism 
behind 5-FU resistance has yet to be fully understood (Deng et al. 2017). Overexpression of 
TS is widely acknowledged as the major mechanism for 5-FU resistance (van Triest et al. 1999; 
Oguri et al. 2005). Moreover, the efficacy of 5-FU treatment can also be changed as a result 
of TS mutation or polymorphism, leading to alteration of enzyme structure and possibly 
affecting the binding of 5-FdUMP. An increasing number of these alterations have been 
analysed, and particular attention has been paid to the presence of different 28-bp variable 
number tandem repeats (VNTR) in the 5’-UTR of TS (Scartozzi et al. 2011). 
Similarly, high expression of dihydropyrimidine dehydrogenase DPD has been shown to be 
associated with a marked reduction in the antitumor effect of 5-FU (Salonga et al. 2000). The 
predictive role of DPD is still controversial, however, since several other studies have reported 
no statistical significance between DPD expression level and response rate to 
Fluoropyrimidine-based chemotherapy (Kodera et al. 2007; Meulendijks et al. 2015). 
Recently, microarray analyses have demonstrated that miRNAs play a vital role in reducing 5-
FU efficiency through different molecular mechanisms in multiple cancer cell lines. Gotanda 
et al. (2013) and Li et al. (2015) found that TYMS is a target of miR-433 and miR-203, which 
modify the chemosensitivity of 5-FU in Hella cells and colonic cancer cells, respectively. 
61 
In addition, several other miRNAs have been implicated in 5-FU resistance, including miRNA-
497 (Guo et al. 2013), miRNA-221 (Zhao et al. 2015), miRNA-141(Shi et al. 2015) and miRNA-
137 (Xiao et al. 2014). 
 
1.6.1.2 Antifolates 
Folate antagonists are structural analogues of folate that use the same facilitative 
transporters as physiological folate for their cellular entry, namely folate receptors (FRs), 
reduced folate carrier (RFC) and proton coupled folate transporter (PCFT) (Zhao et al. 2013). 
In addition to inhibition of the thymidylate biosynthesis pathway, antifolates target other key 
enzymes in folate metabolism, such as DHFR, GARFT and AICARFT (Hagner & Joerger 2010). 
The interest in antifolates started in 1948 when Farber and Diamond noticed that 
administration of folic acid conjugates to children with acute leukaemia exacerbated the 
process of the disease, so they proposed that reversing this phenomenon might be achieved 
by treating leukaemic patients with a folic acid antagonist. Indeed, one of the earliest folate 
analogues, aminopterin, induced temporary remission of childhood leukaemia in 10 out of 16 
children with acute leukaemia (Farber & Diamond 1948). Eventually, aminopterin homologue, 
or MTX, was established with an improved therapeutic index, (Goldin et al. 1955) and clinically 
introduced as a primary antifolate drug that is still successfully used in the treatment of 
numerous malignancies, including leukaemia, lymphoma, osteosarcoma, breast cancer and 
head and neck cancers (Hagner & Joerger 2010; Wilson et al. 2014). After that, several novel 
antifolate drugs with improved pharmacological properties have been developed including 
RTX, pemetrexed and pralatrexate (PTX)(Visentin et al. 2012). 
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1.6.1.2.1 Methotrexate  
The antifolate drug MTX was introduced into clinical practice sixty years ago and is still widely 
used as a chemotherapeutic agent for several types of cancer, including lung and head and 
neck cancers (Wilson et al. 2014). It acts by interrupting folate homeostasis through inhibiting 
several critical folate metabolising enzymes (Kodidela et al. 2014). The major transporters for 
MTX entry into the tumour cell are RFC-1 or SLC19A1. Once inside the cell, MTX is 
polyglutamated by the enzyme folylpolyglutamyl synthase (FPGS) (Figure 1.18). The 
polyglutamated derivatives of MTX (MTX-PGs) are important determinants of its 
pharmacological activity (Genestier et al. 2000) since both MTX and MTX-PGs inhibit the DHFR 
enzyme, resulting in accumulation of dihydrofolates and depletion of tetrahydrofolate stores 
(Kodidela et al. 2014), thereby causing cessation of vital one-carbon dependent cellular 
processes (Zhao et al. 2013). Although DHFR is the primary target, the main cytotoxic driver 
of MTX is thymidylate depletion through potent competitive inhibition of TS by MTX-PGs 
(McBurney & Whitmore 1975; Moran et al. 1979). In addition, MTX has been found indirectly 
to inhibit the thymidylate synthesis reaction through impairment of 5,10-MTHF cofactor 
recycling, resulting in potent suppression of thymidylate synthesis and ultimately impeding 
DNA replication and repair (Hryniuk 1975). Moreover, polyglutamated forms of MTX inhibit 
other folate enzymes including GARFT, AICAR (thereby affecting purine de novo synthesis) 
and MTHFR, which is indirectly influenced by MTX mediated depletion of intracellular folate 
pools (Zhao et al. 2013; Kodidela et al. 2014). Consequently, malignant cells are unable to 
synthesise DNA or RNA, which affects their proliferation capacity and leads to further 
damage, eventually promoting cancer cell apoptosis (Hagner & Joerger 2010).  
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1.6.1.2.2 Pemetrexed 
Pemetrexed (PEM) is a multi-target antifolate drug that is approved by the U.S. Food and Drug 
Administration (FDA) for treatment of locally advanced and metastatic NSCLC (Cohen et al. 
2005) and has been evaluated in a range of solid tumours, including head and neck 
carcinomas (Latz et al. 2006; Argiris et al. 2013). Interestingly, pemetrexed has an histology 
driven specificity for non-squamous NSCLC (Scagliotti et al. 2009; Scagliotti et al. 2011; Rijavec 
et al. 2013). Pemetrexed exerts its antitumour effect through disrupting folate dependent 
metabolic processes important for cellular replication and proliferation (Figure 1.19). The 
drug is transported into the tumour cell by three main folate transporters: Alpha folate 
receptor, reduced folate carrier (RFC) and Proton coupled folate transporter (PCFT). Once in 
the cell, pemetrexed is rapidly and extensively polyglutamated into its active derivatives by 
the action of folylpolyglutamate synthase. Polyglutamated metabolites have a longer half-life 
Figure 1.18: MTX cellular pathway. Taken from Kodidela et al. (2014) 
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and better affinity for target enzymes than the parent drug (Baldwin & Perry 2009). It plays a 
critical role in disturbing DNA synthesis through inhibition of the key enzymes for purine and 
pyrimidine synthesis, TS, DHFR, GARFT and AICART, thereby inducing cell cycle arrest. Several 
studies have demonstrated the potential predictive role of intratumoural expression of TS 
mRNA in respect to the response to pemetrexed therapy in patients with NSCLC (Shimizu et 
al. 2012; Wang et al. 2014; Olaussen & Postel-Vinay 2016; Yang et al. 2017).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.19: Mechanism of action of pemetrexed. Taken from Rijavec et al. 
(2013). 
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1.6.1.2.3 Molecular mechanisms underlying resistance to antifolate drugs in cancer  
Various molecular mechanisms frequently provoke resistance to antifolate containing 
chemotherapy and hinder their therapeutic efficacy (Figure 1.20)(Gonen & Assaraf 2012). The 
documented mechanisms that render antifolate agents ineffective include: 
(i) Impaired cellular uptake  
RCF is the major transporter mediating antifolate cellular entry. A reduced transportation 
capacity of RFC is frequently associated with inactivated mutation, allele loss and reduced 
expression or silencing, thereby contributing to antifolate resistance (Visentin et al. 2012). 
Decreased RFC expression has been reported in several malignancies with resistance to MTX 
(Levy et al. 2003; Kastrup et al. 2008; Wang & Li 2014). To date, however, no mechanism of 
resistance associated with impaired membrane transport has been documented in 
pemetrexed resistant cells (Visentin et al. 2012). 
 
(ii) Loss of FPGS function 
Polyglutamylation is crucial for antifolate cellular retention and pharmacological activity; 
hence impaired FPGS activity is an important mechanism for polyglutamylation-dependent 
antifolate resistance. A large number of studies have documented a markedly reduced activity 
of FPGS in drug-resistant cancer cell lines following treatment with MTX, pemetrexed and RTX 
antifolates (Chéradame et al. 1999; Mauritz et al. 2002; Liani et al. 2003; Stark et al. 2009; 
Wojtuszkiewicz et al. 2016). 
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(iii) Overexpression of the target genes 
The higher the expression level of the target enzymes for antifolates, the smaller the fraction 
of these enzymes required to sustain their normal metabolic function, and the higher the 
concentration of antifolate drugs required to fully block their action (Gonen & Assaraf 2012). 
In fact, DHFR amplification has been identified as one of the underlying mechanisms for MTX 
resistance in both cancer cell lines and tissue samples from cancer patients (Scionti et al. 2008; 
Morales et al. 2009). Likewise, increased expression of the primary target, TYMS, as well as 
other targets such as DHFR and GARFT, has been correlated with pemetrexed resistance in 
NSCLC cell lines (Giovannetti et al. 2005; Ozasa et al. 2010; Yang et al. 2014). 
 
(iv) Overexpression of Gamma-glutamyl hydrolase (GGH)        
 GGH enzyme is responsible for hydrolysing the gamma-glutamyl chain of folates and folate 
antagonists and converting them into monoglutamates, thereby maintaining the cellular 
folate homeostasis (Raz et al. 2016). High GGH hydrolytic activity results in antifolates 
extruding out of the cell, reducing their efficacy and reducing intracellular folate pools 
(Schneider & Ryan 2006; Gonen & Assaraf 2012; Yoshida et al. 2016). Moreover, epigenetic 
modulation and SNPs of GGH promoter and coding regions have been identified as 
modulating GGH expression levels and antifolate responsiveness (Cheng et al. 2006; Adjei et 
al. 2010; Organista-Nava et al. 2010).  
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(v) Expansion of intracellular folate pools 
The expansion of cellular folate THF cofactor pools has a significant impact on the instant 
competition between folates and antifolates in terms of polyglutamylation, target enzyme 
binding and efflux, leading to reduction in the pharmacological activity of antifolates (Zhao & 
Goldman 2003; Gonen & Assaraf 2012). In fact, increasing the folate pools is a well-
established mechanism for resistance to antifolates (Jansen et al. 1999; Zhao et al. 2001)  
 
(vi) Enhanced efflux of antifolates through overexpression of the ATP-driven MDR efflux 
transporters  
Multidrug-resistant proteins (MRPs) are members of ATP-dependent binding cassette (ABC) 
efflux transporters that utilise ATP-driven energy to transport their substrates across the 
biological cell membrane. MRP1 (ABCC1) through to MRP5 (ABCC5) and BCRP (ABCG2) 
mediate folate and antifolate ATP-dependent efflux (Assaraf 2006; Sodani et al. 2012). 
Various studies have shown that elevated levels of MRPs1-4 and ABCG2 efflux pump can 
mediate antifolate resistance (Shafran et al. 2005; Bram et al. 2006; Hooijberg et al. 2014). 
Overexpression of these efflux transporters can also extrude THF cofactors out of the cell, 
however (Assaraf 2006) resulting in a decrease in intracellular folate pools and ultimately 
enhancing the chemotherapeutic effect of antifolates. Elevated MRPs and ABCG2 activity, 
therefore, would result in two opposing effects on antifolate chemosensitivity, and the net 
result depends on the affinity of that particular antifolate towards ABC transporters, as well 
as the impact of the cellular folate pool on antifolate anticancer activity (Gonen & Assaraf 
2012).    
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Figure 1.20: Molecular mechanisms of resistance to antifolates in cancer. Taken from Gonen 
& Assaraf (2012). 
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1.7 Aims and Objectives 
The overarching aim of this thesis is to expand the current knowledge on folate pathway 
deregulation in respiratory tract cancers and deliver conclusions of translational significance, 
i.e. potential utilisation in the diagnosis, prognosis and therapy of the disease. The specific 
objectives are: 
1- To explore the extent of the deregulation of core folate pathway genes in lung cancer 
2- To examine the possibility of modifying the sensitivity of respiratory tract cell lines  to 
antifolate drugs by using the potential epigenetic modifiers, Decitabine and VPA. 
3- To investigate the modulation of the efficiency of antifolate drugs by individual genes of 
the pathway. 
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Chapter 2: Materials and methods 
2.1 Human lung cancer tissue samples 
All the clinical samples were sourced through the Liverpool lung project (LLP) biobank and 
appropriate ethical approval has been granted. One hundred and four (104) pairs of lung 
cancer and adjacent normal tissue were included in this study (49 adenocarcinomas, 53 
squamous cell carcinomas, 1 large cell carcinoma and 1 unclassified NSCLC). Forty-one were 
from females (39%) and sixty-three were from males (61%). Patient ages ranged between 44 
and 87 (mean =66). Most of our specimens were from the pT2 stage group (n=80) while pT1 
and pT3 comprised 11 and 10 respectively, with only three from patients at an advanced 
pathological state (pT4).  
2.2 Cell lines and growth conditions 
Seven non-small cell lung cancer (A549, CALU6, COR-L23, LUDLU, SK-MES-1, SK-LU-1, H358) 
and three head and neck squamous cell carcinoma cell lines (BHY, PE/CA-PJ15 and PE/CA-
PJ41) were used for folate gene expression experiments, in addition to the immortalised, non-
tumourigenic human bronchial epithelial (HBEC-3KT) (Table 2.2). mRNA expression of HBEC-
3KT cells was taken as a calibrator in each qPCR run. All of the cell lines included in this study 
were authenticated using the GenePrint 10 System (Catalogue no. B9510 - Promega)(Table 
2.1) and verified as being mycoplasma free using the e-MycoTM plus Mycoplasma PCR 
Detection Kit (Catalogue no. 17341 - Intron Biotechnology). Cells were grown in Dulbecco 
Modified Eagle Medium DMEM: F12 medium, supplemented with L-glutamine and 5% foetal 
bovine serum (FBS) (Sigma-Aldrich), except for HBEC 3KT, which was cultured in Keratinocyte 
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serum free medium supplemented with Bovine Pituitary Extract (BPE) and human 
recombinant Epidermal Growth Factor (rEGF)(Life Technologies).  
All cells were maintained at 37 oC in an incubator supplemented with 5% CO2. 
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Cell line Histological type p53 status 
NSCLC   
SK-MES-1 SCC  
SK-LU-1 Adenocarcinoma  
CALU6 Adenocarcinoma  
A549 Adenocarcinoma 1Wild type 
COR-L23 Large cell carcinoma  
H358 Bronchioloalveolar 
adenocarcinoma 
 
LUDLU-1 
HTB-182 
DMS-53 
H2073 
CALU-1 
HTB-59 
Normal lung cell lines 
HBEC 3KT 
 
IMR90 
LUNG-14 
SCC 
Squamous cell carcinoma 
Small cell carcinoma 
Adenocarcinoma 
Lung epidermoid carcinoma 
Squamous cell carcinoma 
 
Immortalised non tumourigenic 
normal bronchial epithelial cells 
Normal lung fibroblast 
Normal lung fibroblast 
 
HNSCC   
BHY Oral SCC  
PE/CA-PJ15 Oral SCC  
PE/CA-PJ41 Oral SCC  
   
1 Jia et al. (1997) 
 
 
SK-MES-1 SKLU-1 CALU-6 A549 COR-L23 H358 LUDLU-1 HTB-182 DMS-53 H2073 CALU-1 HTB-59 HBEC-3KT IMR-90 Lung-14 BHY PE/CA-PJ15 PE/CA-PJ41
Amelogenin X, Y X X X, Y X, Y X, Y X X X X X X X X X X, Y X, Y X
CSF1PO 12 10 12 10, 12 11 11, 12 11 10 12 13 10 11 10, 11 11, 13 11, 12 10 10, 12 11, 13
D13S317 11 10 11 11 10, 11 8, 12 12 10, 11 10 13 11, 12 8 12, 13 11, 13 11, 12 12, 13 8, 10 11, 12
D16S539 13 8 13 11, 12 11, 13 12, 13 13, 14 8, 13 12, 13 12 11 11 9, 12 10, 13 11, 12 12 9, 13 11, 13
D5S818 11 11 11 11 10, 12 10, 12 12 12, 13 10, 11 12 10, 12 11 12 12, 13 10, 12 10 11, 13 12
D7S820 8 9 10 8, 11 9 10, 11 10, 12 8, 12 8, 11 12 9, 10 11, 12 8, 12 9, 12 10 11, 12 8, 12 9, 11
THO1 6, 9.3 7 9 8, 9.3 9 6 6 10 8, 9.3 6, 9.3 9, 9.3 8 9.3 8, 9.3 6, 9.3 9 6, 9.3 7
TPOX 8 8, 10 8 8, 11 8, 11 8, 9 8, 11 8 12 9 8 11 11, 12 8, 9 9, 10 8, 11 8, 11 8
vWA 14 16, 17 17 14 19 17 17, 19 18, 19 15, 17 17 15, 16 16 15, 17 16, 19 15, 16 15, 16 17, 19 15, 19
Table 2.1: STR profiles of cell lines employed in this study. 
Table 2.2: Cell lines included in this study with their histological types and p53 status. 
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2.3 mRNA expression analysis 
2.3.1 RNA extraction 
RNA from cell lines and tissues was extracted using Direct-zol™ RNA MiniPrep Kit (Zymo 
Research). Primary tissue RNA was extracted from 10 μm thick tissue sections and 500 μl of 
TRIzol lysing reagent was used per approximately 50 mg tissue. Total cell line RNA extraction 
was performed by lysing the cells in the culture flask, the liquid medium was aspirated and 
cells were washed with Dulbecco phosphate buffer saline (PBS), then 600 μl of TRIzol reagent 
was added. The culture container was then briefly scraped with a plastic cell scrapper and 
TRIzol/cell lysate was collected and deposited into a 1.5 ml Eppendorf tube. Then, the lysate 
(tissue or cell lysates) was vortexed and an equal volume of ethanol (95-100%) was added to 
the homogenised lysate and mixed thoroughly by vortexing for 1 minute. The mixture was 
then loaded into a Zymo-Spin™ IIC Column in a collection tube and centrifuged at 16,000 x g 
for 30 seconds. The column was transferred into a new collection tube and the collection tube 
containing the flow-through was discarded. This was followed by DNAase I treatment which 
was prepared by adding 5 μl DNAase I (6U/μl) with 75 μl DNA digestion buffer in an RNase-
free tube, then the DNase I incubation mix was added directly into the column matrix and 
incubated at room temperature for 20-30 minutes. 400 μl Direct-zol™ RNA PreWash buffer 
was added to the column and centrifuged for 30 seconds at 16,000 x g.  The flow-through was 
then discarded. The previous stage was repeated twice. Subsequently, 700 μl RNA Wash 
Buffer was added to the column and centrifuged for 2 minutes at the same centrifugation 
speed. To ensure complete removal of the washing reagent, a dry spin was performed for an 
additional 4 minutes and the flow-through was discarded. The column was carefully 
transferred into an RNase-free tube then 40 μl of DNase/RNase-free water was added directly 
to the column matrix, incubated at room temperature for 1 minute then centrifuged at 16,000 
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x g for 2 minutes to elute the RNA. Aliquots from the extracted RNA samples were used for 
quality and quantity checking using a NanoDrop 2000 Spectrophotometer (Thermo Scientific) 
and Agilent chip analysis, while the remaining RNA was stored frozen at -80 °C for future use. 
2.3.2 RNA quality control - Agilent RNA 6000 Nano kit 
RNA quality and quantity was assessed by capillary electrophoresis on an Agilent 2100 RNA 
quality and quantity was assessed by capillary electrophoresis using an Agilent 2100 
Bioanalyser (Agilent Technologies). In brief, 550 μl of Agilent RNA 6000 Nano gel matrix were 
placed into the top receptacle of a spin filter. The spin filter was centrifuged for 10 minutes 
at 1500 x g ± 20 % and 65 μl of filtered gel was used per each chip. RNA 6000 Nano dye 
concentrate was vortexed and 1 μl of RNA 6000 Nano dye concentrate was added to a 65 μl 
aliquot of filtered gel.  The gel and dye mix was then vortexed thoroughly and spun for 10 
minutes at room temperature at 13000 x g. 9.0 μl of the gel-dye mix were dispensed at the 
bottom of the well marked with a RNA Nano chip. The gel and dye mix was spread throughout 
the chip under air pressure using a syringe for 30 seconds. After 5 seconds, the plunger of the 
syringe was slowly pulled back, the chip priming station was opened and 9.0 μl of the gel-dye 
mix were pipetted into each of the marked wells. Subsequently 5 μl of the RNA 6000 Nano 
marker were pipetted into the well marked with the ladder symbol and each of the 12 sample 
wells. To minimise secondary structure, RNA ladder and samples were heat denatured at 70 
°C for 2 minutes before loading onto the chip. 1 μl of the RNA ladder was pippeted into the 
well marked with the ladder symbol, and 1 µl of each sample into each of the 12 sample wells. 
The chip was placed horizontally in the adapter of the IKA vortex mixer and was vortexed for 
60 seconds at 100 g. Finally, the chip was inserted in the Agilent 2100 Bioanalyzer and the run 
was started during the following five minutes. 
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2.3.3 Reverse transcription 
A High-Capacity cDNA Reverse Transcription kit (Applied Biosystems) was used to synthesise 
single stranded cDNAs according to the manufacturer protocol. In brief, Reverse Transcription 
Master Mix was prepared by mixing 2 µl of 10x RT Buffer, 0.8 µl of dNTP Mix (100 mM), 2 µl 
of RT Random primers, 1 µl of MultiScribe™ Reverse Transcriptase and 4.2 µl of Nuclease-free 
H2O. The premix was then mixed by brief vortexing and spinning before being placed on ice. 
1 μg of total RNA (10 µl) was then added to the RT Master Mix with subsequent mixing by 
pipetting and brief centrifugation to remove any air bubbles. After that, a reverse 
transcription reaction was performed in a thermal cycler with the following reaction 
conditions: 10 min at 25 oC, 120 min at 37 oC and 5 sec at 85 oC. cDNAs were diluted five times 
with ddH2O and 3 μl were used for the subsequent quantitative PCR reactions. 
2.3.4 Quantitative Real-Time PCR expression assays 
Target selection was based on existing data obtained from a lung-cancer specific microarray 
(Almac platform) study undertaken by the lung group. The pilot validation study involved 120 
NSCLC samples identifying folate genes with frequent deregulation in lung cancer. These 
genes were subsequently selected for comprehensive qPCR-based expression profiling in 
order precisely to determine their expression status in lung cancer. In an attempt to minimise 
the optimisation time, we used predesigned FAM-MGB labelled Taqman expression assays to 
investigate the expression levels of SHMT1, CBS, MTHFR, DHFR, DNMT1, AHCY, MTR, MAT2A 
and TYMS in lung cancer tissues and cell lines (Table 2.3). 
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Table 2. 3: IDs and dye of predesigned FAM-MGB labelled Taqman expression assays for the folate genes 
examined in this study 
Gene Assay ID Dye 
DHFR Hs00758822_s1 FAM 
MTHFR Hs00195560_m1 FAM 
CBS Hs00163925_m1 FAM 
TYMS Hs00426586_m1 FAM 
DNMT1 Hs00945875_m1 FAM 
SHMT1 Hs00541045_m1 FAM 
AHCY Hs00898135-gH FAM 
MTR Hs00165188_m1 FAM 
MAT2A Hs00428515_g1 FAM 
 
ACTB was used as an endogenous control. The RT-qPCR primers and probe (labelled with 
TAMRA-BHQ2 reporter/quencher) were designed using the Primer Express v 3.0 software 
(Life technologies)(Table 2.4). ACTB was selected as a reference gene based on data from a 
microarray experiment (ALMAC platform 2009) that clearly showed similar levels of ACTB 
transcripts among lung normal and tumour samples. Validation experiments demonstrated 
very good linearity and therefore was qualified to be used as a reference (Figure 2.1). 
 
Table 2.4: Designed Primers for detection of ACTB RNA sequence 
Forward primer 
(5’→3’) 
Reverse primer 
(5’→3’) 
Probe 
(5’→3’) 
GGCACCCAGCACAATGAAG 
   (58.7ᵒC) 
CATACTCCTGCTTGCTGATCCA  
   (58.9ᵒC) 
CTCCTCCTGAGCGCAAGTACTCCGTG 
   (68.8ᵒC) 
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Assays were performed to a final reaction volume of 15 μl containing 7.5 μl of 2x QuantiTect® 
Probe PCR Master Mix (Qiagen), 900 nM of each primer and 250 nM probe (targets), 900 nM 
of each primer and 250 nM of the probe of the endogenous control ACTB TAMRA (Life 
Technologies), and 3 μl of cDNA were then added to the premix, following the universal real-
time cycler conditions (95 oC for 15 min, followed by 45 cycles of 94 oC for 15 sec and 60 oC 
for 1 min) on an Applied Biosystems 7500 Fast Real-time PCR system. Data analysis was done 
utilising the 7500 Software v2.3 (Applied Biosystems). mRNA levels were expressed as relative 
quantification values (RQ) which were calculated as: RQ=2(-ΔΔCt), where the mRNA expression 
of HBEC-3KT cells was used as a calibrator in each run. The calibrator, or reference sample, 
was utilised as the basis for the comparative expression results with an RQ value=1. All assays 
were run in duplicate and the mean values were used for the analysis. 
Figure 2.1: The 5-log dilution experiment for the ACTB qPCR assays. Ct=cycle 
threshold. 
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2.4 Detection of CBS/SHMT1 splice variants in human lung-derived cell lines  
According to the CBS/SHMT1 splice variants schematic (Figure 3.10), primer assays were 
designed for the transcript variants using oligo 7.0 primer analysis Eurofins Genomics 
(Molecular Biology Insights, Inc., USA)(Table 2.5). Fifteen lung-derived cell lines were used for 
the preliminary expression assessment (A549, CALU6, CALU1, CALU3, COR-L23, HTB-182, 
DMS-53, H2073, HTB-59, LUDLU, SK-MES-1, SK-LU-1, H358, IMR-90 and LUNG-14) (Table 2.1). 
Endpoint PCR assays were performed to a final reaction volume of 20 μl containing 10 μl of 
2X HotStarTaq Master Mix (Qiagen), 0.8 μl of each primer mixture (5 mM working 
concentration comprised 90 μl ddH2O, 5 μl of forward primers (stock solution, 100 mM), 5 μl 
of reverse primers (stock solution, 100 mM), and 3 μl of reverse transcription product (cDNA 
diluted five times) was then added with 6.2 μl ddH2O. The final reaction mixture was then 
briefly vortexed, spun down and thermal cycled. Endpoint PCR thermal profiles are shown in 
Table 2.6. 
Table 2.5: CBS and SHMT1 transcript variants assay designed assays for endpoint PCR 
 
Assay 
 
Forward primer  (5’→3’) 
 
Reverse primer  (5’→3’) 
Annealing 
temperature 
(x° C) 
 
PCR Product 
 
CBSv1 
 
CCTCTTTTCCATGTATCCGTCC 
(Exon 1)  
 
 
CGGACAGATGGTGCTGACA  
(Exon 2)  
 
 
61 v1 (100bp)  
 
CBSv2/3  
 
GTTTCAAGCTCATCAGTAAAGG 
(Exon 1) 
 
TCTGTAAGGAGACGTGACAAC  
(Exon 2)  
 
 
56 
v2 and v3 
(119bp)  
 
CBSv3  
 
 
CACGAGCAGATCCAGTACC 
(Exon 17a)  
 
 
CTGGCCGACTTCTCTCTC 
(Exon 17b)   
 
 
 
58 
 
 
v1, v2 and v4 
(392bp) v3 
(178bp)  
 
CBSv4  
 
 
GTGTCTTTCGCTGCAGGG 
(Exon 1a-exon 1b junction)  
 
 
 
CGGACAGATGGTGCTGACA 
(Exon 2)  
  
 
 
 
60 v4 (132bp)  
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SHMT1v2  
 
 
CCATTTGAACACTGCCAT 
(Exon 7)  
 
 
TTAAATTCCAGAGTCATAGCTTG) 
(Exon 9)  
 
 
 
56 
 
 
v1 and v3 
(245bp)  
v2 (128bp)  
 
SHMT1v3  
 
 
GCAGTTTTGGAGGCCCTA 
(Exon 3)  
 
 
TTCCACCAGGGCAGTGT 
(Exon 5)   
 
 
 
59 
 
 
v1 and v2 
(222bp)  
v3 (106bp)  
 
 
 
 
                     Table 2.6: Thermal profile of CBS/SHMT1 splice variants Endpoint PCR reaction 
Step Temperature (oC) Time No of cycles 
Taq Activation 95 15 min  
Denaturation 94 30 sec  
Annealing X* 30 sec 40 
Extension 72 30sec  
Final extension 72 10 min  
                                     * (Table 2.5) 
 
The quality and quantity of the PCR amplicons were then confirmed by 2% agarose gel 
electrophoresis and UV visualisation on a UVP VisionWorks LS instrument. 
 
2.4.1 Relative fluorescence quantitation for CBS splice variants 
Fluorescent quantification was performed in order to investigate the expression status of CBS 
transcripts in NSCLC tissue samples paired with adjacent normal counterparts. The 
customised expression CBS variants assays (Table 2.5)(with some modification of the CBSv3 
forward primer by adding 5’-FAM (6- Carboxyfluorescein)), were used for the quantitative 
fluorescence PCR. The reaction mixture was prepared from 10 μl of 2X HotStarTaq Master 
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Mix (Qiagen), 0.5 μl of each primer mixture (which was prepared previously for expression 
assessment in lung cell lines), with 3 μl of lung cancer tissue cDNA. After that, the PCR reaction 
was performed in thermal cycler. The reaction conditions are shown in Table (2.7). 
 
                    Table 2.7: Thermal profiles of CBS variants quantitative fluorescence PCR 
Step Temperature (oC) Time No of cycles 
Taq Activation 95 15 min  
Denaturation 94 30 sec  
Annealing 59 30 sec 32 
Extension 72 30sec  
Final extension 72 30 min  
 
In preparation for fluorescence quantitation, the PCR products were mixed with 9.5 μl 
formamide and 0.5 μl Allelic ladder (500 or 1000 ROX size standard). The mixture was 
denatured at 95 oC for 2 min, cooled on ice, and loaded on to a 3130 Genetic Analyzer (Applied 
Biosystems, USA) for capillary electrophoresis. The Peak Scanner Software v2.0 (Applied 
Biosystems, USA) was used for data analysis.  
2.4.2 Quantitative Real-Time PCR for expression of SHMT1 splice variants  
SHMT1 splice variants expression analysis was conducted using Quantitative real-time PCR 
expression assays. SHMT1 transcripts assays were specifically designed to target SHMT1v2 
and SHMT1 (v1+3) sequences (Figure 3.10)(Table 2.8). 
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Table 2.8: Real time PCR primers and probes designed for the quantitation of the expression of SHMT1 splice 
variants  
Primer/Probe (5’→3’) sequence Position (Figure 3.10) 5’ fluorescent dye 
Forward primer GAACACTGCCATGTGGTGA 
 
(Exon 7) 
 
- 
Reverse primer CCAGAGTCATAGCTTGCTTCA 
 
(Exon 9) 
 
- 
(v1+v3) probe 
 
CAGGCCAGGGAACACAGCAGA 
 
(Exon 8) 
 
6-FAM (518 nm) 
 
v2 probe 
 
CACAGCAACCCCTTTCCTGTAGAAGA 
 
(Exon 7-exon 9 
junction) 
 
TAMRA (582 nm) 
 
RQ values of SHMT1 v2 (Ct) values were normalised to (v1+v3) Ct values and expressed as fold 
changes relative to a calibrator, which is one of the non-tumour normal tissue samples 
(254N). When TATAA-box binding protein (TBP) was included as a reference gene, SHMT1 
variant 2 (v2) and combined variants 1 and 3 (v1+v3) cycle-threshold (Ct) values were 
normalised with TBP Ct values and expressed as a fold change relative to parental cells.   
 
 
2.5 Cellular exposure to chemotherapeutic agents 
2.5.1 Examination of cell growth and phenotypic characteristics 
An Eclipse TS100 inverted microscope (Nikon) was used for phenotypic examination of cell 
lines in addition to monitoring cell growth, confluence and the formation of clonal colonies. 
2.5.2 Cell growth curves 
Cell growth curves were performed in order to define the growth characteristics of each cell 
line involved in drug treatment experiments. The cells were plated at a density of 0.1 x 106 
cells per well in a flat-bottomed 12-well plate in four replicates, cultured in 2 ml growth 
medium (as discussed in 2.2) and allowed to adhere for the subsequent viability assessment 
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using the MTT method. MTT assays were undertaken every 24 hours for four successive days. 
The curve was constructed using the average values of the replicates. 
2.5.3 Treatment of cell lines with chemotherapeutics 
Depending on the proliferation rate of each cell line, (5-8) × 104 cells were plated in each well 
of a flat-bottomed 48-well plate in six replicates and cultured in a 500 μl growth medium. 
Following overnight incubation, the medium was replaced with media containing a range of 
concentrations (0-1mM) of 5-Fluorouracil (Catalogue No. F6627- Sigma-Aldrich), (0.125-8 μM) 
Methotrexate (Catalogue No. M9929- Sigma-Aldrich) and (0.5-64 μM) Pemetrexed 
(pemetrexed)(Catalogue No. 456180010- Acros Organics). Cells were incubated for 72 hours 
with replenishment of the medium with fresh drugs at 36 hours. 
For DNA methylation/ histone acetylation inhibition experiments, the most resistant cell lines 
to the aforementioned drugs were treated with the corresponding IC50 concentrations 
combined with 100 nM of Decitabine (5-Aza-2′-deoxycytidine)(Catalogue No. A3656-Sigma) 
and pre-treated with 1 mM Valproic acid (VPA)(Catalogue No. P4543-Sigma).  
For SHMT1 inhibition experiment, PJ15 cells were exposed to 25 mM of Amonimethyl 
phosphonic acid (AMPA)(Catalogue No. 324817-Sigma) synchronously with seven different 
concentrations of 5-FU ranging from (0-1 mM). Cells were incubated for 72 hours and the 
culturing medium was changed every 24 hours with fresh drugs.  
2.5.4 MTT assay 
MTT assays were used in this study to assess cell metabolic activity. Viable cells with active 
metabolism are capable of reducing the tetrazolium dye MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide into a purple-coloured formazan product with a maximum 
absorbance near 570 nm. Since dead cells have no ability to convert MTT into its insoluble 
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formazan, colour formation serves as a useful marker of viable cells only (Berridge et al. 2005). 
Cells already seeded and/or exposed to the chemotherapeutic drugs in 48 well plates for the 
appropriate time course were washed with PBS and incubated (at 37 ᵒC supplemented with 
5% CO2) with MTT (3-(4,5-dimethy1–2-thioazoyl) 2,5-diphenyltetrazolium 
bromide)(Catalogue No. M5655 - Sigma-Aldrich) made up in a fresh medium to a final 
concentration of 0.75 mg/ml for 3-4 hours (or until purple precipitates became visible). Then, 
the medium was discarded and the converted formazan crystals were solubilised by lysing the 
cells with 200 μl of 0.04 M HCl in isopropyl alcohol. Five minutes later, the quantity of 
formazan quantity (presumably proportional to the number of viable cells) was determined 
by recording changes in absorbance using a GENios plate reader (Tecan Austria GmBH), which 
records the optical density (O.D.) at 590 nm with a 630 nm reference absorbance. 
 
 
2.6 DNA methylation analysis 
2.6.1 DNA extraction 
Total cell line DNAs were extracted using a DNeasy® Blood and Tissue Kit (QIAGEN) (Spin 
column protocol). Briefly, cells were seeded in 75 cm2 until they reached 75%-80% 
confluence. The cells were lysed in the culture flask, the liquid medium was aspirated and the 
cells were washed with PBS, then 500 μl of ATL lysis buffer with 10 μl proteinase K (Qiagen) 
were added. The adherent cells were then scraped off the culture flask using a plastic cell 
scraper.  500 μl of AL lysis buffer was then added and the entire cell lysate was thoroughly 
mixed and transferred into clean 2 ml microcentrifuge tubes. The cell suspension-containing 
tubes were then incubated at 56 ᵒC for 15-60 minutes. After the incubation time, 500 μl of 
ethanol (96–100%) were added to the sample and mixed thoroughly by vortexing. The 
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mixture was then transferred into the DNeasy Mini spin column (which carries a silica based 
membrane) placed in a 2 ml collection tube, and centrifuged at 16000 x g for 1 min. 700 μl of 
Buffer AW1 was added, and the sample was centrifuged for 1 min at 16000 x g . 680 μl of 
Buffer AW2 was then added and the sample was centrifuged for 1 min at 16000 x g. The 
second washing step was repeated and the columns were then spun for an additional 4 
minutes in order to dry the DNeasy membrane. The DNeasy mini spin column was then placed 
in a 1.5 ml microcentrifuge tube and the DNA was recovered into 50 μl Buffer AE and left to 
stand for 5 minutes at room temperature. Then, elution of the sample DNA was completed 
by centrifuging the columns at 16000 x g for 1 min. DNA quality and quantity were then 
assessed by spectrophotometry at a wavelength of 260/280 nm. 
2.6.2 Bisulphite treatment of DNA 
In order to explore the DNA methylation status of CBS and SHMT1 knockdown clones relative 
to their parental controls, we performed bisulphite genomic sequencing using the EZ DNA 
Methylation-Gold™ Kit (Catalogue Nos. D5005 & D5006-ZymoResearch) following the 
manufacturer protocol. The CT Conversion Reagent was prepared by adding 900 μl of water, 
300 μl of M-Dilution buffer and 50 μl M-Dissolving Buffer in that exact order. Then, the 
mixture was vortexed for about 2 minutes and left on a rotating mixer for another 8 minutes. 
The M-Wash Buffer was prepared by adding 24 ml of 100% ethanol to the 6 ml M-Wash Buffer 
concentrate (D5005) or 96 ml of 100% ethanol to the 24 ml M-Wash Buffer concentrate 
(D5006) before use. Then a conversion reaction was performed by mixing 130 μl of CT 
Conversion Reagent with 20 μl of each DNA sample (1 µg) in a PCR tube strip, and samples 
were mixed by flicking the tube or pipetting up and down, before the liquid was briefly 
centrifuged to the bottom of the tube. After that, the sample tubes were placed in the thermal 
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cycler and the following steps were performed: 98 °C for 10 minutes, 64 °C for 2.5 hours. In 
the bisulphite conversion reaction, unmethylated Cytosine (C) is converted to Uracil (U), 
whereas methylated Cytosine (mC) remains unchanged. 
2.6.3 Reaction clean up 
Following the conversion reaction, the converted bisulphite samples were transferred to a 1.5 
ml tube containing 600 μl of M-Binding Buffer, and pipetted very well. The resulting mix was 
then transferred into a Zymo-Spin™ IC Column placed on a provided collection tube. The tubes 
were centrifuged at >10000 x g for 1 minute and the flow-through was discarded. 200 μl of 
M-Wash Buffer were added to the column and centrifuged at >10000 x g for 1 minute. 200 μl 
of M-Desulphonation Buffer was then added to the column and the mixture was left at room 
temperature (20°C–30°C) for 15-20 minutes. Following the incubation period, the columns 
were centrifuged at full speed for 30 seconds and the flow-through was discarded. Then, 300 
μl of M-Wash Buffer was added and the columns were centrifuged at full speed for 30 
seconds. Another 300 μl of M-Wash Buffer were added and centrifuged for additional 4 
minutes to ensure complete removal of alcohol traces. Next, Zymo-Spin™ IC Columns were 
placed onto a 1.5 ml microcentrifuge tube and 35 μl of the M-Elution Buffer, pre-warmed to 
65 °C, was added directly into the column matrix. The columns were then incubated at room 
temperature for 5 minutes and spun down at full speed for 1 minute to elute the DNA.  
2.6.4 Preparation of Pyrosequencing samples 
The first part of our LINE1 pyrosequencing process was started with the preparation of the 
samples that were to be sequenced. The targeted DNA sequence was amplified by PCR using 
LINE 1 assay (Genbank accession no M80343). Primers were designed by the assay design 
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software (PyroMark assay design 2.0 software) with one of the two PCR primers being 
biotinylated (Table 2.9).  
 
         Table 2. 9: Designed Primers for LINE-1 pyrosequencing assays. BIO: biotinylated end. 
 
 
 
 
PCR amplifications were performed using Qiagen HotStarTaq Plus Master Mix Kit, 5 μΜ 
biotinylated primer with 10 μΜ non-biotinylated primer and 3 μl (approximately 60 ng) of 
bisulphite-treated DNA were used. The thermal profile of the LINE1 amplification is shown in 
(Table 2.10). 
  
 
             
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Promoter Forward primer  (5’→3’) Reverse primer (5’→3’) 
Sequencing primer 
(5’→3’) 
LINE-1 BIOTAGGGAGTGTTAGATAGTGG AACTCCCTAACCCCTTAC 
CAAATAAAA 
CAATACCTC 
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Table 2. 10: Thermal profile for LINE-1 amplification PCR reactions. 
 
 
 
 
 
 
 
Following the amplification reaction, the PCR product quality was checked in 2% agarose gel 
and visualised on a UVP VisionWorks LS instrument. At the end of the PCR reactions, Uracil 
(U) is amplified to Thymine (T), whereas methylated Cytosine (mC) is amplified to Cytosine (C). 
Discrimination between mC and C is thereby achieved by transforming mC and C to appear as 
a C/T SNP (Figure 2.2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
Step 
Temperature (oC) Time No of cycles 
Taq Activation 95 5 min  
Denaturation 94 30 sec  
Annealing 58 45 sec 40 
Extension 72 45 sec  
Final extension 72 10 min  
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2.6.5 Pyrosequencing analysis 
The LINE1 methylation status of PE/CA-PJ15 and H358 knockdown clones was evaluated using 
the SQA kit following the suppliers protocol (Qiagen) and the reaction was performed on a 
96MA Pyrosequencer (Qiagen). Briefly, the amplified product was mixed with 75 µl of 
pyrosequencing binding mix (which contains 50 µl of Pyromark Binding Buffer, 23 µl of ddH2O 
and 2 µl of streptavidin-coated sepharose beads. The whole mixture was then directly 
transferred into a 96-well pyrosequencing plate. With the help of a vacuum preparation tool, 
Figure 2.2: An example of a DNA sequence illustrating the principle of sequence 
based methylation analysis. The methylated C (green) and unmethylated C (red) 
are differentiated by PCR and bisulphite conversion reactions. Subsequently, 
pyrosequencing measures the unmethylated C and methylated C as the relative 
content of T and C at the CpG sequence, respectively. The figure is taken from  the 
Qiagen website.  
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the beads, in which the desired PCR product was bound, were held against a filter, thereby 
capturing and holding them during the subsequent purification steps. The tips of the filters 
were then immersed (for 5 seconds) in three successive baths, containing 70% ethanol, NaOH 
and wash solution, respectively.  NaOH denatures and separates the strands, while the wash 
buffer neutralises the immobilised strand. As a result, at the end of the above procedure, only 
the streptavidin beads with the biotinylated strand of the PCR products remained in the tool. 
The beads were then released by gentle shaking into a new 96-well pyrosequencing plate 
containing 45 µl of the annealing mix per well (the annealing mix was composed of 43.5 µl of 
PyroMark Annealing Buffer and 1.5 µl of LINE1 pyrosequencing primers). The sequencing 
plate was then incubated at 80 °C for 2 minutes and left at room temperature for 2 minutes 
to cool down. Meanwhile, nucleotides, substrates and enzyme reagents were dispensed onto 
the appropriate wells of the pyrosequencing cartridge. After the pyrosequencing plate and 
cartridge were loaded inside the pyrosequencer instrument, the template DNA, together with 
the annealed sequencing primer, were incubated with the enzymes DNA polymerase, ATP 
sulphurylase, luciferase and apyrase, in addition to the enzyme substrates adenosine 5’ 
phosphosulphate (APS) and luciferin. The four triphosphates (dNTPs) were injected into the 
reaction one at time repeatedly in a cyclic manner. DNA polymerase catalyses the 
incorporation of the first dNTP into the DNA strand if it forms a base pair with the template 
strand. Each incorporation event is accompanied by release of inorganic pyrophosphate (PPi) 
in an equivalent quantity to the amount of incorporated nucleotide. PPi serves as a substrate 
for the enzyme ATP sulphurylase that converts PPi to ATP in the presence of APS. This ATP 
drives the luciferin to oxyluciferin, which generates visible light signal in amounts that are 
proportional to the amount of the ATP. The light produced in the luciferase-catalysed reaction 
was detected by a charge coupled device (CCD) camera and seen as a peak in a pyrogram. The 
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height of each peak (light signal) is proportional to the number of nucleotides incorporated 
(Figure 2.2). The apyrase enzyme helps to remove the unincorporated nucleotides along with 
ATP. This nucleotide degradation process in between base additions is essential for 
coordinated DNA synthesis. As the process continues, the complementary DNA strand is built 
up and the nucleotide sequence is determined from the signal peaks in the pyrogram (Figure 
2.3).  
 
  
 
  
   
 
 
    
 
 
 
 
 
 
 
 
Figure 2.3: Schematic representation of pyrosequencing technology principles. 
Taken from Russom et al. (2005) 
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2.7 Transfection 
2.7.1 SHMT1 and CBS knockdown by shRNA 
Three different constructs were used to target SHMT1 and CBS mRNA expression (Table 2.11), 
belonging to type TRC2-pLKO-puro Vector along with a scrambled control construct, which 
was MISSION TRC2 pLKO.5-puro Non-Mammalian shRNA Control Plasmid DNA (Sigma-
Aldrich) (Figure 2.4). 
 
 
Table 2. 11: SHMT1 and CBS genes knock down constructs from the MISSION shRNA library (Sigma) 
 
Clone ID 
 
Clone 
legacy 
number 
 
                    Target sequence  
 
Target 
region 
SHMT1    
TRCN00000
34764 
 
NM_00416
9.3-
1141s1c1 
 
CCGGGCAAGCTATGACTCTGGAATTCTCGAGAATTC
CAGAGTCATAGCTTGCTTTTTG 
 
CDS 
 
TRCN00000
34765 
 
NM_00416
9.3-
715s1c1 
 
CCGGCCCAGATACTGGCTACATCAACTCGAGTTGAT
GTAGCCAGTATCTGGGTTTTTG 
 
CDS 
 
TRCN00000
34767 
 
NM_00416
9.3-
1456s1c1 
 
CCGGCCACTTTATTCACAGAGGGATCTCGAGATCCC
TCTGTGAATAAAGTGGTTTTTG 
 
CDS 
 
CBS    
 
 
TRCN00000
45360 
 
 
 
NM_00007
1.1-
409s1c1 
 
 
 
CCGGCTTGCCAGATATTCTGAAGAACTCGAGTTCTTC
AGAATATCTGGCAAGTTTTTG 
 
 
 
CDS 
 
TRCN00000
45361 
 
NM_00007
1.1-
1604s1c1 
 
CCGGCCGTCAGACCAAGTTGGCAAACTCGAGTTTGC
CAACTTGGTCTGACGGTTTTTG 
 
CDS 
 
TRCN00000
45362 
 
NM_00007
1.1-
600s1c1 
 
CCGGACACGATTATCGAGCCGACATCTCGAGATGTC
GGCTCGATAATCGTGTTTTTTG 
 
CDS 
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Figure 2.4: Graphic maps of TRC2-pLKO-puro plasmid with the shRNA insert (A) and 
MISSION TRC2 pLKO.5-puro Non-mammalian shRNA Control Plasmid DNA (B). Both figures 
were taken from the Sigma-Aldrich website. 
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2.7.2 Propagation of MISSION short hairpin RNA (shRNA) constructs 
The MISSION shRNA constructs utilised in this study were propagated in an LB medium. 1 ml 
of construct was inoculated in 150 ml of LB medium supplemented with 100 µg/ml of 
Ampicillin and left overnight at 37 °C in a shaking incubator at 150 rpm. Isolation of the 
plasmid was performed the next day. 
 
2.7.3 shRNA constructs DNA isolation 
The plasmids of the shRNA constructs were extracted using ZyppyTM Plasmid Maxiprep Kit 
(Catalogue No. D4027& D4028-Zymo Research) according to the manufacturer instructions. 
In brief, 150 ml of fresh bacterial culture was split into 3 x 50 ml Falcon tubes and spun at 
3,400 x g for 10 minutes. The supernatant was then discarded in a beaker with triagene. 15 
ml of P1 Buffer (Red) was then added to the bacterial cell pellet (5 ml for each 50 ml tube), 
completely re-suspended by vortexing and combined in a single tube. Then 15 ml of P2 Buffer 
(Green) was added and immediately mixed by inverting the tube 4-6 times, and the tube was 
then let to stand for one minute to lyse the cells completely. 20 ml of P3 Buffer (Yellow) were 
added and thoroughly mixed until a homogenous colour was achieved; the mixture was then 
incubated on ice for 5 minutes. The Zymo-Maxi Filter™/Zymo-Spin™ VI column assembly was 
placed onto a vacuum manifold and the entire mixture was added directly into the Blue Maxi 
Filter column. After the cell debris floated to the surface, the vacuum was turned on until all 
of the liquid had passed completely through both columns. The blue Zymo-Maxi Filter™ 
column was removed and discarded from the top of the Zymo-Spin™ VI column. The columns 
were then placed in 50 ml tubes and centrifuged at 5000 x g for 1 minute to remove any 
mixture left in the column walls. After that, the columns were placed back onto the vacuum 
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manifold and 10 ml of Endo-Wash Buffer were added to the Zymo-Spin™ VI column and the 
vacuum was turned on. After the Endo-Wash Buffer had completely passed through the 
Zymo-Spin™ VI column, 10 ml of Zappy Wash Buffer were added and the vacuum was turned 
on. The Zymo-Spin™ VI column was then transferred into a clean 50 ml tube and centrifuged 
at full speed for 1 minute. The 50 ml tubes were then discarded and columns were placed 
into new 50 ml tubes. 2 ml of Zyppy-Elution Buffer, pre-warmed to 65 °C, was then added 
directly to the column matrix and incubated at room temperature for 5 minutes. Following 
the incubation period, the columns were centrifuged for 1 minute at 5000 x g to elute the 
plasmid DNA that subsequently was transferred to a clean 2 ml microcentrifuge tube. The 
plasmid DNA quality and quantity were assessed by spectrophotometry at a wavelength of 
260/280 nm. 
 
2.7.4 Transfection of Cell lines  
PE/CA-PJ15 and H358 cell lines were transfected with SHMT1 and CBS shRNA constructs using 
two different transfection protocols. For TRCN0000045360, TRCN0000045361, 
TRCN0000045362, TRCN0000034765 and TRCN0000034764, we utilised XfectTM Transfection 
Reagents (Clontech) following the manufacturer protocol. Briefly, 60 mm of tissue culture 
dish was seeded with 5 x 105 cell/ml and cultured in 3 ml of culture medium containing serum 
and antibiotics. Cells were incubated under normal growth conditions (37 oC and 5% CO
2
) until 
they reached 60%-70% confluent. On the day of transfection, 5 μg of plasmid DNA were 
diluted with Xfect Reaction Buffer to a final volume of 100 μl and mixed by vortexing for 5 
seconds at high speed. 1.5 μl of Xfect Polymer was then added to the diluted plasmid DNA 
and mixed by vortexing at high speed for 10 seconds. The entire mixture was then incubated 
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at room temperature for 10 minutes to allow the nanoparticle complexes to form. 
Meanwhile, the medium from the cells was gently aspirated, the culturing disk was washed 
with 4 ml PBS and 3 ml fresh medium (containing 1% serum and antibiotics) were added to 
the cells.  Subsequently the transfection complex was spun down for 1 second and added 
drop-wise onto the cells culture medium and the dish was gently swirled to ensure uniform 
distribution of the transfection complexes before the cells were incubated for 24 hours. Then, 
the Xfect complex was removed from the cells by gentle aspiration and replaced with 3 ml 
fresh complete growth medium and the dish returned back to the incubator under their 
normal growth conditions. 
For the transfection of cells with (TRCN0000034767) shRNA construct we used the FuGENE 
HD Transfection Reagent (Promega) following the manufacturer protocol. One day prior to 
the transfection, cells were seeded at 5 x 105 cell/ml in a 10 cm2  dish and cultured in 8 ml 
fresh growth medium supplemented with 5% serum and antibiotic. The transfection was 
performed at approximately 50% confluence,. Following 10-15 minutes incubation at room 
temperature, 24 μl FuGENE® HD Transfection Reagent were mixed with 8 μg of plasmid DNA 
diluted with fresh culture medium, so that the final volume of FuGENE® Transfection 
Reagent/DNA mixture was 400 μl. The mixture was then briefly vortexed, spun down and 
incubated at room temperature for 7 minutes. While complex formation took place, the 
medium from the cells was gently aspirated, the dish was washed with 10 ml PBS and then 
2 ml of fresh medium (containing serum and antibiotics) was added to the cells. The entire 
mix was then added drop wise to different areas of the dish containing the plated cells with a 
gentle rocking back and forth motion to ensure even distribution of the transfection mixture. 
Subsequently, the culture dish was incubated at normal growth conditions (37 oC and 5% CO
2
) 
for 48 hours. 
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2.7.5 Generation of PE/CA-PJ15-SHMT1 and H358-CBS down regulated stable cell line 
clones 
PE/CA-PJ15 and H358 cells were transfected with the shRNA constructs that are able to 
efficiently silence the expression of the aforementioned genes. These short hairpin constructs 
carry the puromycin resistance gene. In order to determine the optimal concentration of 
puromycin, we examined the kill curve of PJ15 and H358 cells in the presence of various 
concentrations of puromycin. The lowest concentration of puromycin that promoted 
complete death of PJ15 and H358 cell lines was determined as 0.5 μg/ml and 3 μg/ml, 
respectively. 24-48 hours after transfection of cells with CBS/SHMT1 shRNAs and scramble 
plasmids, cells were grown in a complete growth medium containing puromycin. The growth 
medium and antibiotic was replenished every 2-3 days. After 2 weeks of selection, colonies 
were isolated using cloning cylinders, trypsinised and grown in new flasks under normal 
growth conditions and in the presence of puromycin selection antibiotic. CBS and SHMT1 
downregulation was checked at both mRNA (qPCR) and protein (western blot) levels. Clones 
demonstrating >50% knockdown efficiency were grown and used for further functional 
analysis. 
 
2.8 Western blot 
2.8.1 Protein extraction  
PE/CA-PJ15 parental and knockdown cells were seeded in 25 cm2 until they reached 75%-80%. 
The culture medium was then aspirated, and the culture flask was placed on ice and cells were 
washed twice with ice-cold PBS. After that, the cells were lysed with Protein Extraction Buffer 
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(PEB)(25 μl per 1 cm2 of growth area) supplemented with Protease inhibitor cocktail and PMSF 
(0.3M in DMSO) (Table 2.12). 
 
The adherent cells were then scraped off the culture flask using a cold plastic cell scraper, and 
the cell lysate was gently transferred into a pre-cooled microcentrifuge tube. Subsequently, 
the tubes containing the cell suspension were incubated on an ice bath for 15 minutes. An 
additional lysis step was performed by sonication using a Bioruptor Sonication System 
(Catalogue no. B01010001 (UCD 200 TM) - Diagenode) following the manufacturer 
instructions. In brief, The Bioruptor sonicator was pre-cooled with ice-chilled water to keep it 
at 4 oC throughout the sonication time. Cell lysate tubes were placed in the tube holder and 
sonication cycle conditions were 15 sec. on/15 sec. off for 3 minutes. Next, sonicated cell 
lysates were centrifuged at 12000 x g for 15 min at 4 oC to remove any remaining insoluble 
Table 2.12: Reagents used for preparation of Protein Extraction Buffer 
Solution    ml Provider Cat. no. 
1M Tris-HCl pH=7.4 12.5 Fisher Scientific  BP152-1 
Glycerol 
 
12.5 Sigma-Aldrich G5516 
Deoxycholate 6.25% 5 Sigma-Aldrich D6750 
5M NaCl 
 
2.5 Sigma-Aldrich S9625 
0.5M EDTA, pH= 7.4 1 AnalaR 100935V  
Triton X-100 1.25 Sigma-Aldrich T8787 
SDS 20% 
 
0.625 Sigma-Aldrich L3771 
ddH20 
 
64.625 
  
Supplements 
   
Protease inhibitor cocktail  0.1 Sigma-Aldrich S8830 
PMSF (0.3M in DMSO) 0.0035 Sigma-Aldrich P7626 
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material. Then, the supernatants containing soluble proteins were carefully transferred to 
new 1.5 ml tubes and aliquots were taken for quantification, with the remaining protein 
extracts being stored at -20 for further analysis. 
 
2.8.2 Protein quantitation with BicinChoninic Acid (BCA) assay 
2.8.2.1 Preparation of bovine serum albumin (BSA) standard curve 
In order to generate the standard curve, a set of seven standard concentrations of BSA (0.125, 
0.25, 0.5, 1, 2, 4, and 8) mg/ml was prepared from 20 mg/ml stock (Catalogue no. A7906 - 
Sigma-Aldrich) using the same diluent as the samples (PEB). The BCA working reagents were 
prepared according to the manufacturer instructions. 1 unit of reagent B: 50 units of reagent 
A) were mixed and briefly vortexed (reagent A catalogue no.23228, reagent B catalogue no. 
23224 - Thermo Fisher Scientific). Then, 4 μl of each BSA dilution was mixed thoroughly with 
80 μl BCA working reagent by vortexing. The mixture was then incubated at 37 oC for 30 
minutes and left at room temperature for an additional 5 minutes. The BSA standard curve 
was then plotted, and concentrations of unknown protein samples were measured using the 
NanoDrop 2000 Spectrophotometer (Thermo Fisher Scientific) according to the User Manual 
V1.0. 
2.8.3 Electrotransfer, immunoblotting and detection. 
2.8.3.1 Protein samples preparation for electrophoresis 
In order to prepare the samples for SDS polyacrylamide gel electrophoresis, 20 µg of total 
protein from PJ15 cells and down regulated clones were mixed together with 2.5 µg of (4x) 
NuPAGE® LDS Sample Buffer (Catalogue no. NP0008 - Life Technologies), 1 µl of (10x) NuPAGE 
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Reducing Agent (Catalogue no. NP0004 - Life Technologies) and ddH20, up to a total reaction 
volume of 10 µl. The entire mixture was then denatured by incubation at 70 oC for 10 minutes. 
2.8.3.2 NuPAGE® Gels electrophoresis for proteins 
For total protein electrophoresis, NuPAGE Novex Bis-Tris-Acetate (SDS-PAGE) Mini gels 
(Catalogue no. NP0321PK2 - Novex) were used. The comb was removed and gel wells were 
rinsed twice with 1x NuPAGE Tris-Acetate SDS running buffer (Catalogue no. LA0041 - 
Invitrogen). After removing the white tape near the bottom, the gels were placed in the XCell 
SureLock™ Mini-Cell gel running tank (Catalogue no. EI0001 - Invitrogen). The upper chamber 
was filled with 200 ml of 1x NuPAGE Tris-Acetate SDS running buffer mixed with 500 µl of 
NuPAGE Antioxidant (Catalogue no. NP0005 - Invitrogen), while the lower chamber was filled 
with 600 ml of 1x NuPAGE Tris-Acetate SDS running buffer. Then, the denatured protein 
samples were loaded on the gels together with SeeBlue® Plus2 Pre-Stained Standard 
(Catalogue no. LC5925 - Invitrogen). The gels were run at 200 V (110-125) mA/ gel for 45 
minute.  
2.8.3.3 iBlot Western Detection 
For blotting of the electrophorised proteins we used the iBlot®
 
Dry Blotting System (Catalogue 
no. IB1001 Invitrogen). Following electrophoresis, the gels were released from the cassette 
plates. The first gel was rinsed with ddH2O (3X 5 minutes), stained with Commassie Blue (e.g. 
Simple Blue SafeStain by Invitrogen), destained with water (3x 5 minutes), and photographed 
with the aid of a UVP VisionWorks LS instrument. The second gel was used for blotting. It was 
placed onto the PVDF blotting surface of an Anode iBlot Gel Transfer Stack (Catalogue no. 
IB8010-01 - Novex) and covered with pre-soaked (in deionised water) iBlot filter paper. The 
Cathode iBlot Gel Transfer Stack was then placed on the top of the filter paper and toped over 
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with side facing up and aligned to the right edge. The air bubbles were removed using a 
blotting roller. A disposable sponge with a metal contact was placed on the upper right corner 
of the lid. The lid was securely closed and the iBlot Dry Blotting System was switched on at 
program P3 for 9 min. Subsequently, the iBlot Gel Transfer Stacks were disassembled and the 
PVDF blotting membrane was then blocked in 5 ml 1x iBind™ Buffer supplemented with 1x 
iBind™ additive for 5 minutes at room temperature. The iBind Western System (Life 
Technologies) was employed to apply the binding primary and secondary antibodies (at 
dilutions of 1:1000) and the washing steps. Rabbit monoclonal primary antibodies to SHMT1 
(Catalogue no. 80715S - Cell Signaling Technology), and β-actin (Catalogue no. 8457S - Cell 
Signaling Technology) were used as primary antibodies, while Anti-rabbit IgG HRP-linked 
antibody (Catalogue no. 7074S - Cell Signaling Technology) served as secondary antibodies. 
Both antibodies were used as recommended by the manufacturer protocol and, since they 
worked well, no further calibration was required. The immune complexes were detected 
using the Chemiluminescence Imaging System- GENESys (SYNGENE). 
 
2.9 Statistical analysis 
Differences in the expression of folate pathway genes between tumour and adjacent non-
tumour samples were evaluated using Wilcoxon signed rank test, the non-parametric 
statistical test for paired analysis. Overexpression for a tumour sample was designated based 
on the 95% reference range of normal tissues (mean + 2x SD). The study characteristics were 
examined using descriptive statistics. Categorical variables were compared using the chi-
squared test and continuous variables were examined using the Mann-Whitney test because 
of non-normality. The correlation (r) between the mRNA expression of the six folate genes 
was assessed by means of bivariate analysis (Spearman test). 
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Overall survival time was calculated from the date of surgery to the date of death or last 
follow-up date. All statistical analyses were performed using IBM® SPSS® statistics for 
Windows, software version 24.0 (Armonk, NY: IBM Corp). The IC50 values were determined 
using Prism 6.0 (GraphPad), which is able to fit a dose response curve with log concentration 
values (on the X axis), while the response was plotted on the Y axis. Prism calculates IC50s 
using nonlinear regression log (inhibitor) vs. normalised response equation.  
P<0.05 was considered statistically significant. 
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Chapter 3: Deregulation of folate 
pathway genes in NSCLC 
 
This chapter describes the experimental work undertaken in human lung cancer tissue 
samples and cell lines in order to ascertain a detailed mRNA expression profile of major genes 
related to folate metabolism. The aim of this part of the project was to identify which are the 
important targets of deregulation in this pathway, and to investigate potential relationships 
with clinicopathological data. In addition, based on this data, we decided which would be the 
most interesting gene targets to manipulate genetically (Chapter 5) in order to test their 
function in the cancer phenotype and for drug resistance.  Finally, the relative expression of 
CBS and SHMT1 splice variants, which were qualified as major targets for reasons discussed 
below, was also determined in NSCLC surgical tissues and cell lines, as well as three HNSCC 
cell lines. 
 
3.1 Expression status of folate genes in primary lung tumours 
The quality of the RNA from all the primary lung cancer tissue samples included in this study 
was confirmed using the 2100 Agilent Bioanalyser using RIN (RNA integrity number) value ≥ 7 
as an inclusion criterion. Initially, we investigated the mRNA expression of nine folate genes 
(AHCY, MAT2A, MTR, SHMT1, TYMS, CBS, DHFR, DNMT1 and MTHFR) in 54 frozen lung 
tumours and paired adjacent normal tissues. Gene expression analysis demonstrated 
significant expression differences between normal and tumour tissues in six of the examined 
genes (SHMT1, TYMS, CBS, DHFR, DNMT1 and MTHFR) (Figure 3.1). This finding was 
subsequently validated in a new set of 50 pairs of NSCLC samples and adjacent normal lung 
103 
tissue. For all 6 genes in the new set the difference in expression between normal and tumour 
tissues remained statistically significant. mRNA expression levels of DNMT1, CBS, DHFR 
SHMT1 and TYMS were significantly higher in lung cancer tissue than paired adjacent normal 
tissue (Wilcoxon test p<0.001, p<0.002, p=0.003, p=0.015 and p<0.001 respectively) while the 
MTHFR gene demonstrated significant downregulation in the same set (Wilcoxon test, 
p=0.014)(Figure 3.2). 
The original plan of this project included mRNA expression screening for these genes in HNSCC 
tumours as well, however few good quality specimens were available, due to the loss of 
frozen specimens because of a freezer fault. It was therefore decided to proceed with NSCLC 
tissue samples only. 
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MAT2A p=0.587 MTR p=0.398 AHCY p=0.318 
SHMT1 p=0.037 TYMS p=0.001 
Figure 3.1: Preliminary analysis of mRNA expression in 54 pairs of NSCLC tumours and adjacent normal lung tissues. P-values were derived from the Wilcoxon signed ranked 
test. RQ values were calculated using the HBEC-3KT cell line as a calibrator. RQ=relative quantification 
 
CBS p=0.03 
DHFR p=0.009 DNMT1 p=0.013 MTHFR p=0.015 
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DNMT1 p<0.001 MTHFR p=0.014 
CBS p<0.002 DHFR p=0.003 
SHMT1 p=0.015 TYMS p<0.001 
Figure 3.2: Validation of mRNA expression analysis of the top six genes from the preliminary analysis round, in an 
independent set of 50 pairs of NSCLC tumours and adjacent normal lung tissue. P-values were derived from the 
Wilcoxon signed ranked test. RQ values were calculated using the HBEC-3KT cell line as a calibrator. RQ= Relative 
quantification. 
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Having established the significant difference in both independent sets of samples, we 
combined the data of the two sets in order to investigate associations with clinicopathological 
parameters, utilising a larger sample (104 T/N pairs) and therefore potentially increasing the 
statistical power. Ahead of this analysis, we explored the potential correlation between the 
expression of the six highly deregulated genes. Spearman correlation showed a significant 
relationship between DNMT1 and DHFR (r=0.708, p=4.1×10-17) as well as between DNMT1 
and TYMS (r=0.67, p= 4.4×10-15); relationships that both stood true after Bonferroni 
correction (i.e. multiplied by 6 to adjust for six independent comparisons). 
In order to facilitate comparative analysis to clinicopathological features, we dichotomised 
the expression to normal (within the 95% prediction interval1 = mean±2xSD, based on the 
values of normal lung tissues) or abnormal (outside the 95% PI). The analysis only 
demonstrated trends for MTHFR overexpression in adenocarcinoma (chi-square test, 
p=0.029) and DNMT1 and nodal status (chi-square test, p=0.059) (Figure 3.3). No other 
significant relationship to clinical or epidemiological association (age, gender, differentiation 
or T-stage, overall survival) was observed.  
  
                                                          
1 Also referred to as the “Reference Range” 
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Figure 3.3: Histograms demonstrating the distribution of abnormal and normal expression of 
MTHFR in adenocarcinomas and squamous carcinomas (top) and DNMT1 in samples with no 
nodal involvement compared to those with positive nodes (bottom). P-values were derived 
from the Pearson chi square test. RQ=relative quantification, AdenoCa=adenocarcinoma, 
SqCCL=Squamous cell carcinoma. 
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3.2. Expression profiling of folate genes in respiratory tract cell lines 
DHFR, MTHFR, CBS, SHMT1, TYMS, DNMT1 gene expression profiles were also evaluated in a 
panel of seven NSCLC and three HNSCC cell lines, along with the immortalised normal human 
bronchial epithelial cells (HBEC-3KT). The HNSCC cell lines included in this study were of oral 
squamous cell carcinoma origin, while NSCLC cell lines were derived from different 
histological origins including adenocarcinoma, squamous cell carcinoma and large cell 
carcinoma. Gene expression analysis of the six folate genes in the ten investigated cell lines 
in comparison to a normal bronchial epithelial cell line (HBEC), using RT-qPCR, revealed 
consistent overexpression of TYMS and DNMT1  (Figure 3.4 and Figure 3.5). Expression of 
DHFR was elevated in most of the tumourigenic cells with borderline reduction in CALU6, 
SKLU1 and SKMES (Figure 3.6). Likewise, most of the RTCs cell lines demonstrated upregulated 
SHMT1 mRNA, with the exception of SKLU1, SK-MES, CORL23 and BHY (Figure 3.7). The 
MTHFR expression level was consistently lower than that of HBEC-3KT in both the NSCLC and 
HNSCC cell lines, however (Figure 3.8). The CBS mRNA level was also downregulated among 
the tested cancer cell panel ecept for the LUDLU and H358 cells lines (Figure 3.9).  
These findings correlate with the tissue expression results for the DHFR, MTHFR, SHMT1, 
TYMS and DNMT1 genes, except for CBS, which was downregulated in the RTCs cell lines and 
overexpressed in the lung cancer tissues.  
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Figure 3.4: TYMS mRNA expression in NSCLC, HNSCC and non-tumorigenic human 
bronchial epithelial cells (HBEC-3KT). TYMS demonstrated significantly higher mRNA 
expression levels among NSCLC and HNSCC cell lines compared to that of HBEC-3KT. Bars 
represent the mean values of three technical repeats and error bars represent standard 
error of the mean. HBEC-3KT was used as a calibrator. RQ=relative quantification.     
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Figure 3.5: DNMT1 mRNA expression in NSCLC, HNSCC and non-tumorigenic human 
bronchial epithelial cells (HBEC-3KT). DNMT1 demonstrated significantly higher mRNA 
expression levels among NSCLC and HNSCC cell lines compared to that of HBEC-3KT. Bars 
represent the mean values of three technical repeats and error bars represent standard 
error of the mean. HBEC-3KT was used as a calibrator. RQ=relative quantification.   
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Figure 3.6: DHFR mRNA expression in NSCLC, HNSCC and non-tumourigenic human bronchial 
epithelial cells (HBEC-3KT). DHFR was overexpressed in seven out of ten NSCLC and HNSCC cell 
lines compared to immortalised normal bronchial epithelial cell lines. Bars represent the mean 
values of three technical repeats and error bars represent standard error of the mean. HBEC-
3KT was used as a calibrator. RQ=relative quantification.     
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Figure 3.7: SHMT1 mRNA expression in NSCLC, HNSCC and non-tumorigenic human bronchial 
epithelial cells (HBEC-3KT). An upregulation of SHMT1 was observed in seven cell lines with a 
border line reduction in the remaining three (CORL23, SK-MES1 and BHY) compared to 
immortalised normal bronchial epithelial cell lines. Bars represent the mean values of three 
technical repeats and error bars represent standard error of the mean. HBEC-3KT was used as a 
calibrator. RQ=relative quantification.    
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Figure 3.8: MTHFR mRNA expression in NSCLC, HNSCC and non-tumourigenic human bronchial 
epithelial cells (HBEC-3KT). The examined cell lines express MTHFR at different levels, however 
consistently lower than that of the non-tumourigenic human bronchial epithelial cell line. Bars 
represent the mean values of three technical repeats and error bars represent standard error 
of the mean. HBEC-3KT was used as a calibrator. RQ=relative quantification.    
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Figure 3.9: CBS mRNA expression in NSCLC, HNSCC and non-tumourigenic human bronchial 
epithelial cells (HBEC-3KT). The expression levels of CBS varied among the investigated 
cancer cell lines panel being highest in LUDLU-1 and H358 and lowest (undetermined) in 
BHY and CALU6 cell lines. Bars represent the mean values of three technical repeats and 
error bars represent standard error of the mean. HBEC-3KT was used as a calibrator. 
RQ=relative quantification.  
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3.3 Splicing variant expression profiles of SHMT1 and CBS in NSCLC 
Following the establishment of deregulation of the six folate genes in lung cancer, a strategic 
decision was taken to focus on the SHMT1 and CBS genes, since there is negligible information 
in the literature in respect to their involvement in human cancer. Splicing variation was the 
first aspect to investigate. While there is a large body of experimental data about splicing 
isoforms of folate metabolic genes, CBS and SHMT1 splicing is currently less studied.  
Utilising Genbank entries for the identified splice variants of these genes (Figure 3.10), 
endpoint PCR assays were designed (as in the Materials and Methods), initially to ascertain 
the presence of four CBS and three SHMT1 splice variants in 13 human lung cancer cell lines 
and two normal embryonic lung fibroblast cell lines: IMR90 and LUNG14. The results showed 
that all of the splice variants are expressed in the examined cell lines except SHMT1 variant 3 
(SHMT1v3)(Figure 3.11A). Additional screening for this variant was therefore undertaken on 
four pairs of NSCLC tumour and adjacent normal tissue samples, which revealed its 
expression, albeit at a very low level (Figure 3.11B). 
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Figure 3.10: Schematic representation of (A) CBS and (B) SHMT1 splice variants. Exons are depicted 
with blue boxes and numbered in italic form 1-17 for CBS and from 1-12 for SHMT1 (not drawn to 
scales). The green boxes represent coding sequences CDS. Base 1 of the CBS transcripts 
corresponds to base 43053190 of the complement 43053190...43076868 (NCBI reference 
sequence NC_000021.9) while base 1 of the SHMT1 transcripts corresponds to base 18327860 of 
the complement 18327860...18363563(NC_000017.11). R=reverse primer, F=forward primers, P= 
RT probe. Taken from ncbi.nim.nih.gov; ensembl.org; Sultan et al. (2008) 
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For quantitative analysis of CBS and SHMT1 variants in NSCLC, assays that could detect two 
or more transcript variants were designed for SHMT1 (qPCR -Taqman) and CBS (quantitative 
fluorescent fragment analysis on a 3130 sequencer). 
CBSv3 exhibits higher expression in primary lung NSCLC tumours compared to normal 
adjacent lung tissues in a set of 53 normal/tumour pairs (Wilcoxon signed ranked test, 
p=0.032)(Figure 3.12A). In addition, SHMT1v2 demonstrated significant downregulation in 
NSCLC tumours compared to the non-tumour samples in 52 tumour/normal pairs (Wilcoxon 
signed ranked test, p=0.002)(Figure 3.12B).  
The expression of these two variants (CBSv3 and SHMT1v2) was comparatively analysed with 
 
 
 
    B 
SHMT1 
     v3 
Figure 3.11: Endpoint PCR- based expression of candidate CBS and SHMT1 splice variants in fifteen lung 
derived cell lines. PCR products were separated on a 2% agarose gel. Gel picture analysis suggests the 
presence of CBSv1, v2, v3 and v4 and SHMT1 v2 splice variants. While SHMT1 v3 was undetectable in lung 
cell lines with scarce or barely evident expression (lower of two bands) in four NSCLC tumour/normal pairs. 
N=normal, T=tumour.   
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the clinicopathological data in the studied samples set. CBSv3 was found to be expressed at a 
higher level in squamous cell carcinomas compared to adenocarcinomas (Mann-Whitney test, 
p=0.001)(Figure 3.13A). Furthermore, squamous cell carcinoma demonstrates a high mRNA 
level of CBSv3 with respect to the adjacent normal counterparts, whereas the case is not the 
same for adenocarcinoma (Figure 3.13B). Apart from that, there was no significant association 
between CBSv3 and SHMT1v2 transcripts expression and clinicopathological features (age, 
gender, nodal metastasis or differentiation) of NSCLC patients included in this study. When 
CBS/SHMT1 splice variants expression was analysed in relation to the overall mRNA profiles 
of these two genes, a weak association was shown (Spearman rank test, correlation 
coefficient between -0.3 and +0.3). Taken together, our data suggest that CBS and SHMT1 
alternative splicing events might be independent of their upregulated mRNA level in NSCLC. 
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Figure 3.12: qPCR analysis of CBS and SHMT1 splice variants expression in NSCLC.  
(A) Relative quantification (RQ) of CBS splice variants mRNAs, cycle threshold (Ct) was normalised 
to CBSv3 values and expressed as fold changes in relation to (254N) non-tumour sample in 53 
normal/tumour NSCLC samples. CBSv3 was overexpressed in (34/53) tumour samples in 
comparison with normal ones. 
(B) SHMT1 transcripts expression. SHMT1v2 Ct values were normalised to (v1+v3) Ct values. 
SMT1v2 demonstrates lower expression level in tumour samples (36/52) relative to their normal 
counterparts. P values were returned from the Wilcoxon signed ranked test.   
A 
B 
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Figure 3.13: Boxplot representation of CBS transcript variants expression in adenocarcinoma versus 
squamous cell carcinoma. (A) CBSv3 exhibits marked overexpression in squamous cell carcinoma compared 
to adenocarcinoma in 51 tumour samples. CBS (v1+2+4) were normalised to CBSv3. 
(B) CBSv3 expression difference between normal and tumour tissues in both adenocarcinoma and 
squamous cell carcinoma. Squamous cell carcinoma expresses CBSv3 at significantly higher level than 
adjacent normal tissues. This was not true for adenocarcinoma, however. P-values were returned from the 
Mann-Whitney test. 
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The uniqueness of CBSv3 with spliced out 3’-UTR (Figure 3.10) was also examined through 
exploration of predicted miRNA regulation. miRNA target prediction search revealed that 
CBS 3’-UTR region is a potential target of several miRNAs (Table 3.1)(Figure 3.14 )(miRBase 
database)(Kozomara & Griffiths-jones 2014). 
 
Table 3.1: Predicted microRNAs targeting CBS 3’-UTR region   
Predicted microRNA Alignment of CBS mRNA to mature miRNAs Score1 E-value2 
hsa-miR-6850-5p CBS (+)         5’GUCCGGAGCGCUGGGCGGUGCG 3’  
                  || |||| |||||| ||| ||| 
hsa-miR-6850-5p 5’GUGCGGAACGCUGGCCGGGGCG 3’ 
74 3.0 
hsa-miR-663a  
 
CBS (+)         5’GGCGGUGCGGAGCGGGCCCGC 3’  
                  ||||| |||  ||||| |||| 
hsa-miR-663a    5’GGCGGGGCGCCGCGGGACCGC 3’ 
69 7.9 
hsa-miR-4480  
 
CBS (-)         5’UAAUGUAACUUCCUCUUAG 3’  
                  ||| ||||||||| ||| | 
hsa-miR-4480    3’UAAAGUAACUUCCACUUGG 5’  
68 2.1 
hsa-miR-675-5p 
 
CBS (+)         5’GUGCGGAGCGGGCCCGC 3’  
                  |||||||| |||||| | 
hsa-miR-675-5p  5’GUGCGGAGAGGGCCCAC 3’ 
67 2.6 
hsa-miR-5703 
 
CBS (-)         5’CCUUGCCCACUUCUCCU 3’   
                  |||| || ||||||||| 
hsa-miR-5703    3’CCUUCCCGACUUCUCCU 5’ 
67 2.6 
hsa-miR-5088-5p CBS (-)         5’CUCCUUCGCUUUCCUGAGCCCU 3’   
                  |||| ||   | |||||||||| 
hsa-miR-5088-5p 3’CUCCAUCCAAUCCCUGAGCCCU 5’ 
65 3.8 
hsa-miR-6821-3p CBS             5’CUGGGCGGUGCGGAGCGGGC 3’  
                  ||| |||| |||||| || | 
hsa-miR-6821-3p 3’CUGUGCGGAGCGGAGAGGUC 5’ 
64 5.1 
hsa-miR-4259 CBS (-)         5’UCCUGAGCCCUAAACACA 3’  
                  |||||| ||||| || || 
hsa-miR-4259    3’UCCUGACCCCUAGACCCA 5’ 
63 5.6 
hsa-miR-4664-5p CBS (-)         5’UGCGGAGCGGGCCCGCCA 3’   
                  ||||||| |||| | ||| 
hsa-miR-4664-5p 3’UGCGGAGUGGGCACCCCA 5’   
 
63 5.6 
hsa-miR-4268 CBS             5’CUUCCUCUUAGGAUGU 3’  
                  | |||||| ||||||| 
hsa-miR-4268    5’CCUCCUCUCAGGAUGU 3’ 
62 7.5 
hsa-miR-210-5p CBS (+)         5’CCCUGCACACGGCACA 3’ 
                  |||||| ||| ||||| 
hsa-miR-210-5p  5’CCCUGCCCACCGCACA 3’ 
62 6.8 
hsa-miR-7974 CBS (+)         5’GCUUUCCUGAGCCC 3’   
                  ||| |||||||||| 
hsa-miR-7974    5’GCUCUCCUGAGCCC 3’ 
61 8.3 
hsa-miR-6884-3p CBS (+)         5’UCCGUCUCCCCU 3’  
                  |||||||||||| 
hsa-miR-6884-3p 5’UCCGUCUCCCCU 3’ 
60 10.0 
1Numerical description of alignment quality.  
2Number of distinct alignments expected by chance. 
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Figure 3.14: microRNAs predicted to target CBS 3’-UTR. Only portion of the CBS mRNA 3’- 
UTR region (Exon 17) is shown. The spliced out sequence of CBSv3 is underlined with black 
lines. Green lines show regions involved in Crick-Watson base pairing with the miRNAs 
(blue text) while untargeted pentanucleotide Short Tandem Repeats (STR) are marked 
with red lines.  
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3.4 Discussion 
3.4.1 Deregulation of folate genes in lung cancer 
The folate metabolic pathway plays an important role in maintaining genomic stability 
through feeding into, among other pathways, crucial biological processes such as DNA 
synthesis, repair and DNA methylation. Equilibrium imbalances incurred due to deregulation 
of specific genes in this pathway might therefore be critical for cancer growth and 
development. Most of the relevant published studies have examined the possible effect on 
lung cancer development of SNPs in folate pathway genes, while information regarding the 
expression of folate pathway gene members in this devastating neoplasia is limited. 
Nonetheless, mRNA overexpression of DNMT1, CBS, TYMS, DHFR and SHMT1 have been 
reported in several types of human tumours using different techniques (Mutze et al. 2011; 
Szabo et al. 2013; Koumarianou et al. 2014; Sun et al.  2016; Nakano et al.  2017).  
Our study provides comprehensive qPCR-based expression profiling in order precisely to 
determine the expression status of the folate genes in a large number of NSCLC tissues and 
paired normal counterparts. Analysis of this expression profiling demonstrated 
overexpression of TYMS, SHMT1, DNMT1, CBS and DHFR, and downregulation of MTHFR in 
NSCLC tissues when compared to the normal adjacent tissues. These results are largely in 
accordance with previously published data that have documented upregulation of TYMS 
(Kotoula et al. 2012), SHMT1 (Paone et al. 2014) and DNMT1 (Pastuszak-Lewandoska et al. 
2015) in lung cancer. We also demonstrated that the expression level of the investigated 
folate genes varied between different respiratory tract cancer cell lines, including NSCLC cell 
lines, but that this variation consistently matched the NSCLC tissue expression results, except 
for CBS, which exhibits a markedly reduced expression in the tested cell lines panel. A similar 
CBS downregulation pattern has been reported in the A549 NSCLC cell line (Zhang et al. 2005). 
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Given the importance of the CBS gene in promoting cancer cells proliferation, bioenergetics 
and migration through production of hydrogen sulphide (H2S) (Hellmich et al. 2014), the lack 
of correlation between CBS expression patterns in lung cancer tissues and cell lines would be 
a great paradox since one might expect to see increased CBS expression level in both. Indeed, 
analysis of human colon cancer biopsy and colon cancer derived cell lines have shown 
selective CBS upregulation with increased H2S production in both tissue and cell lines samples 
(Szabo et al. 2013). In the same way, CBS overexpression has been reported in primary 
epithelial ovarian cancer samples and ovarian cancer cell lines (Bhattacharyya et al. 2013). 
Nonetheless, it must be noted that this human enzyme has multiple and complex levels of 
regulation that vary from one cell type to another (Singh & Banerjee 2011). CBS 
downregulation has been demonstrated in prostatic cancer cell lines by post-transcriptional 
modification in response to testosterone (Prudova et al. 2007), while in a seminal article, Kabil 
et al. (2006) identified that CBS is a target for cellular sumoylation under both in vitro and in 
vivo conditions. This modification might serve to relocate the CBS gene to the nucleus in an 
attempt to meet the rising glutathione demand of the rapidly proliferating cancer cells 
(Markovic et al. 2007). In addition, modulation of CBS activity is a crucial mechanism for 
tuning the cellular response to adverse environmental conditions, including oxidative stress, 
where sulphur traffic through trans-sulphuration pathways is increased (Singh & Banerjee, 
2011). Together, these suggestions could explain the inconsistent CBS expression results 
observed in lung cancer tissues and cell lines; although the biological relevance of this 
discrepancy in NSCLC clearly needs to be addressed.  
Our current study demonstrated a general consistency of folate gene deregulation across the 
clinicopathological characteristics of NSCLC cancer patients. This indicates that this 
deregulation (a) occurs rather early in development and (b) is potentially critical in sustaining 
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tumour development across histologies. As minor exceptions, MTHFR and DNMT1 
demonstrated statistical trends with histology and nodal involvement respectively, however 
it is unclear at the moment whether this is a circumstantial finding, or whether if the sample 
size were to be increased it would be found to be of more significance.  
The correlation between DNMT1 and DHFR and TYMS expression levels is significant, 
however. This may suggest a need for concerted expression changes in order to maintain an 
increased cycle output, given the different enzymatic processitivity of all the involved 
enzymes. Such a coordinated molecular response might influence the vital cellular processes, 
including DNA methylation, repair and synthesis (Krushkal et al. 2016). Of course, this is a 
complicated biochemical network and it is well acknowledged that mRNA expression is by no 
means the only determinant of enzymatic activity. Nonetheless, the establishment of such 
relationships may assist in hypotheses and relevant future studies that are beyond of the 
scope of this thesis. 
In summary, the data generated from this study (a) confirm the significant distortion of the 
mRNA expression profile among folate pathway genes in lung cancer, (b) provide new 
comprehensive information on SHMT1 and CBS1 as major targets for further research in 
NSCLC, as there is limited information on their relationship to lung cancer to date, (c) 
demonstrate folate cycle deregulation as a potential global mechanism for cancer 
development, and (d) indicate some degree of interdependence between the expression 
levels of different genes of the pathway in order to sustain its effect in cancer.  
In view of the current use of a number of antifolate drugs in cancer management, this study 
provides evidence for the need for further research on the pathway in anticipation of 
identifying molecular modulators of resistance that might be used as clinical tools for 
improving drug efficacy and therefore patient survival. 
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3.4.2 Splicing variants expression profiles of SHMT1 and CBS genes in NSCLC 
Alterations in alternative splicing of cancer-related genes may have a significant impact on 
lung cancer cell biology (Schwerk & Schulze-Osthoff 2005). Although SHMT1 and CBS encode 
important enzymes for normal physiology, no comprehensive attempt has been made so far 
to investigate splicing profiles in human disease. Our results demonstrate that all SHMT1/CBS 
variants are expressed in lung derived cell lines and NSCLC tissue samples, pointing out their 
importance for cell growth following high numbers of duplication in a culture environment. 
The unique, and very important, discovery in this study is that CBS variant 3 (CBSv3) is 
upregulated in NSCLC tissues, while SHMT1 variant 2 (SHMT1v2) exhibits significant 
downregulation with respect to adjacent non-tumorous tissues. This opens up a new research 
question regarding the functional role of these variants in cell growth and phenotype 
sustainability. The association of the differential expression of CBSv3 with the squamous 
phenotype is also of interest.   
The reasons behind this splicing variant difference are currently unclear. Current evidence is 
insufficient to explain if this is because of a de novo expression difference, a difference in 
splicing rates or post-maturation mechanisms, such as the miRNA function, given that there 
is evidence of post-transcriptional modification by microRNAs (miRNAs) (Passetti et al. 2009). 
miRNAs are a group of small regulatory RNAs (~ 22 nucleotides ) involved in post-
transcriptional gene silencing through incorporation into the RNA-induced gene silencing 
complex (RISC), which binds the complementary sequence motifs of the target mRNA, mostly 
at the 3’ untranslated regions (3’UTRs) (Betel et al. 2010; Jansson & Lund 2012) resulting in 
gene silencing, either by degradation or translational repression of the target mRNA 
(Filipowicz et al. 2008). Data from several studies have reported that alternative splicing in 
proliferating cancer cells might generate isoforms with deleted or shortened 3’UTR that 
127 
exhibit more mRNA stability with increased protein expression through a lack of miRNAs-
mediated repression (Mayr & Bartel 2009; Hayes et al. 2014). Based on our data, however, 
CBSv3 lacks 3’ UTR compared to other CBS splice transcripts employed in this study, hence a 
possible explanation for the CBSv3 upregulation in NSCLC might be the absence of 3’ UTR that 
renders CBSv3 mRNA insensitive to miRNAs regulation. 
Data generated from this study have also shown SHMT1v2 downregulation in NSCLC tissue 
compared to adjacent normal ones. As can be seen in Figure 3.10, SHMT1v2 lacks 1 additional 
α-helix, 3 β-sheets in comparison to isoform 1. The absence of these secondary structures as 
a result of a cleavage event might negatively affect the stability of the enzyme homotetramer 
by interfering with pyridoxal 5’-phosphate (PLP) binding (through Schiff base linkage) to the 
active site lysine, and thereby exposing this region to an external solvent (Liu et al. 2001; 
Giardina et al. 2015). Furthermore, the lack of exon 8 from the SHMT1v2 variant (Figure 3.10) 
might disrupt the enzyme amino-terminal domain, since exon 8 specifically encodes for the 
lysine that binds the active site PLP (Liu et al. 2001) and ultimately diminishes the enzyme 
catalytic activity. Collectively, this postulation may justify the decreased expression level of 
SHMT1v2 with the resultant attenuation of the enzyme catalytic activity in NSCLC samples.  
To our knowledge, this is the first study to explore CBS and SHMT1 alternative splicing profiles 
in NSCLC. Our results suggest that the alteration of alternative splicing events affecting 
CBS/SHMT1 genes may have a potential mechanistic role in lung tumourigenesis. It remains 
a significant challenge, however, to identify whether these alterations in splicing profiles have 
the kind of direct role in lung carcinogenesis to make them potential biomarkers and/or 
therapeutic targets, as opposed to simply being bystanders occurring in lung cancer cells. 
Further investigations are therefore required in order to evaluate their impact in NSCLC 
pathogenesis.  
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Chapter 4: Epigenetic sensitisation to 
antifolates in respiratory tract cancer 
cells. 
This chapter describes the experimental work undertaken to test the response of respiratory 
tract cancer cells to anticancer drugs that target folate metabolism and to explore the 
potential for epigenetic sensitisation of cell lines resistant to these agents.  
4.1 Chemosensitivity of respiratory tract cancer cells to 5-Fluorouracil, 
methotrexate and pemetrexed  
We measured the sensitivity to three commonly used anticancer drugs, 5-fluorouracil (5-FU), 
methotrexate (MTX) and pemetrexed (PEM), in a panel of ten respiratory tract cancer cell 
lines SK-MES-1, SK-LU-1, CALU6, A549, COR-L23, H358, LUDLU-1, BHY, PE/CA-PJ15, PE/CA-
PJ41. The chemosensitivity of tumour cells was determined by estimating their half maximal 
inhibitory concentration (IC50), which is the drug concentration required to inhibit 50% of the 
cellular growth in comparison to untreated cells. Cell growth was measured by MTT assay and 
IC50 values were calculated using GraphPad Prism software version 6.0. As expected, a range 
of sensitivities were demonstrated among the studied cell lines. In general, all tested drugs 
reduced cellular viability in a concentration dependent manner, however, MTT analysis 
showed that the effectiveness of pemetrexed and MTX was moderate compared to that of 5-
FU. Analysis of IC50 values at 95% confidence intervals following treatment with (1-64 μM) 
pemetrexed demonstrated that H358, A549 and SKLU1 were the most sensitive cancer cell 
lines (Table 4.1) while LUDLU and CALU6 were the most resistant ones (Figure 4.1). Following 
72 hours treatment with 0.125-8 μM MTX, the studied respiratory tract cancer cell lines 
exhibited lower MTT absorbance readings compared to that of pemetrexed, with IC50 values 
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being highest in LUDLU and CALU6 and lowest in PE/CA-PJ41 cancer cell lines (Figure 
4.2)(Table 4.1). The greatest reduction in cell viability was observed following (0.015-1mM) 
5-FU exposure in most of the studied cancer cell lines, except A549 and SK-MES-1, with IC50 
values of 0.765 and 0.339 mM respectively. The lowest MTT absorbance readings of 5-FU was 
spotted in SK-LU-1 with an IC50 value of 0.031 mM (Figure 4.3)(Table 4.1). Furthermore, the 
obtained IC50s were compared with publicly available data for 5-FU and MTX 
(cancerrxgene.org). 
Table 4.1: IC50 values and their respective 95% confidence intervals in NSCLC and HNSCC cell lines exposed 
to 5-FU (0.015-1 mM), MTX (0.125-8 μM) and pemetrexed (1-64 μM) compared with the publically available 
data.  
 
Cell line 5-FU 
(mM) 
95% C.I Available 
data 
MTX 
(μM) 
95% C.I Available 
data 
PEM 
(μM) 
95% C.I Available 
data 
A549 0.76 0.6-0.96  3.78 2.62-5.47 2.84 45.89 31.1-
67.7 
 
BHY 0.19 0.16-0.21 0.034 7.30 5.31-
10.05 
    
CALU6 0.11 0.09-0.13 0.0133   0.402    
CORL23 0.11 0.08-0.15  7.18 5.19-9.94 0.0817    
H358 0.16 0.12-0.22 0.0113 5.70 4.05-8.02 0.251    
LUDLU 0.22 0.18-0.28        
PJ15 0.25 0.18-0.35 0.0559 2.40 1.81-
3.202 
2.73    
PJ41 0.21 o.16-0.28  0.88 0.6291-     
SKLU1 0.031 0.02-0.04 0.102 2.56 1.71-3.81  48.87 31.61-
75.57 
 
SK-MES 0.33 0.22-0.46 0.061 8.38 6.72-
10.47 
1.4    
 
 
No significant correlation was observed between the sensitivity of the cell lines to 5-FU, MTX, 
pemetrexed drugs (represented by IC50) and corresponding mRNA expression levels of CBS, 
SHMT1, TYMS, MTHFR, DHFR and DNMT1 genes (Chapter 3)(Spearman test, p value> 0.05). 
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Figure 4.1: The effect on the cell viability of respiratory tract cancer cell lines of exposure to pemetrexed for 72 
hours. The mean and error values in all graphs are for six technical replicates, and error bars represent 95% 
confidence intervals. 
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Figure 4.2: Heterogeneous response of the examined respiratory tract cancer cell lines following 72 hours MTX 
incubation. The mean and error values in all graphs are for six technical replicates, and error bars represent 
95% confidence intervals.    
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Figure 4.3: Dose response curves for the examined respiratory tract cancer cell lines following exposure to 
5-FU for 72 hours. The mean and error values in all graphs are for six technical replicates, and error bars 
represent 95% confidence intervals. 
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Since 5-FU has demonstrated superior inhibition of cancer cell viability, with the exception of 
A549 and SK-MES-1, our next step was to evaluate the clinical significance of folate related 
genes in 5-FU resistant NSCLC cells. We employed quantitative real time PCR (qPCR) to assess 
the expression of TYMS, DHFR, MTHFR, SHMT1, CBS and DNMT1 at the mRNA levels in A549 
and SK-MES cell lines following 24 and 72 hours exposure to three different doses; 0.5 mM, 
0.25 mM and 0.0625 mM of 5-FU (Figure 4.4). Analysis of the TYMS mRNA level revealed 
increased expression across 5-FU non-responsive NSCLC cell lines compared to non-treated 
ones, nonetheless TYMS upregulation was not obvious in the first 24 hours of exposure in 
both resistant cell lines (Figure 4.4A). We also found that the expression level of MTHFR was 
upregulated early during 5-FU challenge at a concentration of 0.5 mM in both A549 and SK-
MES-1 cell lines, and remained at similar levels (specially for SK-MES) for the whole incubation 
time (Figure 4.4B). This observation suggests that MTHFR overexpression may be an early 
response to high dose 5-FU therapy.  Interestingly, DNMT1 expression showed significant 
reduction in A549 and the opposite was observed in SK-MES cells, with marked upregulation 
relative to that of the control, at 0.0625mM 5-FU seen late in the treatment course (Figure 
4.5C). When the alteration of DHFR mRNA levels in response to 5-FU treatment was compared 
between the two studied cell lines, A549 was shown to express DHFR at a significantly lower 
level than its untreated counterpart throughout the whole time course, while SK-MES-1 
displayed an upregulated DHFR activity which was more obvious in the subsequent 72 hours 
of 5-FU exposure (Figure 4.5D). Generally, SHMT1 (Figure 4.6E) and CBS (Figure 4.6F) mRNA 
levels were variable across the 5-FU resistant cell lines, but consistently lower than that of 
non-treated cells. 
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Figure 4.4: Bar charts representing the mRNA expression profile of TYMS (A) and MTHFR (B) in A549 and SK-MES following 
24 and 72 hours incubation with 0.5, 0.25 and 0.0625 mM 5-FU. Error bars represent 95% confidence intervals.  
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Figure 4.5: Bar charts representing the mRNA expression profile of DNMT1 (C) and DHFR (D) in A549 and SK-MES following 24 
and 72 hours incubation with 0.5, 0.25 and 0.0625 mM 5-FU. Error bars represent 95% confidence intervals.  
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Figure 4.6: Bar charts representing the mRNA expression profile of SHMT1 (E) and CBS (F) in A549 and SK-MES following 
24 and 72 hours incubation with 0.5, 0.25 and 0.0625 mM 5-FU. Error bars represent 95% confidence intervals.  
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4.2 Epigenetic sensitisation of non-small cell lung cancer cell lines to folate 
targeted drugs  
Since epigenetic deregulation has been associated with cancer cell aggressiveness and 
chemoresistance (Steinhardt & Gartenhaus 2013), we hypothesised that aberrant epigenetic 
mechanisms, including DNA methylation and histone acetylation may contribute to resistance 
to folate pathway targeting drugs in NSCLC. Our hypothesis was founded on previous studies 
that have shown the potential efficacy of combining epigenetic-based therapy with these 
agents in several types of cancers (Kanda et al. 2005; Morita et al. 2006; Leclerc et al. 2010; 
Iwahashi et al. 2011; Bufalo et al. 2014). In this instance, we investigated the epigenetic 
influence on the reversal of 5-FU, MTX and pemetrexed resistance in NSCLC cell lines. Two 
well-known epigenetic modifiers, histone deacetylase (HDAC) class I inhibitor Valproic acid 
(VPA) and the DNA methyltransferase1 (DNMT1) inhibitor Decitabine (DAC), were utilised to 
test the sensitisation of the two most resistant cell lines (with the highest IC50 values, Table 
4.1); A549 and SK-MES-1 to 5-FU, CALU6 and LUDLU to MTX and pemetrexed. Based on the 
preliminary results obtained from previous pilot experiments, cell lines were exposed to a 
tissue culture final concentration of 100 nM DAC and 1mM VPA with the corresponding IC50 
doses of 5-FU, MTX and PEM (Table 4.1). Our results demonstrated a significant reduction of 
MTT absorbance readings for the subsequent 72 hours when A549 and SK-MES cell lines were 
exposed to VPA treatment 48 hours prior to the addition of 5-FU (Figure 4.7A &B). In contrast, 
VPA pretreatment did not change the MTT absorbance values of the normal human 
embryonic lung fibroblast IMR90 cell line following 5-FU exposure (Figure 4.7C). Synchronous 
treatment of DAC and 5-FU significantly reduced A549 cell viability as compared to 5-FU 
treatment alone (Figure 4.8A), whereas the MTT absorbance values of the SK-MES cell line 
demonstrated a minor effect in response to DAC and 5-FU concomitant treatment (Figure 
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4.8B). In addition, the combination of DAC/VPA with MTX did not markedly change the 
absorbance readings for the latter in the LUDLU or CALU6 cell lines (Figure 4.9 A&B). Similarly, 
no obvious difference in cell viability with pemetrexed treatment was seen in the same NSCLC 
cancer cell lines following synchronous treatment with DAC or prior VPA exposure (Figure 
4.10 A&B).  
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Figure 4.7: Bar charts representing MTT absorbance readings following 48 
hours pretreatment with VPA followed by 72 hours 5-FU exposure in (A) A549 
and (B) SK-MES cell lines. Error bars represent 95% confidence intervals. 
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Figure 4.7 C: Bar charts representing the MTT absorbance readings of the IMR90 foetal lung 
fibroblast cell line with 5-FU treatment preceded by 48 hours incubation with VPA. Error bars 
represent 95% confidence intervals.  
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Figure 4.8: Effect of 72 hours 5-FU and DAC combination on viability of A549 (A) and SK-
MES (B) cell lines. Error bars represent 95% confidence intervals. Bars represent the mean 
of four technical replicates. P values were derived from One-Way ANOVA, Post Hoc, 
Dunnett T3 tests. 
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Figure 4.9: Bar charts representing the MTT absorbance reading of CALU6 (A) and 
LUDLU (B) cell lines following exposure to VPA and DAC combination with MTX. Error 
bars represent 95% confidence intervals. The results represent the mean of four 
technical replicates. P-values were derived from One-Way ANOVA, Post Hoc, 
Dunnett T3 tests. 
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Figure 4.10: Bar charts representing the MTT absorbance readings of CALU6 (A) and LUDLU (B) cell 
lines following exposure to VPA and DAC combination with pemetrexed. Error bars represent 95% 
confidence intervals. The results are the mean of four technical replicates. P-values were derived from 
One-Way ANOVA, Post Hoc, Dunnett T3 tests. 
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In order to explore the potential mechanisms behind the enhancement of 5-FU antitumor 
effect against NSCLC cell lines following VPA exposure, we quantified the expression levels of 
our usual six folate target genes in A549 and SK-MES cell lines following 48 hours exposure to 
VPA incubation (Figure 4.11). Gene expression analysis by real time PCR demonstrated the 
ability of VPA to downregulate TYMS mRNA level in 5-FU unresponsive NSCLC cells in 
comparison with non-treated controls (Figure 4.11A). Similar to the TYMS response data, 
DNMT1 was found to be suppressed as a result of VPA treatment (Figure 4.11B). A consistent 
but borderline reduction of SHMT1 expression level was spotted across VPA treated A549 and 
SK-MES cells (Figure 4.11C). Furthermore, there was no alteration in MTHFR or CBS expression 
profiles in VPA treated A549, whereas SK-MES was observed to display these two folate genes 
at a significantly higher level than that of untreated counterparts (Figure 4.11D and Figure 
4.11E). Interestingly, there was a significant reduction of DHFR mRNA expression in SK-MES 
cells exposed to VPA for 48 hours, however A549 expressed the same gene with only a 
borderline increment under the same reaction conditions (Figure 4.11F).  
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Figure 4.11: Altered mRNA expression of TYMS (A), DNMT1 (B), SHMT1 (C), MTHFR (D), CBS (E) 
and DHFR (F) A549 and SK-MES cell lines treated with VPA for 48 hours compared to untreated 
controls. The results are the mean values of two technical replicates. Error bars represent 95% 
confidence intervals. RQ=relative quantification. P-values were derived from Mann-Whitney 
tests. 
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4.3 Discussion 
4.3.1 Chemosensitivity of respiratory tract cancer cells to 5-fluorouracil, methotrexate and 
pemetrexed 
Folate metabolism is a typical example of a biological pathway with critical pharmacological 
relevance. It has been an attractive target for key chemotherapeutics that are widely used in 
medical oncology for several types of malignancies, including respiratory tract cancers (Ulrich 
& Robien, 2002). This study demonstrated a dose dependent reduction of cell viability across 
respiratory tract cancer cells in response to 5-FU, MTX and pemetrexed exposure, with the 
lowest MTT absorbance readings being achieved following 5-FU treatment. In contrast, MTT 
analysis showed a high degree of resistance against MTX and pemetrexed antifolates drugs 
among the cancer cell lines studied. Because of their high response rates combined with low 
toxicity, both MTX and pemetrexed are favourable drugs for the palliative treatment of 
HNSCC and NSCLC respectively (Cohen et al. 2005; Schuler et al. 2010) but our results showed 
poor response levels for these antifolates with several cancer cell lines.  As already described 
in the introduction chapter, the chemotherapeutic efficiency of these anticancer agents is 
frequently hampered by the development of drug resistance. Clinical and preclinical studies 
have identified a plethora of mechanisms by which cancer cells develop resistance to these 
antifolate drugs (Gonen & Assaraf 2012). In addition, cell lines are usually established from 
tumour biopsies of patients who might be treated with antifolates, or those who may have a 
recurrent disease. It is therefore reasonable to notice some lack of responsiveness to 
antifolates in some of the investigated cell lines.  In terms of IC50 values, 5-FU displayed low 
MTT absorbance values in eight out of ten RTCs cell lines. It is worth noting that we have 
observed a marked difference between some of 5-FU and MTX IC50 values generated from 
this study when compared with publicly available data. This might be attributed to the 
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different experimental conditions. In addition, it is widely accepted that cancer cell lines 
evolve genetically too fast through hundreds of thousands of duplications that have 
undergone in each lab. Another point is that they can be phenotypically different and do not 
relate to the original cell line. 
In the general effort towards identifying the potential mechanisms behind 5-FU resistance, 
we explored the expression profiles of folate pathway related genes in cell lines that were 
less responsive to 5-FU.  
So far, the majority of pharmacogenetic studies related to 5-FU have focused on TYMS 
expression as a key determinant of 5-FU antiproliferative effect, stating that an increase in 
TYMS mRNA expression has been a prominent feature for 5-FU resistance (Leichman et al. 
1977; Johnston et al. 1995). In agreement with these reports, we found that the survival of 
A549 cells following treatment with three different concentrations of 5-FU for 48 hours, 
seems to depend on a high TYMS expression. In fact, there is even a trend of expression being 
associated with the dose. Additional supporting information comes from our epigenetic 
sensitisation experiments. VPA sensitises A549 cells to 5-FU. Interestingly, VPA results in a 
reduction of TYMS expression at both 24 and 72 hours of exposure. Although it is highly 
probable that other potential regulators contribute to 5-FU resistance, including FPGS, GGH, 
UNG, UMP kinase and DTYMK (Muhale et al. 2011), our data strengthens the case for the 
involvement of TYMS expression in 5-FU resistance. This finding was less clear cut in SK-MES 
cells, however. While at low 5-FU doses, the result resembled that for A549, at higher doses 
we observed a reduction in the effect. Based only on current data, this is not easy to explain, 
however it clearly reflects the clinical problem in respect to cancer heterogeneity in treatment 
response, and it is most likely due to the different histological origin of the cell lines, and their 
individual molecular profile.  
148 
We observed that MTHFR expression was higher in surviving cells following 5-FU exposure, in 
both A549 and SK-MES cell lines and in a dose-dependent manner at 72 hours. This has also 
been shown previously (Scartozzi et al. 2011; Wang et al. 2014). A probable explanation for 
this is that MTHFR is a key enzyme involved in intracellular folate haemostasis, through 
catalysing the irreversible conversion of 5,10 methylene tetrahydrofolate (CH2FH4) into 5-
methyltetrahydrofolate (CH3FH4). 5-FU exerts its antitumor effect through binding of 5-
fluorodeoxyuridine monophosphate to TYMS, thereby forming an inactive ternary complex 
together with CH2FH4. The stability of that complex is primarily based on a high CH2FH4 level 
(Scartozzi et al. 2011; Wang et al. 2014). One can therefore hypothesise that cancer cells 
exhibiting an increased MTHFR activity might be refractory to 5-FU treatment by minimising 
the bioavailability of CH2FH4, and that this might be an early event in the development of 5-
FU resistance. 
In the case of MTHFR, results from VPA exposure were less conclusive, however. MTHFR 
expression does not change in A549 after VPA treatment, while in SK-MES VPA leads to 
MTHFR overexpression, apparently contradicting the potential role of MTHFR in 5-FU 
resistance. One has to keep in mind, however, that VPA, as with every HDAC inhibitor, triggers 
expression changes in hundreds of genes and 5-FU resistance can be modulated by multiple 
genes within or outside the folate pathway. 
DNMT1 mRNA expression following 5-FU treatment demonstrated an interesting profile. 
A549 cells surviving at 72 hours demonstrated lower DNMT1 expression compared to control 
cells. A marginal increase observed from lower to higher 5-FU dose does not change this 
trend. SK-MES cells demonstrated a puzzling overexpression at low level exposure, but, at 
higher doses, this reverts to under expression compared to unexposed cells. Interestingly, 
DNMT1 expression was reduced in the presence of VPA, suggesting this gene as another 
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potential mediator of epigenetic sensitisation to 5-FU. In the absence of any published report 
connecting DNMT1 expression and sensitivity to 5-FU, this data is unique, but very difficult to 
interpret with confidence. This is especially because of DNMT1 role as a global DNA 
methylation maintenance enzyme, affecting therefore the expression of many genes. 
A rather inconclusive result was derived for the potential association of DHFR and 5-FU. 
Reduced DHFR expression was observed in the surviving A549 cells following 5-FU exposure, 
while the exact opposite was shown for SK-MES. Combining the lack of DHFR expression 
change in the VPA experiment for A549 and the downregulation of the gene by VPA in SK-
MES increases the uncertainty regarding the role of this gene in 5-FU resistance. Furthermore, 
to date, there is no published work on this aspect. 
 SHMT1 and CBS gene expression patterns showed a remarkable reduction in the surviving 
A549 and SK-MES cells exposed to 5-FU. As we will see in Chapter 5, SHMT1 knock down in 
PJ15 head and neck cancer cells results in sensitisation to 5-FU, apparently contradicting these 
results. Once again, there is no published information on the role of SHMT1 in regulating drug 
resistance. The discrepancy of results between the two experiments could be explained by 
the different origin and molecular profile; however, it is fair to state that it is currently not 
understood what may be mediating the potential action of SHMT1 on 5-FU resistance and the 
different effects may be subject to its variable availability in the different cell lines. This is 
discussed further in Chapter 5.  
Overall, the expression data in 5-FU resistant NSCLC cell lines demonstrated a substantial 
heterogeneity of responses and potential survival contingencies to gene expression. While 
the role of TYMS, MTHFR and DNMT1 in 5-FU resistance is strengthened, at this point, little 
can be concluded for the remaining genes. Nonetheless, this data offers a good baseline for 
further research. 
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4.3.2 Epigenetic sensitization of non-small cell lung cancer cell lines to folate targeted 
drugs 
In this study, we also examined the potential of VPA and DAC epigenetic modifiers to act as 
chemosensitisers to 5-FU, MTX and pemetrexed in NSCLC cell lines. Pretreatment of A549 and 
SK-MES with VPA for 48 hours sensitised these cells to 5-FU, while no such sensitising effects 
were seen in MTX or pemetrexed resistant cells. Thus, our data showed the potential 
synergistic effect of the combined treatment with 5-FU and VPA in 5-FU resistant lung cancer 
cell lines. These findings are in accordance with Noro et al. (2010), who established that 
combined therapy of 5-FU and another HDAC inhibitor (SAHA) enhances 5-FU response in 
resistant NSCLC cell lines. The potentiation of 5-FU anticancer activity when combined with 
different types of HDACi has been reported in gastric (Lee et al. 2006), colorectal (Abaza et al. 
2014), hepatic (Ocker et al. 2005), pancreatic and cholangiocarcinoma (Iwahashi et al. 2011). 
To our knowledge, this is the first report to show that VPA enhances the therapeutic effect of 
5-FU in NSCLC cell lines.  
The present study also demonstrated that DAC demethylating agent produced a pronounced 
reduction in the viability of A549, with a minor effect in the SK-MES cell line when treated 
simultaneously as compared with 5-FU alone. Similar results have been previously reported 
in breast cancer cell lines (Mirza et al. 2010) and hepatoma and pancreatic cancer cell lines 
(Kanda et al. 2005). While DAC was not efficient in reducing chemoresistance to MTX or 
pemetrexed in our data, epigenetic reprogramming and enhancement of 5-FU sensitivity 
among tumour cells following the addition of DAC might be achieved through breaking the 
silence and reactivation of transcriptional activity of certain genes involved in 5-FU metabolic 
pathway following aberrant promoter hypermethylation at specific sites (Humeniuk et al. 
2009). Up to now, however, almost nothing is known about the effect of DNA demethylating 
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agents in 5-FU resistance in lung cancer, therefore the synergistic antineoplastic action of 
combined 5-FU chemotherapy with DAC observed in our experiments merits further 
investigation.  
The toxicity profile of DAC has been linked with numerous issues when used in combination 
with chemotherapeutic agents in cancer clinical trials. For example, myelosuppression has 
been reported as the major side effect (Momparler et al. 1997), in addition to the limited 
capacity to reactivate enough tumour suppressor genes through inhibition of DNA 
methylation (Stephan & Momparler 2015). On the other hand, VPA has been a relatively safe 
and commonly prescribed antiepileptic and mood stabiliser for decades (Detich et al. 2003). 
We therefore chose to further pursue the synergistic antitumor promise observed when 
combining 5-FU based chemotherapy with VPA in A549 and SK-MES cell lines. For this, we 
investigated the influence of VPA treatment against the mRNA expression profiles of 5-FU 
metabolism-related genes in drug resistant NSCLC cell lines. Importantly, VPA exposure of 
A549 and SK-MES cells led to a marked reduction of TYMS mRNA expression levels, as 
discussed before. This observation suggests that VPA induced TYMS downregulation, the 
primary target for 5-FU, may serve as one of the mechanisms involved in the tumour 
inhibitory effect of the 5-FU and VPA combination. Indeed, TYMS has been reported as one 
of the predictive biomarkers for 5-FU response in lung cancer (Longley et al. 2003; Oguri et al. 
2005). Similar results were observed with DNMT1, suggesting that VPA is a downregulator 
and potent inducer of DNMT1 degradation (Zhou et al. 2008).  
It is worth noting that the effect of VPA treatment on CBS expression patterns was markedly 
different between the tested cell lines, with significant overexpression in SK-MES but not in 
A549. As we mentioned before, DHFR transcriptional activity was reduced to approximately 
50% following VPA incubation in SK-MES, while no significant alteration was observed in A549 
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under the same experimental conditions. Still, it is unclear if this downregulation is a major 
consequence of VPA treatment as a result of cell cycle arrest, or simply a passive observation 
in response to reduced cellular viability. Furthermore, the cell specificity in terms of gene 
expression changes in response to VPA challenge observed in this study might be attributed 
to differences in the molecular, phenotypic characteristics, or in the histology and growth rate 
between the two NSCLC cell lines.  
Collectively, we have identified potential synergistic interaction between 5-FU and VPA that 
may point the way to a novel therapeutic regime allowing for lower doses of each drug to be 
administered to NSCLC patients with less chemotherapeutic toxicity, while maintaining the 
same therapeutic effect. Further research is warranted in order to adapt this combination 
therapy successfully in clinical studies. Comparative gene expression (VPA treated vs. 
untreated) data of folate genes in 5-FU resistant NSCLC cell lines indicates an alteration of 
mRNA profiles that might be related to mechanisms of lung cancer-drug sensitivity and could 
be useful predictive biomarkers for epigenetic sensitisation of NSCLC to 5-FU based 
chemotherapy.  
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Chapter 5: CBS and SHMT1 
involvement in respiratory tract 
cancer cell line response to 5-FU.  
 
In the previous chapters, CBS and SHMT1 were found among the folate pathway genes with 
the most highly deregulated expression in lung cancer. It was intriguing that there is so little 
information regarding these two genes and cancer development, and virtually nothing on lung 
cancer. We therefore set their further investigation as a major priority in this study. The main 
objectives of this part of the study were:  
(1) To investigate the role of CBS and SHMT1 expression in the respiratory tract cancer cell 
line phenotype.  
(2) Most importantly, to assess if CBS and SHMT1 expression can modulate the resistance of 
cancer cells to antifolates.  
(3) To further investigate the mRNA expression pattern of CBS and SHMT1 splice variants in 
order to gain preliminary evidence of potential post-transcriptional involvement.  
5.1   CBS and SHMT1 downregulation in respiratory tract cancer cells  
Following the observations regarding deregulated expression profiles of folate genes in lung 
cancer tissues and respiratory tract cancer cell lines (chapter three), we picked two genes; 
SHMT1 and CBS for genetic manipulation and response modulation to folate pathway 
targeting chemotherapeutics. Based on the mRNA expression profiles of SHMT1 and CBS in 
respiratory tract cancer cell lines included in this study (chapter three), representative cells 
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with the highest mRNA levels of each gene were selected as models for genetic manipulation 
experiments, utilising a small hairpin (shRNA) mediated gene silencing approach. LUDLU, PJ15 
and PJ41 were selected for SHMT1, with LUDLU and H358 for CBS knock down experiments. 
Individual transfections were performed with two shRNAs for SHMT1 and three shRNA 
constructs for CBS. These constructs are known to be effective at knocking down the mRNA 
expression of the aforementioned genes. Stable cell transfectants were therefore achieved 
from the TRCN0000034765 SHMT1 silencing construct in PJ15 and three CBS-targeting 
constructs (TRCN0000045360, TRCN0000045361 and TRCN0000045362) in the H358 cell line. 
RT-qPCR based mRNA expression analysis confirmed the manipulated SHMT1 and CBS down 
regulation across their derivative clones.  
The knock down efficiency of SHMT1 transcript expression in PE/CA-PJ15 cells was 
approximately 46%-73% (Figure 5.1) while that of CBS was 52%-60% (Figure 5.3). Suppression 
of SHMT1 expression in PJ15 derived clones was also validated by western blotting analysis 
(Figure 5.2). We decided to proceed to the subsequent experiments with clones 
demonstrating > 50% knocking down efficiency. 
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Figure 5.1: Real time PCR analysis of SHMT1 mRNA expression in PE/CA-PJ15 derived knockdown clones. 
shRNA mediated silencing was variable among the knockdown clones, being >73% reduction PJ15-F12E, 
69% in PJ15-F12O while PJ15-F12C exhibited ~50% reduction. The expression levels were normalised to 
ACTB and depicted as a fold change relative to PE/CA-PJ15 PAR. Error bars represent 95% confidence 
intervals. RQ= relative quantification, PAR=parental, SCR=scramble 
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Figure 5.2: Representative western blotting of SHMT1 protein expression in PE/CA-PJ15 
parental, scramble and knockdown clones. Blotting analysis showed a significant 
reduction of the SHMT1 protein level in the downregulated clones relative to that of 
scramble and parental ones. β-ACTIN was used as an endogenous control.   
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In order to assess the phenotypic effect of SHMT1 and CBS suppression, growth rates were 
analysed using MTT assay for four successive days. Both CBS and SHMT1 knocked down clones 
exhibited reduced MTT absorbance readings compared to the parental and scramble cells 
(Figure 5.4 and Figure 5.5).  
 
 
 
  
Figure 5.3: CBS mRNA expression profiles in H358-derived CBS knockdown clones. The 
expression levels were normalised to ACTB and depicted as a fold change relative to H358-
PAR. Error bars represent 95% confidence intervals. RQ=relative quantification, 
PAR=parental, SCR=scramble 
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Figure 5.4:  Exponential growth curves of SHMT1 silenced PE/CA-PJ15 cell line. It seems that shRNA-
mediated knockdown of SHMT1 expression significantly attenuates viability of PE/CA-PJ15 derived clones 
relative to that of parental and scramble controls. O.D=optical density, PAR=parental, SCR=scramble 
 
 
 
Figure 5.5: Effect of CBS knockdown on the viability of H358 cell line. A significant reduction in MTT 
absorbance readings was observed in CBS downregulated clones compared to parental and scramble 
controls. O.D=optical density, PAR=parental, SCR=scramble 
 
  
159 
Next, we examined the functional significance of SHMT1/CBS silencing on respiratory tract 
cancer cell sensitivity to chemotherapeutic drugs. Our results showed that SHMT1 
suppression significantly decreased cellular viability in PJ15-F12O and PJ15-F12E knockdown 
derived clones treated with an IC25 dose of 5-FU with respect to parental and scramble cells 
(Figure 5.6A). Similarly, treatment of SHMT1 knockdown clones with an IC25 concentration 
of MTX resulted in a prominent reduction in clonogenic MTT absorbance readings when 
compared with the parental and scramble lines (Figure 5.6B). Pemetrexed exposure data, 
however, demonstrated that SHMT1 silencing did not sensitise the PE/CA-PJ15 cell line to an 
IC25 dose of multitarget pemetrexed treatment (Figure 5.6C). 
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Figure 5.6: Bar chart representing the response of SHMT1 knockdown clones to an IC25 dose of 5-FU (A) and MTX (B). Down regulation of SHMT1 expression 
seems to sensitise PE/CA-PJ15 line to 5-FU and MTX as indicated by reduction of MTT absorbance values when compared to that of parental and scramble 
controls. The results represent the mean values of six technical replicates. Error bars represent 95% confidence intervals. PAR= parental, SCR= scramble.   
A B 
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Based on these results, SHMT1 downregulated clones were then exposed to a range of seven 
different doses of 5-FU (0.015-1 mM) and MTX (0-8 μM), applied for 72 hours, along with the 
parental and scramble cells. MTT analyses showed lower values of 5-FU relative IC50 in PJ15-
F12O and PJ15-F12E than those noted in the parental and mock (scramble) cells (Table 5.1) in 
a manner directly correlating with the level of SHMT1 suppression (Figure 5.7). These findings 
indicate that SHMT1 knockdown affords a possibility of a significant reduction of cell viability 
following 5-FU treatment in the PE/CA-PJ15 HNSCC cell line. This result was not replicated for 
MTX, however. Although SHMT1 silencing in PJ15-F12O and PJ15-F12E resulted in a reduction 
Figure 5.6 C: Effect of SHMT1 silencing on the response of the PE/CA-PJ15 cell line 
to an IC25 dose of pemetrexed. No significant reduction of MTT absorbance values 
was observed in PE/CA-PJ15 derived SHMT1 knockdown clones with respect to 
that of parental and scramble controls. The results represent the mean of six 
technical replicates. Error bars represent 95% confidence intervals. PAR= 
parental, SCR= scramble.   
162 
of IC50 values for MTX (Table 5.1), we did not observe a significant change in drug sensitivity 
relative to that of parental and shRNA control. In fact, MTX exposure line graphs show an 
overlapping response (Figure 5.8). These results suggest that SHMT1 has no contributory role 
in sensitising PE/CA-PJ15 head and neck cancer cell lines to MTX treatment. 
 
163 
  
Figure 5.7: Effect of SHMT1 silencing in PE/CA-PJ15 cell line sensitivity to 5-FU. (A) Knocking down of SHMT1 expression resulted in significant reduction 
in cell viability of the PE/CA-PJ15 derived knockdown clones reflected by MTT absorbance readings relative to the SHMT1 suppression levels (B). Results 
represent the mean of six technical replicates. Error bars represent 95% confidence intervals. RQ=relative quantification, PAR= parental, SCR= scramble.   
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Table 5.1: IC50 values, with their respective 95% confidence intervals, in PE/CA-PJ15 parental, scramble and 
SHMT1 knockdown clones following treatment with 0-1 mM 5-FU and 0-8 μM MTX.  
 
 
 
 
 
 
Clone IC50-5FU mM 95% C.I IC50-MTX μM 95% C.I 
PJ15-PAR 0.491 
 
0.35 to 0.68 
 
3.734 
 
2.639 to 5.284 
 
PJ15-SCR 0.519 
 
0.40 to 0.66 
 
4.018 
 
2.982 to 5.415 
 
PJ15-F12O 0.126 
 
0.08 to 0.19 
 
2.355 
 
1.854 to 2.993 
 
PJ15-F12E 0.066 0.047 to 0.09 
  
 
2.274 1.737-2.976 
Figure 5.7: Effect of SHMT1 silencing in PE/CA-PJ15 cell line sensitivity to MTX. Knocking 
down of SHMT1 expression did not have a significant effect in reducing PE/CA-PJ15 derived 
knockdown clones viability following MTX exposure as reflected by their MTT absorbance 
readings. Results represent the mean of six technical replicates. Error bars represent 95% 
confidence intervals. PAR= parental, SCR= scramble.   
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Furthermore, our data demonstrated that artificial suppression of CBS induced by specific 
shRNAs did not sensitise H358 cells to 5-FU (Figure 5.9). The same is true for the MTX and 
pemetrexed response among CBS knockdown H358 derived clones (data not shown). We 
therefore decided to continue with the PE/CA-PJ15 cell line and 5-FU anticancer drug for the 
subsequent functional analysis experiments. 
 
 
 
 
Figure 5.9: Effect of CBS knockdown on the response of H358 cells to an IC25 dose of 5-FU 
chemotherapy. No significant reduction in the viability of CBS downregulated clones with respect 
to that of parental and scramble control was observed. Error bars represent 95% confidence 
intervals. PAR=parental, SCR=scramble.  
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In order to confirm the link between SHMT1 and 5-FU sensitivity in PE/CA-PJ15 HNSCC cells, 
we next utilised a different shRNA construct (TRCN0000034767) effective at knocking down 
SHMT1 mRNA expression. Of several independent PJ15 clones generated, three (PJ15-G2-8, 
PJ15-G2-9 and PJ15-G2-14) demonstrated ~60% reduction in SHMT1 mRNA levels as 
determined by qPCR analysis (Figure 5.10B). Suppression of SHMT1 expression in the new 
PE/CA-PJ15 derived clones was also validated by western blotting analysis (Figure 5.2).  
Consistently with our previous findings, PJ15-G2-8, PJ15-G2-9 and PJ15-G2-14 clones 
exhibited a marked drop in absorbance readings following 5-FU exposure in comparison to 
that of parental or scrambled controls (Figure 5.10A). MTT analyses have shown lower values 
of 5-FU relative IC50 in PJ15-G2-8 and PJ15-G2-9 and PJ15-G2-14 downregulated clones than 
those noted in the parental and mock (scramble) cells (Table 5.2). These findings imply that 
SHMT1 knockdown in PE/CA-PJ15 cells enhances their sensitivity to 5-FU.  
 
Table 5.2: IC50 values with their 95% confidence intervals of 5-FU therapy in PE/CA-PJ15-derived SHMT1 
silenced clones (with G2 shRNA constructs) compared to that of the parental (PAR) and scramble (SCR) 
control. 
PJ15 Clones 5-FU IC50 (mM) 95% CI 
PJ15-PAR 0.446 0.365 to 0.544 
PJ15-SCR 0.639 0.559 to 0.731 
PJ15-G2-8 0.178 0.143 to 0.221 
PJ15-G2-9 0.133 0.101 to 0.174 
PJ15-G2-14 0.156 0.125 to 0.195 
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Figure 5.10: Effect of SHMT1 silencing (with different shRNA construct) in PE/CA-PJ15 cell line sensitivity to 5-FU. Knocking down of SHMT1 
expression resulted in a significant reduction of PE/CA-PJ15 derived knockdown clones viability as reflected by their MTT absorbance readings (A) 
relative to the SHMT1 suppression levels (B). Results represent the mean of six technical replicates. Error bars represent 95% confidence intervals. 
RQ=relative quantification, PAR= parental, SCR= scramble.   
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To further confirm the influence of SHMT1 expression on 5-FU drug sensitivity in HNSCC, 
aminomethyl-phosphonic acid (AMPA), a known effective SHMT1 inhibitor, was used to 
investigate cancer cell growth response to SHMT1 suppression induced by this glycine 
analogue. According to previous optimisation experiments, 25 mM was determined as an 
optimal concentration of AMPA to be used in this study.  When the PE/CA-PJ15 cell line was 
exposed to a combination of 25 mM AMPA with s IC50 concentration of 5-FU, a significant 
enhancement of 5-FU anticancer effect was observed (Figure 5.11A). The cell line was then 
treated with seven variable concentrations of 5-FU (0-1 mM) in combination with 25 mM 
AMPA. MTT analysis demonstrated a significant reduction of absorbance readings with a 5-
FU-AMPA combination compared to the PE/CA-PJ15 cell line treated with 5-FU only (Figure 
5.11B) and an associated marked drop in the IC50 value (Table 5.3). 
 
 
 
 
                                                                                                                                                                                                                               
Table 5.3: IC50 values and their respective confidence intervals (95%) in PJ15 cells after treatment with 0-1 
mM of 5-FU in the presence of 25 mM AMPA 
 
 
 
 
 
 
  
Treatment 5-FU IC50 (mM) 95% CI 
5-FU only 0.957 
 
0.813 to 1.126 
 
5-FU+AMPA 0.327 
 
0.250 to 0.427 
 
169 
  
Figure 5.11: Sensitivity of PE/CA-PJ15 cells to 5-FU treatment in the presence of an 
SHMT1 inhibitor (AMPA). PE/CA-PJ15 cell line was treated with a combination of (A) 
an IC50 concentration, (B) a range of seven different doses of 5-FU with 25mM AMPA 
for 72hours. In both graphs, AMPA seems to cooperate with 5-FU as reflected by MTT 
absorbance values. The results represent the mean of six technical replicates. Error 
bars represent 95% confidence intervals. 
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5.2 SHMT1 and CBS Splice variants expression profiles in their knock down 
clones 
In order to investigate whether shRNA mediated knockdown of SHMT1 and CBS genes can 
specifically target splice variant sequences, we assessed the relative expression of different 
CBS/SHMT1 splicing isoforms (previously discussed in chapter three) in the knockdown 
derived clones using quantitative RT-PCR. Expression profile analysis revealed depletion of 
SHMT1v2 in PJ15-F12O, PJ15-F12E (which showed an increased sensitivity to the 5-FU based 
anticancer agent) as well as PJ15-F12C, which demonstrated a 46% reduction of SHMT1 
expression at the mRNA level (Figure 5.13). Similarly, CBSv3 was found to be downregulated 
in H358-C9A, H358-C10B and H358-C11C CBS knockdown clones (Figure 5.14). We reasoned 
that mRNA levels of CBS/SHMT1 splicing isoforms that were underrepresented in the 
knockdown clones might be attributed to specific targeting by the short hairpin RNA that was 
utilised to downregulate the CBS/SHMT1 expression in these clones. To test this hypothesis, 
we next checked the shRNA target regions using The Genetic Perturbation Platform web portal 
(portals.broadinstitute.org). As shown in Table 5.4, the shRNA mediated CBS/SHMT1 silencing 
employed in this study targets exons that are present in all splice variants (CBS exons 4, 5 or 
15 and SHMT1 exon 6). These data potentially exclude the possibility of specific splice 
targeting through RNA interference in SHMT1 and CBS genes. Furthermore, analysis of the 
minimum free energy (data not shown) and predicted centroid secondary structures 
(rna.tbi.univie.ac.at) (Package et al. 2011) demonstrated a subtle difference in the 
CBS/SHMT1 shRNA target regions (Figure 5.12), suggesting that variation in RNA 
conformations might not justify the differential knockdown across downregulated clones.    
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 Table 5.4: shRNA constructs utilised in CBS and SHMT1 knockdown assays 
* The 5’ stem region is highlighted with red while its reverse complement is green 
  
Assay Knock-
down 
clone 
Clone ID Oligosequence* Target 
region 
Match 
(%) 
CBSv3 H358-C9 TRCN0000045
360 
CCGGCTTGCCAGATATTCTGAAGAACTCGAGTTCTTCAG
AATATCTGGCAAGTTTTTG 
Exon 4 100 
 H358-C10 TRCN0000045
361 
CCGGCCGTCAGACCAAGTTGGCAAACTCGAGTTTGCCA
ACTTGGTCTGACGGTTTTTG 
Exon 15 100 
 H358-C11 TRCN0000045
362 
CCGGACACGATTATCGAGCCGACATCTCGAGATGTCGG
CTCGATAATCGTGTTTTTTG 
Exon 5 100 
SHMT
1v2 
PJ15-F12 TRCN0000034
765 
CCGGCCCAGATACTGGCTACATCAACTCGAGTTGATGT
AGCCAGTATCTGGGTTTTTG 
Exon 6 100 
Figure 5.12: Predicted RNA secondary structures of CBS and SHMT1 splice variants. Subtle 
differences were observed between CBS and SHMT1 knockdown targets. Target regions in CBS 
Exon 4 and SHMT1 Exon 6 are shown as red insets while yellow and blue ones denote targets in 
CBS Exon 15 and 5 respectively. shRNA nucleotide sequences are presented as circles within the 
insets.   
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Figure 5.13: qPCR-based analysis mRNAs of SHMT1 and its splice variants in SHMT1 knockdown clone derivatives. (A) SHMT1 (left panel) and 
SHMT1v2 (right panel) demonstrated downregulation across the PJ15-derived knockdown clones. Results from all samples were normalised 
to ACTB and SHMT1 (V1+V3) respectively and presented as a fold change relative to that of PJ15-PAR cell population. (B) Variable expression 
levels of SHMT1(v1+v3) and SHMT1v2 alternative transcripts in SHMT1 downregulated clones (middle and right panels) as compared to 
decreased expression of SHMT1 (all variants, the left panel) in the same clones. Quantification of SHMT1 gene was normalised to that of 
ACTB whereas (V1+V3) and V2 splice isoforms data were separately normalised to TATAA-box binding protein (TBP). PJ15-PAR was used as 
an internal calibrator.  
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Figure 5.14: Fluorescent quantification-based analysis of the mRNA expression of the CBS 
gene and its splice variants in H358-derived CBS knockdown clones. Results show 
downregulation of the CBS gene (left panel) and CBSv3 (right panel) across H358 clones. The 
H358-PAR cell population was used as a technical calibrator. RQ values of the CBS transcript 
and CBS (v1+v2+v4) mRNAs of all samples were normalised to that of ACTB and CBSv3 
respectively. 
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5.3 Discussion 
5.3.1 CBS and SHMT1 downregulation in respiratory tract cancer cell lines 
The de novo thymidylate biosynthesis pathway is essential for maintaining cellular dTTP pools 
and ensuring faithful replication of cellular DNA. SHMT1 is a critical player in this pathway, 
which also includes SHMT2α, TYMS and DHFR (MacFarlane et al. 2011). Among these 
enzymes, SHMT1 is the only one that has not currently been extensively studied (Paone et al. 
2014). Moreover, the impact of SHMT1 suppression on cancer growth and progression has 
not been sufficiently investigated (Pandey et al. 2014). Our study highlighted the relevant role 
of SHMT1 expression in controlling cancer cell growth and viability. We demonstrated that 
shRNA induced suppression of SHMT1 reduces cancer cell viability in the PE/CA-PJ15 HNSCC 
cell line. This is in line with recent reports on SHMT1 silencing in xenograft mice (Pandey et 
al. 2014), lung (Paone et al. 2014) and ovarian cancer cell lines (Gupta et al. 2017). Moreover, 
we used Kaplan Meier estimator software in order to assess the biological relationship 
between SHMT1 expression and lung cancer patients survival (Győrffy et al. 2013). As shown 
in Figure 5.15, high SHMT1 expression is associated with low survival among lung cancer 
patients, especially those not receiving chemotherapy. This provides a further line of evidence 
for the role of SHMT1 in disease progression and, ultimately, patient survival.  
Importantly, we showed for the first time, that artificial suppression of SHMT1 produced a 
cell sensitisation phenotype to 5-FU treatment. Our data demonstrated that shRNA-based 
knockdown of SHMT1 expression increases 5-FU response in the PJ15 HNSCC cell line. SHMT1 
is a critical player in the de novo synthesis of thymidylate; its chief function is to catalyse the 
reversible conversion of serine to glycine, thereby generating the one-carbon donor essential 
for the methylation of dUMP to dTMP. In addition, it acts as a scaffold protein for the 
thymidylate synthesis metabolic complex (Anderson et al. 2012). Consequently, SHMT1 
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activity is correlated with the increased nucleotide biosynthesis demand evidenced in rapidly 
proliferating cancer cells. In line with this, we observed SHMT1 upregulation in lung cancer 
tissue and respiratory tract cancer cell lines (Chapter 3). TYMS inhibition has been established 
as the main mechanism of 5-FU anticancer action through formation of a covalent ternary 
complex involving 5-FU metabolite 5-fluoro-2’-deoxyuridine (FdUMP), TYMS and 5,10 MTHF 
(Santi & McHenry 1972). Moreover, 5-FU can also be converted through a complex 
intracellular metabolic network into 5-fluorouridine monophosphate (FUMP), which is the 
precursor of two cytotoxic 5-FU metabolites: 
5-fluorouridine triphosphate (5-FUDR) and deoxyuridine triphosphate (dUTP). Following DNA 
incorporation, dUTP causes irreparable DNA damage, while 5-FUDR misincorporates into 
ribosomal RNA (rRNA) molecules, thereby disturbing rRNA processing, resulting in the 
induction of cell cycle arrest/or apoptosis in a p53 dependent manner. SHMT1 is a limiting 
factor in thymidylate biosynthesis reactions; hence suppression of SHMT1 expression causes 
disruption of these reactions leading to dUTP misincorporation within DNA during the DNA 
replication process, and ultimately cell cycle arrest and apoptosis. A recent study 
demonstrating that knockdown of SHMT1 in lung cancer cell lines induces p53 dependent 
apoptosis supports this contention (Paone et al. 2014). In the same direction, Anderson & 
Stover (2009) reported an abnormal uracil accumulation in mice lacking SHMT1. Accordingly, 
we may conclude that the synergistic apoptotic effect imparted by concurrent SHMT1 
silencing and 5-FU treatment confers potent chemosensitisation of PE/CA-PJ15 cells. 
We further present evidence that combined treatment with the SHMT1 inhibitor AMPA 
potentiates the effect of 5-FU in PE/CA-PJ15 HNSCC cell line. Although co-treatment with 5-
FU and AMPA has not been attempted yet, AMPA has been identified as inhibiting 
proliferation and promote apoptosis in prostatic cancer cells in vitro (Li et al. 2013) and in vivo 
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(Parajuli et al. 2016). These findings align with the present data of manipulated SHMT1 
expression in PE/CA-PJ15PJ15 cell line. 
To our knowledge, this is the first report to demonstrate the in vitro efficacy of SHMT1 
knockdown and the marked reduction in cell viability achieved when combined with 5-FU 
treatment in PE/CA-PJ15 HNSCC cells.  
We have also examined the effect of shRNA mediated down regulation of CBS on NSCLC cells. 
Our data have shown that CBS knock down clones displayed reduced MTT absorbance values 
in the H358 cell line as compared with parental control. A similar observation has been 
reported in colonic (Hellmich et al. 2014) and ovarian cancer cells (Bhattacharyya et al. 2013). 
Of course, due to the important role of CBS-derived H2S in promoting bioenergetic fuel for 
the rapidly proliferating cancer cells, silencing/inhibition of this mammalian gene contributes 
to energy starvation of tumour cells thereby impairing their growth and proliferation 
(Hellmich et al. 2014).  
Moreover, we also demonstrated that CBS genetic silencing did not influence the growth 
inhibitory effect of 5-FU, pemetrexed or MTX anticancer drugs in H358 knocked down clones 
as compared with the parental or scrambled cells. On the contrary, Pagliara et al. (2016) 
reported that CBS silencing was associated with a remarkable increase in 5-FU mediated 
anticancer effect in colon cancer cell lines lacking p53. They assume that 5-FU treatment 
induces nuclear stress and activates some ribosomal proteins (rp), specifically rpL3, which 
binds CBS and represses its activity at transcriptional and post-translational levels along with 
induction of the mitochondrial apoptotic pathway in colonic cancer cells lacking functional 
p53. Another recent report from the same group demonstrated that rpL3 has the potential to 
promote the antitumour effect of 5-FU effect through downregulation of CBS and NFkB 
transcription factor in p53 mutated lung cancer cell lines (Russo et al. 2016). This 
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inconsistency probably exists because of a difference in the p53 expression or mutational 
status of the cancer cell line examined. Further studies are needed to investigate the 
therapeutic potential of CBS modulation in respiratory tract cancer.    
 
 
 
 
Figure 5.15: Kaplan Meier survival analysis of lung cancer patients in relation to SHMT1 mRNA expression 
comparing OS and PFS results in the presence and absence of treatment history. OS= Overall survival, 
PFS= Progression free survival, Chemo=Chemotherapy. Taken from Kaplan Meier- Plotter software (Lung 
cancer). 
 
OS 
All Chemo 
PFS 
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5.3.2 SHMT1 & CBS Splice variants expression profiles in SHMT1 and CBS knock down 
clones 
In the current study, we also analysed SHMT1 and CBS splice variants expression levels in their 
corresponding knockdown clones. Both SHMT1v2 and CBSv3 have relatively lower mRNA 
levels in all of the three PJ15 and H358 knockdown clones, respectively. Furthermore, we fail 
to provide evidence for differential silencing of specific SHMT1/CBS mRNA isoforms, either by 
unique exon or via RNA conformation. These data suggest that splice variants controlling 
mechanisms might be independent of those involved in mRNA regulation (Doriguzzi et al. 
2016). An alternative suggestion is that a change occurs in the alternative splicing of 
CBS/SHMT1 following the knocking down event. This might lead to variation in the splicing 
pattern with induced production of a specific mRNA isoform over the others (Grosso et al. 
2008; Wang et al. 2008). Additional studies are necessary on the regulatory mechanisms that 
govern CBS/SHMT1 splicing processes in respiratory tract cancer. 
In summary, the current study provides new information regarding the in vitro efficacy of 
SHMT1 as a potential enhancer for 5-FU activity. Our findings suggest that SHMT1 might have 
a clinical relevance in 5-FU based chemotherapeutic regimens in respiratory tract cancer and 
underline the need for further evaluation. In addition, we report for the first time the 
expression profiles of SHMT1/CBS splice transcripts in their respective knockdown clones. Our 
results might raise the possibility of specifically targeting aberrant respiratory tract cancer 
associated splicing isoforms. Detailed experiments to assess the CBS/SHMT1 knockdown 
effect on their corresponding splicing events would be crucial for this scenario.   
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Overall study discussion and final 
conclusion 
The folate metabolic pathway has long been an attractive target for cancer therapy given its 
importance to DNA synthesis, methylation and repair. The development of drug resistance 
has, however, posed a major obstacle to clinical success. A full understanding of the 
mechanisms of resistance to these anticancer agents has yet to be achieved. Furthermore, 
development of rationally-based novel strategies that could overcome cancer cells 
chemoresistance remains an attractive objective for both the academia and the 
pharmaceutical industry.  
The overarching aim of this study was to expand the knowledge around the folate pathway in 
respiratory tract cancer and explore potential new, less studied, targets for therapeutic 
exploitation. In this respect, our starting point was the expression profiling of the “core genes” 
of the folate pathway in primary respiratory tract cancer. Unfortunately, the head and neck 
samples available proved to be of insufficient quality; a possibility we had in mind as they 
were stored in a freezer that failed some time ago. Profiling was therefore undertaken only 
in RNA from NSCLC samples. Using a two-phase approach (training and validation in 
independent sample sets) we acquired a detailed expression profile of TYMS, DHFR, MTHFR, 
CBS, SHMT1 and DNMT1 in NSCLC tissue compared to normal tissue from the adjacent lung. 
Our results revealed a significant distortion of the mRNA profile among folate pathway genes. 
TYMS, DHFR, CBS and SHMT1 showed significant overexpression in lung tumours, while 
MTHFR gene showed downregulation in the same tumour set. Expression profiling in a panel 
of ten respiratory tract cancer cell lines demonstrated similar results TYMS, DHFR, MTHFR and 
SHMT1 (upregulation) and MTHFR (downregulation) compared to a non-tumorigenic 
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bronchial epithelial cell line (HBEC). The CBS gene, however, exhibited downregulation in 
most of the studied cell lines relative to the non-tumorigenic bronchial epithelial cells (HBEC-
3KT). While this is not understood currently, one can hypothesize that low CBS may provide 
a selective advantage under culture conditions. At the end of this part of the project we 
decided to focus on the deregulated genes in SHMT1 and CBS as they were the least studied, 
with very few reports on their involvement in cancer and hardly anything in respect to lung 
cancer.  
Several previous studies have underlined the critical impact of irregular splicing in cancer 
development but, to date, very little, if anything, exists on CBS and SHMT1. To our knowledge, 
this report represents the first attempt to explore the relative expression of the splice variants 
of these two genes in lung cancer. Our data show that CBS/SHMT1 variants are expressed in 
lung-derived cell lines and NSCLC tissue samples, demonstrating their importance in 
maintaining growth and biological activities in the cellular context. More importantly, CBS 
variant 3 (CBSv3) is upregulated in NSCLC tissues, being more prominent in squamous 
carcinomas, while SHMT1 variant 2 (SHMT1v2) exhibits significant downregulation with 
respect to adjacent non-tumorous tissues. This is an important observation that opens the 
way for further research to provide mechanistic evidence for (a) what drives this irregular 
splicing and (b) the differential function of those splice variants in cancer development. No 
solid hypotheses can be drawn currently as there is virtually no information on the function 
of those splice variants, but our attempt to model the structural configuration of the mRNAs 
from the different variants may be a helpful start. 
Having identified the significant distortion in the mRNA expression levels of the key players in 
folate metabolism, our next step was to examine the potential sensitisation of respiratory 
tract cancer cell lines to 5-FU, MTX and pemetrexed; these are very common drugs, used 
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today as routine treatment for many cancer types, including respiratory ones. The first step 
in this route was to test well-known epigenetic modifiers (VPA to inhibit histone deacetylation 
and DAC for the induction of global DNA hypomethylation) and to investigate whether folate 
gene expression alterations might coincide with the sensitivity levels of cell lines to these 
epigenetic modifiers. Despite the fact that several studies employed other HDACi for 
potentiating 5-FU antitumour effect in lung, colorectal, gastric, hepatic, pancreatic and 
cholangiocarcinoma cell lines, the role of VPA in modulating lung cancer cells response to 5-
FU has remained unexplored. As a subsidiary technical finding, we demonstrated for the first 
time that pretreatment (as opposed to concurrent treatment) of A549 and SKMES cell lines 
with VPA 48 hours prior to 5-FU addition significantly enhanced the efficiency of the latter. 
We also demonstrate the ability of VPA to downregulate TYMS and DNMT1 mRNA while, in a 
separate experiment, these two genes presented a high expression in the 5-FU 72-h exposure 
surviving NSCLC cells. This triangle of evidence suggests, apart from the profound benefit of 
VPA in 5-FU sensitisation, certain molecular routes leading to this epigenetic sensitisation. 
Given the importance of the SHMT1 gene in the metabolic reprogramming of cancer cells, we 
hypothesised that this gene may have a critical role in 5-FU based chemotherapy in 
respiratory tract cancer. To explore this possibility, we developed shRNA-mediated 
knockdown clones from PE/CA-PJ15 HNSCC cell lines. Our data demonstrated that SHMT1 
knockdown in PE/CA-PJ15 cell line was associated with decreased cell viability and, more 
importantly, sensitised tumour cells to 5-FU anticancer drug. The synergistic antitumor 
benefit of concurrent SHMT1 silencing and 5-FU treatment in PE/CA-PJ15 cells was further 
validated using the SHMT1 selective inhibitor AMPA. This is the first study uncovering the 
marked potentiation of 5-FU activity via SHMT1.  
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In conclusion, this study was successful in adding detail to existing information and producing 
significant new evidence demonstrating the potential exploitation of folate genes as targets 
to improve antifolate-based therapy for cancer.  The three key findings, i.e. irregular  CBS and 
SHMT1 splice isoforms in NSCLC, VPA-based epigenetic sensitisation  to 5-FU through TYMS 
and DNMT1 repression, and SHMT1-mediated sensitisation to 5-FU, provide important new 
insights into the molecular basis of 5-FU based therapy, and pave the way for further research 
for clinical utilisation in respiratory, and potentially other, cancer types. 
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Future directions 
SHMT1 appears to be a good candidate target for enhancing the efficiency of 5-FU in vitro. 
Although the present study provided important data regarding the role of SHMT1 expression 
in PE/CA-PJ15 cancer cell line response to 5-FU anticancer effect, there are a number of issues 
that should be investigated further. 
Knocking down of SHMT1 expression should be performed in at least three NSCLC and HNSCC 
cell lines to establish whether it produces a similar result on a different genetic background, 
or it only affects a subset of cell lines, i.e. it is contingent to pre-existing genetic changes. 
Following establishment of SHMT1 knockout derivative clones with multiple shRNA 
constructs, cell sensitivity to 5-FU should be measured. If a positive outcome is obtained, 
rescue experiments should be undertaken in the SHMT1 knockdown clones. The re-
expression of SHMT1 would further establish the relationship between this gene and 5-FU 
antitumour effect. Furthermore, this rescue experiment would demonstrate whether the 
indication that SHMT1 knockdown leads to sensitisation of respiratory tract cancer cell line to 
5-FU anticancer drug is true or not. 
We also provide evidence for the potential synergy between 5-FU and VPA in A549 and SK-
MES NSCLC cell lines. Cell apoptosis assays would determine whether the VPA-dependent 
sensitisation to 5-FU is due to apoptosis reactivation or an alternative mechanism. 
In addition, the observed alteration of CBS and SHMT1 alternative splicing in NSCLC tissues 
should be investigated further. CBS and SHMT1 splice variants mRNA and protein expression 
could be studied in a large cohort, together with investigation of the functional role of these 
variants in cancer phenotype and drug response in order to evaluate their impact in cancer 
development and response to chemotherapeutic agents. 
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